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“As with most of life's problems, this one can be solved by a box of pure radiation.”  
― Andy Weir, The Martian 
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Summary 
In the last decades 99mTc has dominated the market as the most frequently used 
radionuclide for diagnostic purposes in the clinics. The unparalleled success of 
technetium stems from its near-ideal properties, such as a half-life of 6 hours, optimal 
energy for SPECT imaging as well as easy, cost-friendly and worldwide availability. 
However, in recent years there has been a severe lack of new technetium based 
nuclear imaging agents, with only two new compounds being approved since 2001. 
This can partly be attributed to the preference for a so-called pendent approach in the 
design of radiotracers. The concept of the pendent approach is to attach a targeting 
unit via a linker to a chelator of the radiometal. This approach is synthetically 
straightforward and hence the most frequently pursued one, even though the use of 
linkers and usually bulky chelators affects the biodistribution of the radiotracer in 
unpredictable ways. The more elegant but in turn more challenging integrated 
approach involves the rational introduction of the radiometal and its chelator into the 
chemical structure of a biomolecule with known in vivo distribution profile. This 
application would also enable a theranostic approach were the 99mTc complex is used 
for diagnostics and the analogous non-radioactive Re-compound for therapy.  
Cyclopentadiene (Cp) is well-suited ligand to address the issues of current systems. It 
is small in size and forms stable neutral complexes with both Re and 99mTc. 
Additionally, the vast potential for the chemical functionalization Cp-ligands has been 
relatively unexplored. The goal of this work was the development of a chemically 
versatile Cp-ligand synthesis and its application towards pendent as well as integrated 
approaches with Re and 99mTc. 
In the first and main part of this thesis a novel synthetic route towards multifunctional 
Cp-ligands was developed. The synthesis was optimized for routine preparation of up 
to gram-scale batches of Cp’s containing at least three functionalities. With these 
ligands, the corresponding rhenium and technetium-99m complexes could be prepared 
in a straightforward manner. The respective complexes are homo- or hetero 
functionalized, depending on the specific requirements. In a second part, these ligands 
were applied in biological settings by synthesizing Cp-complexes conjugated to one or 
two prostate cancer targeting moieties. It was shown that the species containing two 
inhibitor-units exhibits binding affinity in the low nanomolar range and was significantly 
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more potent than the complex containing only one. In a third project the same ligand 
platform was used to prepare a rhenium-mimic of the anticancer drug pemetrexed 
following an integrated approach. The aromatic ring in pemetrexed was replaced by a 
Cp-ring, leading to a Re-analogue of unprecedented structural similarity to the lead-
compound. 
Part B explores the applicability of multifunctional Cp’s with other metals. Both 
metallocene and mixed-sandwich type complexes were prepared with ruthenium and 
iron, introducing the potential for further functionalization of these types of complexes 
with possible applications in catalysis and medicinal chemistry. 
The more fundamental Part C deals with the study of basic rhenium building blocks 
and their behavior in solution towards ligand exchange. It is shown that rhenium 
tricarbonyl can undergo rapid carbonyl exchange in solution. 13C NMR spectroscopy 
was the tool to study the intricate mechanism of CO exchange in these complexes. 
These findings enable the targeted preparation of 13C-labeled rhenium synthons which 
are key to study the basic reaction mechanisms of these complexes. 
Finally, Part D focuses on the different synthetic strategies towards hitherto unexplored 
polynuclear complexes of Re incorporating 99mTc. By comparing pure Re-clusters with 
99mTc-containing ones it is shown that radiolabeled multinuclear complexes can be 
prepared by both pre-assembly and self-assembly approaches. The easy and well-
defined synthesis of these complexes lends itself to nuclear imaging applications 
where such structures have not found much notice yet. 
Overall, this thesis entails the design and implementation of a Cp-ligand platform for 
the synthesis of cancer-targeting diagnostic and therapeutic metal complexes. 
Additionally, this toolkit is generally relevant to the field of organometallic chemistry 
and will find applications in different domains of this field. 
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Zusammenfassung 
Der radiopharmazeutische Markt der letzten Jahrzehnte wurde von dem am häufigsten 
klinisch eingesetzten Radionuklid Technetium-99m dominiert. Der beispiellose Erfolg 
von 99mTc kann seinen nahezu idealen Eigenschaften wie der vorteilhaften 
Halbwertszeit von sechs Stunden, optimalen Zerfallsenergie für SPECT-Bildgebung 
sowie der einfachen, kostenfreundlichen und globalen Verfügbarkeit zugeschrieben 
werden. In den letzten Jahren hat sich jedoch ein deutlicher Mangel an neuen 
Technetium-basierten Pharmazeutika für nukleare Bildgebungsverfahren 
abgezeichnet. Seit 2001 wurden nur zwei neue Verbindungen zur klinischen 
Anwendung zugelassen. Dieser Mangel kann teilweise dem Trend, wonach 
Radiodiagnostika anhand des sogenannten pendenten Ansatzes konzipiert werden, 
zugeschrieben werden. Beim pendenten Ansatz wird das Radiometall durch einen 
Chelator über einen Linker an eine zielorientierte biologische Einheit angehängt. 
Obwohl der Einsatz von Linkern und normalerweise sperrigen Chelatoren die 
Bioverteilung des Tracers auf unvorhersehbare Weise beeinflussen ist dies der 
synthetisch einfachere und daher öfters verwendete Ansatz. Beim eleganteren aber 
auch schwierigerem integrierten Ansatz wird das Radiometall und der Chelator in die 
chemische Struktur eines Biomoleküls mit bekanntem in vivo Verhalten eingefügt. Dies 
würde eine theranostische Anwendung ermöglichen, in welcher der 99mTc-Komplex für 
die Diagnose und die analoge nicht-radioaktive Rhenium Verbindung für eine 
anschliessende Therapie benutzt wird. 
Cyclopentadien (Cp) ist ein gut geeigneter Ligand, der die Schwachstellen von 
heutigen Chelator-Systemen umgehen kann. Cp-Liganden sind klein und bilden 
stabile, neutrale Komplexe mit Re und 99mTc. Das grosse Potential der chemischen 
Derivatisierung von Cp-Liganden wurde zudem bisher erst wenig erforscht. Das Ziel 
dieser Arbeit war die Entwicklung einer chemisch vielfältigen Cp-Ligandsynthese und 
dessen Anwendung in sowohl pendenten als auch integrierten Ansätzen mit Re und 
99mTc. 
Der erste Teil dieser Dissertation beschreibt die Entwicklung eines neuen 
Syntheseweges für multifunktionelle Cp-Liganden. Diese Synthese wurde optimiert um 
routinemässig Cp-Liganden mit mindestens drei Funktionalitäten im Gramm-Massstab 
herzustellen. Die Rhenium und Technetium-99m Komplexe dieser Liganden konnten 
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auf einfachem Weg hergestellt werden und können je nach Bedürfnissen homo- oder 
heterofunktionell substituiert sein. Im zweiten Projekt wurden diese Liganden in einem 
biologischen Kontext eingesetzt. Es wurden Cp-Komplexe synthetisiert, die mit einer 
oder zwei Einheiten derivatisiert waren, welche vorzugsweise von Prostatakrebszellen 
aufgenommen werden. Die Verbindung mit zwei Prostatabindungseinheiten wies eine 
Affinität im tiefen nanomolaren Bereich für diese Krebszellen auf und war der Substanz 
mit nur einer Bindungseinheit um ein Vielfaches überlegen.  
In einem dritten Projekt wurde dasselbe Ligandensystem benutzt um ein 
Rheniumanalogon des Krebsmedikamentes Pemetrexed nach einem integrierten 
Ansatz zu synthetisieren. Dazu wurde der aromatische Ring im Medikament durch 
einen Cp-Ring ersetzt, was zu einem Rheniumkomplex mit neuartiger struktureller 
Ähnlichkeit zur Ausgangsverbindung führte. 
Teil B befasst sich mit der Komplexierung von diesen multifunktionellen Cp-Liganden 
mit anderen Metallen. Sowohl Metallocene als auch gemischte Sandwichkomplexe 
konnten mit Ruthenium und Eisen hergestellt werden. Dies ergab Komplexe, welche 
potentiell weiter funktionalisiert werden und somit mögliche Anwendungen in der 
Katalyse oder der medizinischen Chemie haben könnten. 
Im Teil C wird das Ligandenaustauschverhalten von grundlegenden Rhenium-
Synthesebausteinen in Lösung untersucht. Es wird gezeigt, dass bei Rhenium-
Tricarbonyl Verbindungen in Lösung schneller CO-Austausch beobachtet werden 
kann. Mithilfe von 13C NMR-Spektroskopie konnte dieser komplizierte Mechanismus 
im Detail studiert werden. Diese Ergebnisse ermöglichen eine gezielte Anreicherung 
von 13C in elementaren Rhenium-Bausteinen, welche essentiell sind, um die 
grundsätzlichen Reaktions-mechanismen dieser Verbindung zu untersuchen. 
Im letzten Teil D liegt der Fokus auf bisher wenig studierten Synthesestrategien um 
99mTc in mehrkernigen Rhenium-Komplexen zu inkorporieren. Durch Vergleich von 
rein Rhenium-haltigen Komplexen mit 99mTc enthaltenden Verbindungen konnte 
gezeigt werden, dass radiomarkierte Komplexe sowohl nach einem "Voranordnungs" 
als auch nach einem "Selbstanordnungsansatz" synthetisiert werden können. Diese 
einfache und wohldefinierte Synthese bietet sich zur Anwendung in nuklearen 
Bildgebungsanwendungen an wo solche Strukturen bisher wenig Beachtung fanden. 
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Insgesamt beinhaltet diese Doktorarbeit die Entwicklung und Umsetzung eines Cp-
Ligandensystems welches die Synthese von Krebspezifischen diagnostischen und 
therapeutischen Metallkomplexen ermöglicht. Generell ist dieses Ligandensystem 
auch für das Forschungsgebiet der Organometallchemie relevant, wo es 
Anwendungen in verschiedenen Gebieten dieses Feldes finden wird. 
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Riassunt 
Dürant ils ultims decennis ha dominà il radioisotop tecnetium-99m (99mTc) il marchà 
sco radionuclid chi vegn dovrà il plü suvent illas clinicas. Quist success unic as poja 
ingrazchar a las qualitats plü o main idealas, sco il temp da mezza-vita da ses uras, 
optimala energia per la diagnostica SPECT e la disponibilità globala favuraivla. Ma i’ls 
ultims ons as ha manifestada üna s-charsdà da farmaceuticas chi’s basan sül 
tecnetium. Be duos formulaziuns sun stattas admissas per l’adöver in clinicas daspö il 
2001. Quista mancanza as poja declerar per part cul trend da concipir radiodiagnostics 
tenor la metoda pendenta. Pro la metoda pendenta vegn attachà il metal radioactiv ad 
ün chelator intuorn il qual es attachà per travers üna colliaziun ad ün’unità biologica 
cun ün böt specific. Cumbain cha l’adöver da colliaziuns e chelators chi sun 
normalmaing massitschs ha ün effet sün la distribuziun biologica da l’unità diagnostica 
chi nu’s riva da preverer es quista metoda la plü simpla e perquai la plü populara. 
Ün’otra metoda plü eleganta, ma eir plü difficila es quella integrada. In quist cas sun il 
radiometal ed il chelator inchastrats aint illa structura chemica dad ün molekül cun 
cumportamaint e culla distribuziun biologica cuntschainta. Quai pussibilitess 
ün’applicaziun theranostica, ingiò cha’l cumplex cun 99mTc vain dovrà per la diagnosa 
e la colliaziun analoga na-radioactiva cun rhenium (Re) per la terapia. 
Cyclopentadien (Cp) es ün ligant chi’d es fich adattà per surmuntar ils puncts debels 
da chelators actuals. Ligants da Cp sun pitschens e fuorman cumplex stabils e neutrals 
cun Re e 99mTc. Implü nun esa fin uossa amo gnü fat blera retschercha a reguard il 
grond potenzial aint illa derivatisaziun chemica da Cp’s. L’intenziun da quista lavur 
d’eira da sviluppar üna sintesa multifaria per ligants da Cp e lur applicaziun tant illas 
metodas pendentas sco eir in quellas integradas cun Re e 99mTc. 
La prüma part da quista dissertaziun descriva il svilup dad üna nouva ruta sintetica per 
ligants da Cp multifuncziunals. La sintesa es gnüda optimada per la preparaziun da 
rutina aint illa scala da grams da Cp’s cun almain trais funcziunalitats. Ils cumplexs da 
rhenium e tecnetium cun quists ligants sun gnüts preparats in maniera simpla e pon 
esser funcziunalisats in maniera omogena o eterogena. Aint il seguond progect sun 
gnüts applichats quists ligants in ün context biologic. I sun gnüts sintetisats cumplexs 
cun ligands da Cp chi d’eiran derivatisats cun üna o duos unitats specificas chi vegnan 
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tuttas sü pustüt da cellas da cancar dal pancreas. Il molekül cun duos unitats ha 
muossà ün’affinità illa regiun nanomolara per quistas cellas da cancar e seis effet es 
stat bler plü grond co quel dal molekül cun be üna unità. 
Aint il terz project es gnü dovrà l’istess sistem per sintetisar ün analog dal medicamaint 
da cancar pemetrexed chi cuntegna rhenium, inspirà da la metoda integrada. Il rinch 
aromatic dal medicamaint es gnü substitui cun ün Cp, quai ha manà ad ün cumplex da 
rhenium cun üna gronda sumglientscha structurala al medicamaint original. 
La part B da quista lavur as occupa culla cumplexaziun da quists ligants da Cp 
multifuncziunals cun oters metals. Id eis stat pussibel da preparar cumplexs dal tip 
metallocen ed eir cumplexs masdats da "sandwich", cun ruthenium e fier. Quists 
cumplexs as pudessa funcziunalisar inavant per applicaziuns aint illa catalisa o illa 
chemia medicinala. 
Illa part C vain examinà il cumportamaint da barat dals ligands aint in blocs da sintesa 
basics dal rhenium in soluziun. I’s po observar chi dà ün barat svelt tanter moleküls da 
rhenium cun trais ligands da monoxid carbonic. Cun l’agüd da la spectroscopia da 
resonanza magnetica da charbun-13 esa stat pussibel dad eruir in detagl quist 
mecanissem cumplichà. Ils resultats da quist proget permettan üna concentraziun da 
charbun-13 aint in blocs da sintesa basics da rhenium. Quai es essenzial per examinar 
ils mecanissems da reacziun da quistas substanzas. 
L’ultima part D as focussescha sün strategias da sintesa per incorporar 99mTc aint 
cumplexs da rhenium poly-nuclears. Cun congualar cumplexs chi cuntegnan be 
rhenium cun quels chi cuntegnan eir technetium s’haja pudü muossar cha cumplexs 
radiomarcats pon esser sintetisats tenor il princip da pre-arrandschamaint opür il 
princip dad auto-arrandschamaint. Quista sintesa simpla as douvra per l’applicaziun 
illa diagnostica nucleara ingiò cha quistas structuras nu sun fin uossa amo gnüdas 
resguardadas uschè suvent. 
Tuot in tuot cumpiglia quist doctorat il svilup e l’implementaziun d’ün sistem da ligands 
chi’s basan sün Cp. Grazcha a quist sistem es statta pussibla la sintesa da cumplexs 
cun tecnetium e rhenium, diagnoistics e therapeutics specifics pel cancar. In general 
sun quists ligands da Cp eir interessants per il chomp da perscrutaziun da la chemia 
organometallica ingio chi chattaran applicaziuns in diversas domenas da quist chomp. 
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1. Introduction 
1.1 Inorganic Medicinal Chemistry 
While the pharmaceutical market is dominated by purely organic compounds, metal-
based drugs have firmly established themselves as an essential cornerstone of 
modern medicine. Inorganic compounds often have access to properties and modes 
of action which are not achievable with organic compounds alone, such as ligand 
exchange, reactive oxygen species (ROS) generation, redox activity and a significantly 
more pronounced 3D geometry.1, 2  
The prime example of a metal-based drug is the anticancer drug cisplatin (Figure 1), 
approved for clinical use in 1978, and still used in over 50% of all cancer treatments 
today.3, 4 Even though it suffers from significant drawbacks, such as various side-
effects (ranging from nausea and vomiting to nephro- and neurotoxicity) and the 
development of resistance amongst certain cancer cell lines, cisplatin has increased 
the cure rate for testicular cancer to over 95 %.5 Inspired by its outstanding success, 
many thousands of platinum based compounds have been synthesized in the last 
decades. However, only two Pt(II) compounds (carboplatin and oxaliplatin, cf. Figure 1) 
have been globally approved by the clinics. More recently, a series of studies have 
reported the promising preclinical results of platinum(IV) prodrugs, which are 
reductively activated to the cytotoxic Pt(II) compound in the tumor cells.6  
In the last two decades, the field of metal-based medicinal chemistry has widened its 
focus and compounds based on ruthenium, gallium and iron have made it into human 
clinical trials.7 The first ruthenium-based compound to make it into a phase I clinical 
trial is known as NAMI-A ([ImH][trans-RuCl4(dmso-S)(Im)] (dmso-S = sulfur-bonded 
dimethyl sulfoxide, Im = imidazole, Figure 1), developed by the group of Alessio.8, 9 
This compound had shown favorable and selective anti-metastatic activity in mice, but 
without significant effects on the primary tumor growth. The phase I study followed by 
a limited phase II clinical trial however deemed it “insufficiently effective for further 
use”.10 It is uncertain if the failure is attributable to a design flaw of the clinical trials as 
stated by Alessio in a recent personal view. It is however evident, that NAMI-A paved 
the way for non-platinum metal-based drugs to enter clinical trials.9 The second and 
so far only other ruthenium complex to make it into human trials is NKP-1339 
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(Figure 1). Based on a lead compound (KP418) reported by Keppler and Rupp in 
1986,11 NKP1339 showed encouraging activity against both primary tumors and 
metastases and minimal side effects were reported in a first small clinical phase I 
trial.12, 13  
 
Figure 1. Overview of the structures of metal-based drugs in clinical use or that have been 
evaluated in human clinical trials 
Gallium, an element that shares many physicochemical characteristics with Fe(III) in 
its +3 oxidation state has also shown promising antitumor activity.14 Two compounds 
are currently in early clinical trials, KP46 and gallium maltolate (Figure 1). Both 
complexes showed no dose-limiting toxicities and more potent tumor cell proliferation 
inhibition than gallium salts in phase I studies.15 
Another up-and-coming metal-based drug candidate comes from the field of anti-
malaria drugs. Ferroquine is a ferrocene-based derivative of the known drug 
chloroquine (Figure 1). In contrast to the previous examples, this compound does not 
represent an entirely new chemical structure but an integration of the redox-active 
ferrocene-moiety into the active scaffold of chloroquine. This has been shown to 
circumvent the chloroquine resistance in certain strains of malaria.16 Ferroquine has 
very recently completed a phase II clinical trial with promising results.17 Furthermore, 
phase II trials in combination with other antimalarial compounds are currently 
ongoing.18 
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While metals have most definitely proven their potential in a clinical setting, there has 
not been a metal-based compound approved for human use in decades. Part of the 
hurdle of getting more compounds tested in humans is both the challenge to 
understand the metabolic fate of these drugs but also a certain resistance of 
established pharmaceutical companies to “touch” these, in their eyes, un-orthodox 
molecules. Since clinical development is a high-risk and very expensive endeavor, the 
aversion of “Big Pharma” to consider them is partially understandable. It is probably 
going to be up to smaller and less risk-averse biotech companies to show the world 
that metals will still play an important role in modern medicine in the future. 
 
1.2 Radiochemistry 
1.2.1 A Brief History of Diagnostic Radiochemistry 
Modern medicine has contributed significantly to the drastic increase in life expectancy 
in the last 100 years. New and better drugs keep prolonging our lives by curing 
previously untreatable diseases, but the early diagnosis and detection of malignancies 
as well as the monitoring of therapy progress also plays a crucial role in better 
treatment outcomes. Diagnostics is a very widespread field ranging from optical 
observations by doctors to intricate detection of specific molecules in the bodies of 
patients. Since its discovery, radioactivity represented an interesting potential tool to 
investigate patients bodies as the primary radiation from γ-decays and the secondary 
radiation from β+-decays penetrate human tissue easily and without causing significant 
damage. From the discovery of radioactivity by Henri Becquerel in 1896 it only took 
four decades until the first use of radioactive material (32P) in animals in 1935.19 The 
radionuclide iodine-131 was first produced in 1938 and its use as the first radioactive 
diagnostic tool in humans was published in 1939.20, 21 Today, a vast array of 
radionuclides are used or being investigated for their use in clinical diagnosis.22-24 For 
reasons that will be highlighted in the following chapters, 99mTc has become the most 
widely applied radio-isotope. 
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1.2.2 The Rise of 99mTc  
By accounting for over 80 % of all diagnostic nuclear medicine studies, 
technetium-99m is the most widely used radionuclide today.25, 26 Originally discovered 
by Perrier and Segré in 1937 and isolated by deuteron bombardment of molybdenum, 
technetium-99 (from the greek “technètos” = artificial) was the first artificial element 
made by man.27 It’s relatively shortlived isomer 99mTc was reported by Seaborg and 
Segré in 1939.28 The dominance of 99mTc in the field of diagnostic nuclear medicine 
can be attributed to its many favorable properties. The radionuclide decays to 99Tc with 
a half-life of 6 hours, emitting a 141 keV gamma photon with 89% abundance.29 This 
is ideal for the gamma cameras used in nuclear medicine. The half-life allows for a 
long enough signal detection, while also ensuring that the patients are only exposed 
to the radioactive radiation for the minimum time.  
Another decisive factor in the success of 99mTc is its cost. Most other radioisotopes 
require a nearby synchrotron for their generation and therefore have a significant price-
tag. Technetium-99m on the other hand, can be obtained continuously during multiple 
weeks from so-called generators where 99Mo (t1/2 = 66 h) continually decays into the 
desired isotope. The development of these generators in the Brookhaven National 
Laboratory (BNL) in 1950 allowed the 99Mo to be packaged as [99MoO4]2- and shipped 
in the form of an alumina column, from which the 99mTc can easily and safely be eluted 
as [99mTcO4]- in sterile saline with high radionuclide purity.30 The 99Mo on the other 
hand is conveniently a side product of nuclear fission and is readily available and 
transportable. However, the current global movement away from nuclear energy is 
threatening this constant supply stream and other production methods might have to 
take over in the near future.31-33 An additional advantage of 99mTc over its competitors 
is its diverse chemistry. Being a group VIIB element, it exists in 9 different oxidations 
states which opens up a plethora of possibilities in terms of geometries and structures 
available.27  
The favorable properties of 99mTc are validated by its unparalleled success in the 
clinics. As of now, a total of 67 imaging agents based on 99mTc have been approved 
by the FDA, of which 28 are still in use today.34 The two most successful agents, 
cardiolite and myoview (Figure 2), are both heart imaging agents and accounted for 
  
 
25 
 
over 600 million USD in revenue in 2007. However, since 2001, only two new kits 
based on molecular entities have been approved.35 
 
 
Figure 2. Structure of the two 99mTc “blockbusters” cardiolite and myoview. 
 
1.2.3 The [TcCO3]+ Kit 
In the early 2000s, Alberto et al. reported the convenient synthesis of 
[99mTc(OH2)3(CO)3]+ in one step from [99mTcO4]-.36, 37 This procedure, and it’s 
subsequently commercially available kit-formulation, promised a re-invigoration of the 
somewhat stagnant field. This new Tc(I) building block offered both a stable backbone 
through the three carbonyl ligands, as well as the possibility for chemical diversity 
through the labile aquo ligands. In subsequent years, a myriad of new technetium 
tricarbonyl complexes were synthesized and reported.26, 38 The fact, that the 
corresponding “cold” rhenium analogue can usually readily be prepared, significantly 
facilitates the characterization of the new 99mTc compounds. Generally, the technetium 
concentration available through 99Mo generators is too low for most analytical 
techniques such as mass spectrometry (MS), nuclear magnetic resonance (NMR) 
and/or X-ray crystallography. Hence, a HPLC-coinjection of both the 99mTc and the 
beforehand completely characterized Re-complex is commonly accepted as proof-of-
identity. Despite the large number tricarbonyl-based 99mTc(I) complexes that have been 
prepared and studied, to date only one tricarbonyl based compound has made it to 
clinical trials in 2010. 99mTc-MIP1404 consists of a hydrophyilic tridentate chelator that 
coordinates the 99mTcCO3-core attached to a short tripeptide (Figure 4). This tripeptide 
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is a high affinity binder for the prostate specific membrane antigen (PSMA), a receptor 
which is highly overexpressed on prostate cancer cells.39 It completed phase III clinical 
trial testing in late 2017 with very encouraging results, suggesting that there is indeed 
a future for 99mTcCO3-based radiopharmaceuticals when a “rational design” approach 
is followed.40 
In summary, the rich chemistry of technetium with its many oxidations states has been 
extensively explored since its discovery in 1937. Its favorable properties and low cost 
have made it the “work-horse” of clinical imaging. While supply problems and a lack of 
new imaging compounds in the pipeline are looming over its spotlight, the very recent 
success of the tricarbonyl-based prostate imaging agent 99mTc-MIP1404 may just be 
the spark needed to re-ignite the field of 99mTc chemistry. 
 
1.3 Principles in the Design of Nuclear Imaging Probes 
One of the most important goals when designing an imaging probe, is to achieve a 
high signal-to-noise ratio between the area of interest that is to be imaged and the rest 
of the patient. Hence, the focus of radio-imaging research has more and more shifted 
towards the development of more target-specific compounds. In general, two 
approaches are possible: the pendent approach and the integrated approach. 
 
Figure 3. Schematic overview of the pendent and the integrated approach in the development 
of a nuclear imaging probe. 
 
1.3.1 The Pendent Approach 
The modular nature of the pendent approach makes it the synthetically more 
straightforward and hence also the more pursued one. The well-understood and vast 
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amount of different small chelators available, as well as a large array of chemical tools 
for coupling the chelator to the bioactive and/or targeting functions are the main drivers 
of this approach. Over the years, hundreds if not thousands of 99mTc-chelates were 
conjugated to a bioactive and/or targeting function. The results of these studies are 
summarized in numerous excellent reviews.41-51 Giving a complete summary of these 
results would exceed the scope of this thesis. Hence an overview on targeted 99mTc-
complexes that have been approved for clinical use or have recently entered clinical 
trials is given.  
The last approval of a “pendent imaging agent” based on technetium-99m dates back 
to the year 2000. [99mTcO]depreotide (NeoTect®) is a somatostatin receptor binding 
sequence containing a cyclic hexapeptide connected to a tetrapeptide which forms a 
coordination complex with a technetium(V) core by coordinating with three amide 
nitrogens and a cysteine-derived sulfur (Figure 4). The compound behaved as a 
somatostatin mimic in vivo and was successfully used in the differentiation of malignant 
and benign lung tumors. However, due to poor commercial performance, the 
compound was withdrawn from the market in 2010.48, 52  
The only other clinically approved technetium-labeled targeting peptide is 
[99mTcO]apcitide, which was approved as AcuTec® by the FDA in 1998. Analogous to 
NeoTect®, the technetium core is coordinated by a short peptide sequence (namely 
the C-terminal Gly-Gly-Cys), which is part of the native sequence of the 13 amino acid 
peptide apcitide (Figure 4). This compound was used for the detection and localization 
of deep vein thrombosis but has since also been discontinued.52 The commercial 
failure of these two compounds might be one of the reasons why the field has been 
rather unfruitful in the last two decades. Only five 99mTc compounds have been in active 
clinical development since the turn of the century (Figure 4).  
The elevated metabolic rate of cancer cells has the downstream effect of increased 
folate-dependent enzyme expression in certain types of cancer.53 Thus, both 
therapeutics and diagnostic agents targeting folate receptor (FR) over-expressing cells 
have been widely explored in the current literature and some drugs are already used 
in clinics today. 99mTc-EC20 (99mTc-etarfoladite) is an effort to use FR-positive cells as 
an imaging target with 99mTc (Figure 4). The Tc(V)-based complex was first reported 
by Leamon et al. in 2002 and displayed promising tumor accumulation in a mouse 
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model.54 The imaging agent candidate first entered human clinical trials the same year 
and has since completed multiple phase I & II studies. A phase III trial was suspended 
in 2015 for unknown reasons. However, at least two further phase II studies are 
currently ongoing, underscoring the continued interest in folate-mimicking nuclear 
imaging agents.55  
 
 
Figure 4. Overview of 99mTc-based radiotracers previously approved for clinical use or 
currently in clinical trials. 
Another promising target in cancer targeting is integrin αvβ3. Briefly, integrins are 
membrane-attached receptors and are involved in many fundamental cellular 
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processes ranging from cell-matrix adhesion to stress response. The reason integrins 
are interesting for cancer imaging is the observation that certain classes of them are 
overexpressed on tumor cells.56 The integrin αvβ3 is involved in tumor angiogenesis 
and metastasis, usually the stage where a cancer transitions from a minor malignancy 
to a life-threatening disease. It is therefore not surprising that significant efforts have 
been made to develop both the drugs to target these proteins as well as the tools to 
monitor the effect of the latter. Cyclic, so-called RGD (Arg-Gly-Asp) peptides have early 
been shown to be potent inhibitors of αvβ3 and to induce apoptosis.57 Since αvβ3 is 
located on the cell surface it was hypothesized that higher binding affinity could be 
obtained with multimeric cyclic RGD peptides.58 The verification of this idea led to the 
development of a range of multimeric RGD-based technetium imaging agents 
culminating in the clinical candidate 99mTc-3PRGD2 (Figure 4). The separation of a 
cyclic RGD-peptide dimer and the metal core by a PEG4 linker lead to significantly 
enhanced tumor targeting.59 The compound has entered early phase I clinical trials for 
diagnosis of esophagus, breast, and lung cancer as well as for rheumatoid arthritis. In 
the case of lung cancer, preliminary results indicate that in patients with suspected 
lung lesions the imaging sensitivity with visual analysis could be drastically improved. 
Unfortunately, the specificity was somewhat lower.60 More results from these early 
studies are expected in the next years and most likely the success or failure of 99mTc-
3PRGD2 will have a significant effect on the future of the field of technetium-based 
integrin imaging agents.61  
In 99mTc-EDDA/HYNIC-TOC the somatostatin mimic, octreotide, is conjugated via a 
tyrosine to the established hydrazinonicotinyl (HYNIC) linker and ligand to a 99mTc(V)-
core with ethylenediaminediacetic acid (EDDA) as the co-ligand system (Figure 4). 
Preclinical evaluation showed that the peptide retained somatostatin receptor affinity 
upon technetium coordination and the compound displayed higher tumor/organ ratios 
than the clinically approved agent 111In-DTPA.62 Early reports of small clinical studies 
further demonstrate the potential of the compound.63 Since 
2016, 99mTc-EDDA/HYNIC-TOC is in a phase II clinical trial for the diagnosis of 
neuroendocrine tumors.64 
The increased metabolism of cancer cells also leads to a higher demand for energy, 
which can be obtained, for example, in the form of glucose. Hence, many glucose-
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receptor targeting imaging agents such as the 18F agent fluorodeoxyglucose (FGD) 
have been developed (Figure 5). Though highly successful and widely applied in 
clinics, the use of 18F comes with several disadvantages such as its short life, long 
synthesis times, limited availability and high cost of the isotope. Hence the demand for 
a 99mTc-based glucose-mimic remains high. 
 
Figure 5. Chemical structures of native glucose and FGD. 
99mTc-ECDG is currently the clinically most advanced of these candidates (Figure 4). 
The oxo-Tc(V) core is coordinated by a ethylenedicysteine moiety (EC) which in turn 
is functionalized with two deoxyglucose residues (DG). In vitro experiments showed 
that 99mTc-ECDG displayed higher tumor/brain and tumor/muscle uptake ratios than 
FDG.65 The compound entered clinical trials for non-small cell lung cancer in 2010 and 
a phase III trial was started in 2017. Additionally it is also being investigated in a further 
phase II study for imaging coronary artery disease.66 A 99mTc based FGD-replacement 
appears close to commercial clinical use. This would be a significant contribution to 
the field of nuclear medicine due to the easy, widespread availability and relatively low 
cost of the radioisotope. 
All the compounds described to this point are built around a 99mTc(V)-core. The 
previously mentioned [Tc(I)CO3]+-core seems to be out of favor. Clinical candidate 
99mTc-MIP1404 might be able to reverse this trend. As mentioned in the previous 
chapter, the structure consists of a PSMA-targeting tripeptide connected to a 
hydrophilic chelator and the technetium tricarbonyl core. The first clinical trial for 
prostate cancer imaging with this compound was started in 2010. The compound has 
now passed four phase I trials as well as a follow-up phase II trial.64 A very recent 
report on the ongoing phase III study indicates that 99mTc-MIP1404 has a high 
probability of detecting PSMA-positive lesions and medical professionals could 
recommend treatment adjustments for 74% of the screened patients.67 
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Altogether, even though thousands of molecules have been synthesized, only a 
handful of them made it into human studies. This is of course partially a reflection of 
what is commonplace in the drug-discovery world. But it also seems that the full 
potential of 99mTc-chemistry has not been exploited yet, especially with regards to the 
[Tc(I)CO3]+-core. 
 
1.3.2 The Integrated Approach 
One can strive to design the imaging unit in such a way, that its physicochemical 
properties allow a targeted accumulation without further intervention. In practice, even 
with the vast knowledge of chemistry, drug design, pharmacology and biochemistry 
available today, such a de novo approach is of insurmountable difficulty. The next best 
thing to designing a completely new molecular entity is to start from something that is 
known. In what was coined as the “integrated approach”, a known molecular entity with 
established biological distribution and/or activity is taken as a starting point (Figure 6). 
The radionuclide is then rationally introduced into the lead compound with a minimum 
amount of chemical alteration. A compound where the integrated approach has 
probably been applied with unsurpassable simplicity is the previously mentioned 18F 
derivative of glucose FDG (Figure 5).68, 69 Of course, the inclusion of a radiometal into 
an active structure poses a considerably more difficult challenge. The example of 
ferroquine (and to a lesser extent the tamoxifen analogue ferrocifen70) has 
demonstrated that it is possible to very elegantly introduce a metal into a bioactive 
structure without tampering with its native activity, even going as far as introducing 
additional mode of actions.16  In the realm of 99mTc, only a handful of such attempts 
have been reported, as the synthetic obstacles towards an integrated approach are 
often of prohibitive difficulty.  
One of the first examples for the implementation of the integrated approach was 
reported in 1992 by Chen and Janda. In their communication they described the 
synthesis of a water-stable adenosine-99mTc(V) complex (Figure 6), which displayed 
binding affinity to ribonuclease comparable to the bench-mark vanadate complexes.71  
These results together with the more in-depth studies with the respective Re(V) 
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complex indicate that the introduction of the oxometal-moiety does not  have a 
deleterious effect on the native properties of the adenosine.72  
Neurotransmitter receptors have long been in the spotlight as there is still a lack of 
appropriate technetium brain imaging agents. In 1994, Lever et al. described the 
preparation of a 99/99mTc-complex based on the very potent muscarinic acetylcholine 
receptor (mAChR) inhibitor I-QNB (Figure 6). Although the technetium-99m compound 
did accumulate in the brain, the in vitro binding affinity to mAChR was found to be too 
low to warrant further investigations.73 Nevertheless, this work demonstrated that 
technetium-analogues of neuroreceptor ligands could be prepared in an integrated 
way. In another example, Brandau and co-workers synthesized 99mTc compounds 
inspired by the potent nonspecific antagonist spiperone in 1995 (Figure 6). 
Unfortunately, their complexes showed poor brain uptake in in vivo experiments. 
However, the authors did observe significant uptake in heart, kidney, and lung tissues, 
which also contain high concentrations of dopamine receptors. This indicates that while 
binding the appropriate target, their complexes may just not have been able to cross 
the blood-brain-barrier (BBB).74  
A synthetically very creative approach was pursued by the group of Katzenellenbogen. 
Systematically, they prepared a series of estradiol mimics containing an oxorhenium 
species (representative example shown in Figure 6).75-77 The initial stability issues 
could be overcome with more refined compounds, but all of them showed only poor 
binding affinities for the estrogen receptors and were rather lipophilic in nature. 
Although it is an elegant execution of the integrated approach, the geometric and 
electronic differences between the native ligand and the oxorhenium complex were 
probably too stark in this case.  
In recent years even fewer studies on the integrated approach have been reported. It 
is likely that lack of success as in the previously mentioned examples resulted in a shift 
of focus towards the synthetically more feasible pendent approach. Though in 2006, 
Caiyun et al. described a further attempt of integrating oxometal(V) species of rhenium 
and technetium-99m into a σ-receptor ligand framework (Figure 6).78 In vivo 
biodistribution studies showed moderate tumor uptake suggesting that further 
modifications to the chelate-structure could generate higher affinity tumor imaging 
agents.  
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Figure 6. Overview of selected applications using the integrated approach. 
Remarkably, as with the pendent approach, most hitherto published examples were 
based on the oxometal(V) synthon of rhenium and technetium. Recently, our group 
has turned its attention to Re(I) and 99mTc(I) complexes of the type [(Cp-R)M(CO)3] and 
we reported on their synthesis as selective human carbonic anhydrase (CA) 
inhibitors.79 The structure of the complexes is very similar to the structure of Indisulam 
(E7070), one of the most potent sulfonamide CA inhibitors ever reported.80  Both the 
rhenium and 99mTc complexes could be readily obtained and the binding affinity of one 
rhenium complex was found to be higher than the current standard.79 
Mimicking the structure of a compound with known bioactivity opens up the possibility 
for a theranostic system with rhenium and technetium-99m. In this case, the 99mTc 
complex is the diagnostic tool. Additionally, the rhenium complex, which can be 
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obtained in macroscopic quantities, is used as the therapeutic entity with a homologous 
structure to the radiotracer. Effectively both diagnosis and therapy can then be 
achieved with the same ligand framework. Since the integrated approach has not been 
explored very extensively yet it is not surprising that a theranostic system with Re and 
99mTc has also not been investigated yet. 
 
1.3.3 Cyclopentadiene and 99mTc, a Perfect Match? 
It is undeniable that the implementation of the integrated approach is a synthetically 
daunting task. This is also reflected by the very limited examples that are found in the 
current literature compared to the myriad of examples on the pendent approach. 
Nevertheless, the elegance of the approach remains alluring. The small 
cyclopentadiene ligand as the chelating unit has early-on caught the eye of several 
researchers, including the Alberto group. Cyclopentadiene (Cp) is most famously 
known for its use in the synthesis of ferrocene, one of the most iconic compounds of 
organometallic chemistry.81, 82 Since then, the field of Cp-chemistry has highly 
diversified with complexes with nearly every element having been reported. Scifinder 
lists almost 4000 publications with the key-word “cyclopentadiene” for the last five 
years, indicating that it is still a highly relevant compound today. Already in 1962, the 
first 99Tc-Cp complex was prepared through neutron bombardment of the analogous 
molybdenum compound.83 But it took another 30 years until the corresponding 99mTc 
could be synthesized by Wenzel et al. in 1992.84 In 1998, Katzenellenbogen and 
coworkers reported the “double ligand transfer” (DLT) reaction for {(ƞ5-C5H5)99mTc and 
{(ƞ5-C5H5)Re}. The previously mentioned octreotide and estradiol were successfully 
conjugated to a 99mTc moiety via a CP-ligand along the DLT approach.85, 86 However, 
the scope of the DLT reaction is limited by the accessibility of the corresponding 
ferrocene precursor and the high temperatures required to transfer the functionalized 
Cp and the CO ligands to 99mTc.  
All these approaches have the sensitivity of the Cp-precursors and a limitation in 
biomolecules in common. Nonetheless, the Cp-ligand remains an interesting ligand 
due to its small size, low-molecular weight and innocence towards the metal center. 
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Additionally, the complexes formed with the fac-[M(CO)3]+ core are very stable and  
neutral in charge. In practice, two major problems remain to be solved: 
1.) The low water solubility of simple Cp-ligands prevents its use in the synthesis of 
radiopharmaceuticals with 99mTc, as these syntheses must be carried out in 
aqueous solutions. 
2.) The number of synthetic routes available to Cp-ligands to either be conjugated or 
integrated to/into a bioactive and/or targeting function is very limited. 
In the last years, the Alberto group has worked towards addressing these issues of 
Cp-ligands. The first milestone was the development of a  convenient synthesis of 
mono-functional complexes of the type [(Cp-R)99mTc(CO)3] in one step from 
functionalized “Thiele’s acid” (the Diels-Alder dimer of HCp-COOH) and 
[99mTc(OH2)3(CO)3]+ (a direct “one-pot” reaction from [99mTcO4]- is also possible).87, 88 
In further work, a bifunctional, water-soluble and stable sodium salt of the form 
C5H3(COOR)2 was prepared.89 
 
 
 
 
 
  
  
 
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
37 
 
2. Objectives 
The goal of this PhD thesis is the development of a synthetically versatile Cp-ligand 
synthesis and its application to both pendent and integrated approaches (Figure 7). 
The Cp-ligands should be easy to synthesize in useful quantities as well as air-, water- 
and temperature-stable. They should possess multiple sites for functionalization and 
ideally their physicochemical properties can be manipulated through the 
insertion/modification of functional groups. Finally, their respective Re and 99mTc 
complexes should be synthetically accessible. In the case of 99mTc the synthesis of the 
Cp-complexes has to proceed at tracer-level concentrations of metal (nM), in water 
and within short reaction times. 
In a second step, the developed Cp-ligands and their complexes are to be implemented 
into a model pendent approach by conjugating a biological targeting unit to the system.  
The final goal is to use the versatility of the Cp-platform to prepare a CpM(CO)3 
compound that can be integrated into a known bioactive molecule in a way that the 
rhenium complex could be used for therapy and the technetium for diagnosis. 
 
Figure 7. Overview of main objectives of this thesis. 
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3. Results & Discussion 
Part A: Multifunctional Cp-Complexes for the Development of 
Pendent and Integrated Theranostic Agents. 
3.1 Development of a Versatile Cp-Ligand Platform 
 3.1.1 Preface 
In 2008, the Alberto group reported the synthesis of monofunctional Cp-complexes of 
both rhenium and technetium-99m (Scheme 1).87  
 
Scheme 1. General reaction scheme towards monofunctional Cp99mTc(CO)3 complexes via a 
retro-Diels-Alder reaction. 
In a follow-on project we prepared a difunctional Cp with two ester groups in either 1,2- 
or 1,3-position from sodium cyclopentadienide. The ligands S1a and S1b could be 
obtained in gram quantities as an inseparable mixture in a 9:1 ratio. The respective Re 
and 99mTc complexes could be synthesized in both water and organic solvents and the 
ester groups could readily be cleaved off under basic conditions.89 
  
Scheme 2. Synthetic route towards 1,2- and 1,3-bifunctional CpRe and Cp99mTc-complexes 
(S2a, S2b) 
The subsequent functionalization of either the ligand or the metal complexes turned 
out more difficult than expected. Hydrolysis of the free ligands S1a and S1b, was not 
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possible under basic conditions. Furthermore, attempts at direct amide bond formation 
did not yield any detectable product.  
 
Scheme 3. Summary of synthesis attempts towards functionalization of 1,2- and 1,3-
substituted Cp-ligands and complexes. 
After complexation with rhenium, the 1,2- and 1,3-isomers of the complex were isolated 
and hydrolyzed. However, the functionalization of the latter with a model amine 
(benzylamine) only led to product formation for the 1,3-isomer (Scheme 3, 13). This 
complex could be characterized by MS, 1H-NMR and an X-ray crystallography 
(unrefined, Figure 8). 
 
Figure 8. Unrefined X-ray structure of 13 
However, since the functionalization only worked with the rhenium complex and also 
only with the minor 1,3-isomer (S2b), it became clear that a different Cp-ligand system 
was needed to further pursue the goal of multifunctional compounds. 
An unconventional synthetic route to both multifunctional Cp-ligands and complexes 
was reported by Kuninobu et al. in 2008. They found that dirhenium decacarbonyl could 
catalyze the formation of substituted Cp’s from α,β-unsaturated ketimines and α,β-
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unsaturated carbonyl compounds (Scheme 4). Addition of equimolar amounts of the 
rhenium catalyst resulted in the direct formation of the respective CpRe(CO)3 complex. 
It was also shown that the reaction was relatively substrate tolerant and different 
substituents could be introduced into the Cp-system. 90 
 
Scheme 4. General synthetic route to substituted Cp-ligands and Re-complexes reported by 
Kuninobu et al. 
Based on this information, 16 was designed as a model compound to expand the 
Kuninobu-route to poly-substituted Cp-ligands that could be functionalized further 
(Scheme 5, route A).  
 
Scheme 5. Reaction conditions: A i) conc. H3PO4, 85 °C, overnight, 32 %. ii) benzylamine, 
HBTU, DIPEA, DMF, RT, 4h, 28 %. iii) benzylamine, toluene, 170 °C, 16 h, 41 %. B i) PPh3, 
dry toluene, RT, 16 h, 91%. ii) DCM, NaHCO3 (10%), RT, 30 min, 77%. iii) 2,3-butanedione, 
DCM, RT, 24 h, 55%. iv) aniline, toluene, 175 °C, 16 h, 62%. 
Starting from commercially available starting materials the first step was an aldol 
condensation according to a literature procedure (14).91 In the next step the free 
carboxylic acid (which was found to hinder the imine formation in the following step) 
was “protected” through an amide bond formation with benzylamine forming 15. 
Finally, the imine was formed under Dean-Stark conditions yielding compound 16 as 
characterized by 1H-NMR.  
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Unfortunately, 1H-NMR-NOE experiments showed that the compound was present 
exclusively as the cis-isomer and not the required trans-isomer (Figure 9).  
 
Figure 9. 1H-NMR-NOE spectra showing an NOE between the cis-lying proton (2) and methyl 
group (3), which would not be observable in the trans-isomer. 
An alternative synthetic route was hence devised (Scheme 5, route B). Compounds 17 
and 18 could be prepared according to literature procedures.92, 93 The imine 19 could 
then be obtained using the same Dean-Stark conditions as for 16. Unfortunately 
reacting 19 under the reported conditions to form the corresponding rhenium complex 
was not successful.  
Another interesting route to poly-substituted Cp-ligands was published very recently 
by Ichitsuka et al. They reported a nickel-mediated [3+2] cycloaddition of 2-
trifluoromethyl-1-alkenes with alkynes yielding multifunctional Cp’s containing a 
fluorine atom.94 Due to the relative novelty of the publication, a reproduction of a 
sample reaction was first attempted (Scheme 6). Following the literature procedure, 
product 20 could indeed be isolated and characterized by 1H-NMR. 
F3C O
O
F
O
O
i)
20
 
Scheme 6. Reaction conditions: [Ni(cod)2], PCy3, toluene, 23 °C, 48 h. 
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Multiple attempts to expand the synthesis with dimethyl acetylenedicarboxylate as the 
alkyne yielded no desired product. It is possible that the proximity of the ester functions 
to the alkyne altered its electronical properties in a detrimental way. Introducing an 
alkyl chain between the alkyne and the ester functions could potentially solve this 
problem. Unfortunately, the synthesis suffers a number of other draw-backs. Firstly, 
the nickel cyclooctadiene precursor is highly air and temperature sensitive and hence, 
reactions have to be carried out in a glovebox. Also, the nickel compound is expensive 
(177 CHF for 2 g from Sigma-Aldrich/Merck) and used in stoichiometric amounts in 
these reactions, making them hard to scale up. 
Finally, both mentioned approaches were abandoned in favor of a third one. Building 
upon work reported by Hatanaka et al.95 the following manuscript was put together and 
submitted for publication. 
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3.1.2 Manuscript 
Multi-functional Cyclopentadiene as a Scaffold for Combinatorial 
Bioorganometallics in [(η5-C5H2R1R2R3)M(CO)3] (M = Re, 99mTc) 
Piano-stool Type Complexes 
Angelo Frei,[a] Bernhard Spingler[a] and  Roger Alberto*[a] 
[a]
 Department of Chemistry, University of Zürich, Winterthurerstr. 190, CH-8057 Zürich 
Switzerland 
Introduction 
The combination of organometallic complexes with biologically active, organic 
molecules or fragments has become a strongly researched (sub)field in medicinal 
inorganic chemistry. Bioorganometallic complexes benefit from a series of properties 
different from typical coordination compounds. They can form integrated structures in 
pharmaceutically active lead structures such as the tamoxifen/ferrocifen couple70, 
exert cytotoxicity through metal-mediated interactions with proteins or nucleic acids as 
in the case of the [(η6-arene)Ru]2+ fragment96 or form  de novo parts in existing 
inhibitors as in bioorganometallic kinases for instance.97 Ferrocene (Fc) probably 
represents the main fragment in this field and the cyclopentadiene (Cp) ligand plays 
an important role in all Fc-based bioorganometallic concepts. The majority of Cp-based 
bioorganometallic complexes comprises one additional functionality, a pendent 
targeting moiety, a cytotoxic or otherwise biologically active agent. Cp-ligands are not 
only found in ferrocene but also in Re/99mTc piano-stool type complexes. We reported 
recently two examples in which such Re/99mTc complexes were conjugated to carbonic 
anhydrase inhibitors or cytotoxic doxorubicin.79, 98 Since biological activities of group 7 
piano-stool complexes are rather overall structure- than metal-based, a combination of 
rhenium and 99mTc complexes is a complementary strategy in theranostics; the 
rhenium complex for therapy and its 99mTc homologue for imaging. This combination is 
interesting since 99mTc is still core in Single Photon Emission Tomography (SPECT)42, 
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99-101
 due to its half-life (t1/2 = 6.02 h), decay characteristics and, of growing importance, 
its price.29, 35, 102, 103 Since 2001 only a limited number of new 99mTc imaging agents 
have been introduced into clinical routine. This mirrors the challenges encountered 
when aiming at introducing a well-defined transition metal complex into a targeting 
molecule in quantitative yields and in one step.104-106 The preparation of fac-
[99mTc(OH2)3(CO)3]+ was a step in this direction and a wide variety of complexes based 
on the fac-[99mTc(CO)3]+ core have been explored since.36, 37, 79, 107, 108 Recently, a 
PSMA targeting biovector made it into phase III clinical trials.109-113 The general 
concept of targeted radiotracers is the conjugation of a receptor binding molecule with 
a ligand for coordination to the respective metal center or complex fragment, also 
referred to as the bifunctional ligand approach.  
Current pharmaceutical research aims at combining multiple modalities such as 
targeting and cytotoxicity, in one single molecule. However, this approach has not yet 
found the consideration it deserves in bioorganometallic chemistry, probably due to the 
fact that the modalities should typically be conjugated to one single ligand. This 
concept is further hampered by the fact that a multi-modality 99mTc complex must be 
synthesized in one single step from [99mTcO4]- and in water.  
Cp-ligands represent a scaffold to which multiple functionalities can be bound 
according to elaborate organic synthetic strategies. In addition, Cp is small, has a low 
molecular weight and is innocent. After coordination to the fac-[M(CO)3]+ core, the 
complexes are highly inert and of zero charge. Our group reported a one-pot synthesis 
of singly functionalized {(η5-C5H5)99mTc} complexes in water under moderate 
heating.114, 115 By derivatizing di-cyclopentadiene “Thiele’s acid” through amid bond 
formation, chemically stable and functionalized Cp-precursors and complexes of the 
type [(η5-C5H4R)99mTc(CO)3] became accessible.79, 87, 116 The bifunctional ligand 
approach, with or without Cp, does not immediately comprise the option of combining 
multiple, different or equal, targeting vectors. Multimeric molecular imaging agents 
would offer many new opportunities such as targeting of different sites, enhancing 
binding affinities and/or addition of a cytotoxic payload. Only a few multimeric 
molecular 99mTc imaging agents have been reported thus far, mainly by Liu et al. on 
integrin αvβ3 targeting multimeric cyclic-RGD peptide oligomers.117, 118 For Cp, all 
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approaches described above are synthetically incompatible with multi-functionalization 
as required for multimeric targeting agents.  
We reported recently the synthesis of water soluble Re/99mTc complexes, comprising 
a Cp-ligand for coordination to the {99mTc(CO)3}+ core and two carboxylato groups in 
1,2-position for potential conjugation to two biomolecules.89  
In this study, we extend the flexibility of the multi-functional Cp-approach to a 
C5H3R1R2R3-type scaffold, which can be mono- (Figure 10A) or homo (Figure 10B) and 
hetero (Figure 10B) di-functionalized with respect to targeting molecules or other 
biovectors. The choice of biovectors or molecular functionalities attached to the central 
Cp-core is highly flexible which allows for the discovery of new imaging compounds. 
The ligands as such do not undergo Diels-Alder dimerization and are water and air-
stable at room temperature and up to 220 °C. Mono-, homo- and hetero-
functionalization of the ligand was demonstrated with model vectors on both the free 
ligand and the “cold” rhenium complexes. The corresponding 99mTc complexes could 
be prepared in a one-pot reaction from [99mTcO4]- and in high radiochemical yields. 
Altogether we present a ligand platform that allows for the synthesis of tetra-functional 
Re/99mTc complexes. Combinatorial variation of all pendent groups will lead to a wide 
variety of structurally different but functionally identical matched-pair complexes. 
 
Figure 10. Overview of the different poly-modalities accessible with the new multifunctional 
Cp’s. 
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Results and Discussion 
Design of Cp-Ligands. 
The syntheses of the multi-functional Cp-ligands in this study as shown in Figure 10 
were based on a procedure by Hatanaka et al.95. A variety of triphenyl-phosphonium 
salts with different substituents R1 react with α-bromo-ketones under mild conditions 
to form triply substituted Cp’s in good yields. The most general concept towards such 
multi-functionalized Cp's is shown in Scheme 7 (top). The carboxylate group directly 
attached to the Cp-ring (R4, green in Scheme 7) and the terminal carboxylate in R2 
(blue) allow for later conjugation of two equal or different biological functions V1 and 
V2. This synthetic approach thus enables a versatile alteration of three functionalities; 
R1 for guiding the chemical properties and the two carboxylate groups for conjugation 
of bioactive functionalities (Scheme 7, A and B). The original literature also highlights 
the possibility to vary R2 and to introduce further functionalities at R3, while 
modifications of R4 and R5 are also conceivable.  
 
 
Scheme 7. General synthesis of multifunctional Cp-ligands (top) and the synthetic strategy 
pursued in this study (bottom): A) variation of R1 to modify the chemical properties of the Cp. 
B) variation of the conjugated vectors (V1, V2) to modify biological properties of the Cp. 
 
We did not alter all these positions on the central cyclopentadiene scaffold but choose 
ethyl 5-bromo-4-oxopentanoate (0.1 Scheme 8) as the standard α-bromo-ketone for 
the bi-functionalization, keeping R2 thereby constant with the option of conjugating a 
biovector V2 to this position. The (CH2)2-spacer in R2 was introduced in this building 
block design to reduce interference of the terminal ester group with the reactivity of the 
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α-ketone. Furthermore, this spacer suppresses the undesired rearrangement of the 
Cp-double bond in the final ligand, as previously observed in our group in mono-
functional Cp’s with one CH2 group between Cp and the ester group. The ester group 
on the phosphonium building block (R4, green in Scheme 7) was also kept constant 
but will enable the conjugation of a 2nd bioactive moiety V1 to the Cp-scaffold after 
cyclization. In its essence, the approach towards multi-functionalized Cp derivatives 
focuses on the building block A in Scheme 7, prepared from ethyl 5-bromo-4-
oxopentanoate and phosphonium salts with a methyl (1a), a phenyl (4a) and a methoxy 
(6a) group as R1, red in Scheme 7 to show that both electron donating and withdrawing 
groups can equally be bound to the Cp-ring. Introduction of V1 and V2 will lead to the 
trifunctional Cp derivatives as shown with B in Scheme 7. We suggest that Cp 
derivatives of type B can equally be applied to other metal centers such as iron, to 
make corresponding ferrocene derivatives.  
 
Synthesis and Characterization. 
The ligands 1a, 4a and 6a represent the cores of the later trifunctional Cp-systems. 
These precursors were synthesized following the reported procedure with minor 
changes to improve yields and isolations (see Supplementary Information for details).95 
Notably, the radical brominations of 1.1, 4.1, and 6.1 (Scheme 8) to yield 1.2, 4.2 and 
6.2 were carried out under microwave conditions in less than 15 min (30s at 85 °C for 
6.1). The harmful solvent CCl4 could be replaced by methylacetate without loss of 
performance. Subsequent reactions with triphenyl-phosphine and cyclizations with 5-
bromo-4-oxopentanoate lead straight to the Cp-ligands 1a, 4a and 6a in moderate to 
good yields and in up to gram quantities after purification by silica column 
chromatography. 
The rhenium complexes 1b, 4b and 6b with all three Cp-derivatives were obtained by 
refluxing the respective ligand 1a, 4a and 6a with Re2CO10 for multiple days in o-xylene 
(Scheme 9). Under microwave conditions, the reaction solutions were heated to 220 °C 
and the reaction time reduced to 15 min as described in the supplementary information 
without loss of yields. For 1b quantitative conversion was observed and no purification 
was necessary. Complexes 4b and 6b were purified by column chromatography on 
silica. Ester hydrolysis to 2b, 5b and 7b was achieved under basic conditions by either 
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refluxing overnight under basic conditions or by microwave heating at 120 °C for 15 
min.  
 
Scheme 8. Synthetic route to the Cp-ligands 1a, 4a, 6a. Reaction conditions: a) Br2, MeOH, 
0 °C, 24 h, 23%. b) cat. H2SO4, EtOH, reflux, overnight, 87%. c) NBS, cat. AIBN, MeOAc, MW; 
110 °C, 15 min (1.2, 83%); 110 °C 12 min (4.2, 97%); 85 °C, 30 s (6.2, 73%). d) PPh3, dry 
toluene, 25 °C, 24 h (1.3, 84%; 4.3, 65%; 6.3, 54%). e) 0.1, DCM/sat. NaHCO3, 25 °C, 48 h 
(1a, 66%; 4a, 27%; 6a, 23%). f) Trimethoxymethane, H2SO4, 25 °C, 25 h, 82%.  
 
Bis-homo functionalization of rhenium complexes: Complexes 2b, 5b and 7b are 
the precursors for introducing two identical functionalities, either for targeting of for any 
other interaction with biological modalities. To demonstrate these possibilities and for 
preparing rhenium model complexes for later comparison with the 99mTc homologues, 
two molecules of benzyl-amine were coupled to the two carboxylate groups in 2a. 
Standard peptide coupling was achieved with the reagents Hydroxybenzotriazole 
(HOBt) and 1-Ethyl-3-(3-dimethyl-aminopropyl)carbodiimide (EDC) at room 
temperature (Scheme 9). The products were then purified by preparative HPLC and 
fully characterized by NMR, HPLC and high resolution ESI-MS. For complexes 2b and 
3b single crystals suitable for X-ray diffraction were obtained by slow evaporation of 
methanolic solutions of the compounds. ORTEP presentations for these two 
complexes are given in Figure 11. 
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Scheme 9. Synthetic route towards homo-functionalized Re and 99mTc complexes. Reaction 
conditions: a) Re2CO10, o-Xylene, MW, 220 °C, 15 min (1b, 76%; 4b, 83%; 6b, 44%). b) NaOH, 
MeOH, MW, 120 °C, 15 min (2b, 68%; 5b, 92%; 7b, 48%). c) benzylamine, HOBt, EDC, DMF, 
25 °C, 24 h, (3a, 38%; 3b, 16%) d) [TcO4]-, sodium boranocarbonate, sodium tartrate, sodium 
tetraborate, H2O, MW, 120 °C, 30 min.  
 
Bis-hetero functionalization of the Cp-ligand 1a: To assess the full potential of this 
approach and to open a scope towards two different functions V1 and V2, thus bis-
hetero functionalized Cp-ligands and complexes, the individual carboxylato groups 
must be conjugated stepwise to biovectors. We exemplify this strategy with the Cp 
ligand 1a, which comprises the methyl group at the R1 position. The first mono-
functionalization was achieved by hydrolysis of 1a with slightly less than one equivalent 
of NaOH, yielding exclusively 8a (Scheme 10). One could expect a statistical 
distribution of hydrolysis at both ester functions but the one at the R2 position is 
obviously more susceptible, leaving R4 untouched. Subsequent amide bond formation 
under the previously mentioned conditions gave 9a in good yields. By further and 
careful tuning of the reaction conditions, 9a could selectively be hydrolyzed to 10a. 
Reaction times longer than 5 min and pressures over 5 bar usually resulted in 
decomposition of the compound. For subsequent bis-hetero-functionalization, we 
chose O-tbutyl-L-phenylalanine to demonstrate that our approach is substrate tolerant 
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with the option of extension to e.g. peptides. Along a standard peptide bond formation 
strategy (see experimental section), 10a was converted into 11a, containing two 
different functionalities on the Cp-ring. 
 
Bis-hetero functionalization of the rhenium complex 2b: Unlike the Cp-ligand 1a 
itself, selective mono-hydrolysis of 1b was not possible. Addition of one equivalent of 
NaOH and subsequent heating gave a statistical mixture of ester-hydrolyzed products. 
Thus, to accomplish the rhenium complex 8b, a direct reaction between the mono-acid 
ligand 8a and Re2CO10 in DMF under microwave irradiation was performed. The 
obtained crude mixture was directly reacted under standard peptide coupling 
conditions to give 9b after purification by preparative HPLC (Scheme 10). Complex 9b 
was then easily further hydrolyzed and functionalized with O-tbutyl-L-phenylalanine, 
yielding 11b after preparative HPLC in 26% yield. The tert-butyl protecting group of 
11b could be cleaved by treatment with TFA in DCM at 80 °C, yielding 12b as a model 
for the later 99mTc complexes. The chiral center in the attached amino acid together 
with the chiral planarity of the asymmetric Cp-ligand leads to the formation of two 
diastereomers (see Figure 69). This was confirmed by the observation of two identical 
sets of NMR signals in both 1H and 13C NMR spectra of 11b and 12b (Figure 67-68). 
All compounds were fully characterized by NMR, HPLC and high resolution ESI-MS.  
 
Figure 11. Crystal structures of 2b and 3b. Displacement ellipsoid representation. Ellipsoids 
are drawn at 50% probability. Important bond lengths (Å): 2b Re-centroid of Cp: 1.950(2), 3b 
Re-centroid of Cp: 1.945(3). 
 
These synthetic results clearly imply that more complex biomolecules can be 
conjugated to both, the free ligand and to the rhenium complexes themselves. For 
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rhenium, ligand 8a and complex 8b are key since they will allow the consecutive 
introduction of two different functionalities on the ligand (8a) for later labeling with 99mTc 
(vide infra) or on the rhenium complex (8b) for biological evaluation and comparison 
with the 99mTc complex. 
 
Radiolabeling with 99mTc: It is the common notion that cyclopentadiene systems, 
capable of binding in aqueous solution to the [99mTc(CO)3]+ fragment, have to comprise 
electron withdrawing groups directly on the Cp scaffold. This would sufficiently acidify 
the ring to have at least small amounts deprotonated and therefore prone to 
coordination. Accordingly, most of the approaches towards [(η5-C5H4-R)99mTc(CO)3] 
type complexes comprise a carbonyl function directly on the Cp ring.79, 87, 107 First, we 
radiolabeled the basic ligands 1a, 4a and 6a which follow this concept and should 
therefore readily react with the [99mTc(OH2)3(CO)3]+ precursor. 
 
Scheme 10. Synthetic route towards hetero-functionalized Re and 99mTc complexes. Reaction 
conditions: a) NaOH, MeOH, MW, 120 °C, 15 min. b) benzylamine, HOBt, EDC, DMF, 25 °C, 
48 h, 69%. c) i) NaOH, MeOH, MW, 120 °C, 15 min. ii) O-tertbutyl-L-Phenylalanine, HOBt, 
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EDC, DMF, 25 °C, 24 h, 26%. d) [TcO4]-, sodium boranocarbonate, sodium tartrate, sodium 
tetraborate, H2O, MW, 140 °C, 30 min. e) Re2CO10, DMF, MW, 220 °C, 15 min. f) TFA, DCM, 
MW, 80 °C, 15 min, 80%. 
 
In a two-step approach, fac-[99mTc(OH2)3(CO)3]+ was prepared and then reacted with 
ligands 1a, 4a and 6a at millimolar concentrations. Along this path, the 99mTc 
complexes 2c, 5c and 7c (Scheme 3) could all be obtained in high radiochemical yields 
under alkaline conditions and microwave heating at 120 °C for 30 min (see 
experimental part). Having shown that radiolabeling of these ligands with fac-
[99mTc(OH2)3(CO)3]+ was straight- 
forward, we attempted the direct synthesis of the 99mTc complexes (2c, 5c and 7c) 
directly from [TcO4]- in a “one-pot” approach. Mixing all components together in a vial 
and adding directly the generator eluate containing the [99mTcO4]- complexes 2c, 5c 
and 7c formed quantitatively through an improved procedure under microwave 
conditions in 30 min at 120 °C (Figure 12). We emphasize that these are conditions 
compatible with routine applications in clinics. As typical 99mTc concentrations are too 
low for standard chemical characterizations of the formed complexes by e.g. NMR, the 
accepted procedure for their characterizations is HPLC co-injection with the “cold” 
rhenium homologue and comparison of retention times (γ-trace for 99mTc, UV-trace for 
Re). Figure 12 shows the HPLC traces of the respective 99mTc complexes as obtained 
after direct preparations in quantitative yields with all three ligands from [99mTcO4]-. 
Further purification was not required. Due to the basic conditions, the ester groups 
hydrolyzed during the labelling process, wherefore co-injections were performed with 
the di-acid rhenium analogues (2b, 5b and 7b). The retention times match, 
corroborating the identity of the two homologous complexes with Re and 99mTc. The 
Cp compounds 3a and 11a bear two model functionalities V1 and V2 at positions R2 
and R4 in the basic Cp structure, conjugated via an amide to the two carboxylate 
groups. These ligands represent the basic structure for a combinatorial approach since 
essentially any two biovectors can be added at this time point. The labeling of such 
more complex systems in general and 3a and 11a in particular is an exemplary step in 
the preparation of multi-functional molecular imaging agents. Accordingly, by following 
the preparations as described above, ligands 3a and 11a could be labelled along the 
one-pot procedure directly from [99mTcO4]-, giving the corresponding 99mTc complexes 
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3c and 12c in good yields (Figure 13).  Slightly higher temperatures and reaction times 
were required. As a convenient "side effect", the tert-butyl protective group was 
concertedly cleaved of during the reaction in case of 11a. 
 
 
Figure 12. General reaction scheme for the one-pot reaction of ligands 1a, 4a and 6a with 
[TcO4]- (top). Reaction conditions: [TcO4]-, sodium boranocarbonate, sodium tartrate, sodium 
tetraborate, H2O, MW, 120 °C, 30 min. UV- and y-traces of the co-injection of the rhenium 
compounds 2b, 5b and 7b with the 99mTc compounds 2c, 5c and 6c respectively (bottom). 
Differences in retention times are due to detector separation. 
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Figure 13. UV/vis- and y-traces of the co-injection of the rhenium compounds 3b and 12b 
with the 99mTc compounds 3c and 12c respectively. Time differences are due to detector 
separation. 
Taken together, these results demonstrate the possibility to synthesize 99mTc piano-
stool type molecular imaging agents with structurally complex and multifunctional Cp 
ligands in one step and from [99mTcO4]- in a straightforward and efficient way. The 
option of altering V1 and V2 (phenyl-alanine and benzyl-amine in our case) opens a 
path towards further combinations of biologically active moieties. 
 
Conclusion 
In this work, we present versatile synthetic routes towards multiply substituted 
cyclopentadiene, which are base for the subsequent preparation of multifunctional 
ligands. Both, the physico-chemical (group R1) as well as the biological properties (V1 
and V2) can be tuned individually in the same ligand. We have furthermore shown that 
these cyclopentadiene scaffolds serve as a ligand platform in bioorganometallic 99mTc 
chemistry that allows the introduction of multiple modalities in a straightforward way. 
The ligands as such can be prepared separately with functionalities V1 and V2 
according to the targets needs. The "innocent" group R1 on the Cp scaffold influences 
the physico-chemical properties such as lipo/hydrophilicity while leaving the targeting 
properties untouched. The three representative ligands (1a, 3a, 5a) with different R2 
groups have been synthesized, fully characterized and coordinated to the fac-
[Re(CO)3] moiety. As a further proof-of-concept, 1a was both bis-homo - and bis-hetero 
functionalized with two simple biovector-models. Established amide bond formation 
chemistry for the vector conjugation, ensures its applicability to a wide variety of 
modalities. The combination of these ligands with the theranostic pair Re and 99mTc 
leads to tetra-functional complexes. Their synthesis is both straightforward, highly 
tolerant to different functionalities and, most importantly, the 99mTc homologous are 
prepared in one step directly from generator eluted [99mTcO4]-. We envision that this 
ligand platform will enable a combinatorial approach towards targeted and multimodal 
bioorganometallic complexes. 
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3.1.3 Extended Discussion of the Manuscript 
Analogous to 3b, complexes 5b and 7b were also homo-functionalized with 
benzylamine with the standard procedure (Scheme 11). The bis-amide complexes 21 
and 22 were purified by preparative HPLC and characterized by 1H- and 13C-NMR, HR-
ESI-MS and IR spectroscopy. 
 
Scheme 11. Reaction conditions: benzylamine, HOBt, EDC, DMF, 25 °C, 48 h, 21, 49%; 22, 
25 %). 
In addition to the Cp-ligands discussed in the above manuscript several other Cp-
ligands were pursued as well. An overview of the attempts is shown in Scheme 12.  
To obtain a simpler kind of Cp, the synthesis of Cp-A was pursued. Starting from 
commercially available 4-bromo-trans-crotonic acid ethyl ester, a white precipitate was 
isolated upon stirring at room temperature in dry toluene overnight with 
triphenylphosphine. The presumed 23 was dried and directly reacted with 0.1 under 
standard conditions. No product formation was observed by UPLC even after 48 h. 
Another strategy was the introduction of a third ethyl ester at the same position to 
obtain a Cp with three sites that could potentially be functionalized (Cp-B). 25 was 
obtained staring from citraconic acid in two steps following literature procedures.119, 120 
By reacting 25 with triphenylphosphine in dry toluene, the phosphonium salt 26 could 
be isolated as the precipitate and was characterized by 1H-NMR. However, the reaction 
of 26 with the bromoketone 0.1 was not successful. The route towards a 
trifluoromethyl-substituted Cp-ligand (Cp-C) had a similar fate. The radical bromination 
of (E)-3-trifluoromethyl-2-butenoic acid ethyl ester could be carried as described in the 
literature.121 The synthesis of the phosphonium salt 28 was performed under the same 
conditions as for 26, yielding a white powderish solid that could be characterized by 
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1H-NMR. Again, the final Cp-forming step to Cp-C was not successful. It seems that 
introducing a strongly electron-withdrawing group at this position prevents the ring-
forming step from occurring. Potentially introducing a linker between the ring and the 
functional group could lead to better results. 
 
Scheme 12. Reaction conditions:  i) PPh3, dry toluene, 24 h, RT. ii) EtOH, cat. H2SO4, reflux, 
overnight. iii) NBS, cat. AIBN, CCl4, reflux, 4 h. iv) PPh3, dry toluene, 24 h, RT. v) NBS, cat. 
AIBN, CCl4, reflux, 4 h. vi) PPh3, dry toluene, 24 h, RT. 
Several more approaches to introducing different functional groups at various positions 
of the Cp-ring were pursued and are summarized briefly in the following section.  
The introduction of an amine group directly to the Cp was of high interest, as the 
resulting ligand and complex would have aminoacid-like character. The first step 
involved protection of the free amine with the boc-protecting group leading to I. 
Unfortunately, all attempts to brominate both the protected as well as the free amine 
were not successful. 
Another strategy involved the modification of the bromoketone instead of the 
phosphonium salt (Scheme 13). Both the introduction of an alcohol and a protected 
amine group failed at the Cp-ring forming step. Protecting the bromoketone carboxylic 
acid orthogonally to the ester on the phosphonium salt e.g. with a tert-butyl ester group 
(VI), would have led to another path towards hetero-functionalization of the Cp. 
However, the conditions of the bromination to VII were such, that the tert-butyl group 
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was mostly cleaved off in the process. Also, this strategy was abandoned when the 
mono-hydrolysis of 1a was found to be successful.  
 
Scheme 13. Overview of explored paths to the introduction of different functionalities into the 
Cp-ligand. *This reaction was later on optimized and successful in the hands of another group-
member. 
The azide functional group and the robust “click”-chemistry developed around it 
prompted the investigation into azide-Cp derivatives. Although first steps were 
successful (VIII and IX), the synthesis of a N3-containing Cp-system could not be 
achieved (of note, Cp-N3 could recently be synthesized and characterized by a fellow 
group member).  
 
3.1.4 Outlook 
The possibilities that are accessible through the synthetic strategy to multifunctional 
Cp’s presented in this work are numerous. The recent success in the introduction of 
an azide group via the bromoketone has opened up the whole field of “click”-chemistry 
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to this system. Modifications on the two remaining sites of the Cp-ring were not 
explored within this work but could very well lead to even more versatile ligands.  
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3.2 The Pendent Approach: Synthesis and Biological Evaluation of 
Novel PSMA-Cp-M Conjugates 
3.2.1 Preface 
Having developed a Cp-ligand platform that is both versatile and can readily coordinate 
both rhenium and technetium-99m, the next obvious step was the application of the 
latter in a biological setting. We decided to start with a pendent approach and chose a 
well-established prostate specific membrane antigen (PSMA) inhibitor as the targeting 
moiety. The synthesis, characterization and in vitro evaluation of both mono- and di-
substituted Re and 99mTc complexes led to the following manuscript. 
(Note: at the time of submission, the 99mTc-PSMA binding experiments were not 
completed yet and could hence not be included). 
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3.2.2 Manuscript 
Two is Better than One. Dimeric High-affinity PSMA 
Probes Based on a [CpM(CO)3] (M = Re/99mTc) Scaffold 
Angelo Frei,[a]Eliane Fischer, [a] Bradley Childs, [a] Jason Holland[a] and Roger Alberto*[a] 
[a]
 Department of Chemistry, University of Zürich, Winterthurerstr. 190, CH-8057 Zürich 
Switzerland 
In the 21st century, one out of nine men will be diagnosed with prostate cancer during 
his lifetime. While current treatments have vastly increased the mean survival rate of 
patients, 30’000 people are still expected to die from prostate cancer in 2018 in the US 
alone.122 The most common cause for mortality in prostate cancer patients is the 
occurrence of metastases. A major factor in reducing the death toll of this disease is 
the improvement of early detection and monitoring techniques. The prostate specific 
membrane antigen (PSMA) is an extracellular receptor and a promising target for 
nuclear imaging as its overexpression is proportional to the stage and grade of tumor 
progression.123 PSMA-binding imaging agents based on 11C, 18F, 64Cu, 68Ga, 99mTc, 
111In have been reported, but so far, only 11C, 18F and 111In-based radiotracers are used 
in the clinics for prostate cancer imaging.124 These isotopes share the disadvantage of 
requiring a cyclotron for their generation and the associated limited availability and high 
cost of production compared to the cheaper and generator-available radio-isotopes 
68Ga and 99mTc. New imaging agents based on both gallium and technetium chelators 
coupled to a high PSMA-affinity Lys-urea-Glu (LuG) motif are currently in advanced 
clinical trials.40, 125 Multimeric radiotracers containing more than one binding unit are 
thought to possess higher binding affinity to membrane-proteins. This has already 
been exploited with integrin αvβ3 protein-targeted radiotracers linked to cyclic arginine-
glycine-aspartic (RGD) peptides.126, 127 Multiple studies found superior binding for 
dimeric RGD-chelates compared to their monomeric counterparts. Indeed, 99mTc-
3PRGD2 is a dimeric cyclic RGD-based imaging agent which is currently undergoing 
multiple phase I clinical trials. In the light of these promising results it is surprising that 
only little work has been done on multimeric PSMA-targeting compounds. In 2012, 
Schäfer et al. reported a 68Ga-based structure containing two LuG units that displayed 
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improved PSMA affinity, higher cell uptake and prolonged cell surface retention time 
compared to the monomeric analogue.128 To the best of our knowledge, the only 99mTc-
complexes conjugated to multiple binding units were reported by Frangioni and 
coworkers in 2007. They prepared dimeric and trimeric compounds based on a 
phosphinyl-containing PSMA-ligand. The bi- and trifunctional complexes showed 
significantly higher PSMA affinities than their monomeric counterpart.129 These 
promising preliminary results clearly indicate that there is unexplored potential in 
multimeric PSMA-targeted radiotracers. 
In this work we describe the synthesis and evaluation of a compact Re/99mTc system 
containing either one or two LuG units. By using a multifunctional cyclopentadiene (Cp) 
as both the metal-coordinating moiety as well as the linker to the two PSMA-ligands 
the chelator only accounts for a small fraction of the resulting complex.  
 
Scheme 14. Synthesis of LuG. Reaction conditions: i) triphosgene, NEt3, dry CH2Cl2, 0 – 
25 °C, 6 h, 65 %. ii) H2, Pd/C (10 %), MeOH, 25 °C, 16 h, 96 %.  
The “cold” rhenium complexes 30 and 32 were prepared from 1a based on a synthetic 
strategy recently reported by our group (Scheme 15).130 LuG was prepared according 
to a previously reported procedure (Scheme 14) and reacted with 8b and 2b using 
HOBt and EDC.131 The resulting complexes (29 and 31) were purified by preparative 
HPLC. In the case of 31, the two diastereoisomers resulting from combining the planar 
chirality of the rhenium complex with the enantiomerically pure LuG could be separated 
and characterized individually. The tert-butyl protecting group cleaved with NaOH in 
MeOH under microwave conditions and further purification by preparative HPLC 
yielded pure 30 and 32 (For 32 a 1:1 mixture of 31a and 31b was used). The complexes 
were characterized by NMR spectroscopy and high-resolution mass spectrometry.    
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Scheme 15. Synthetic route to 30 and 32. Reaction conditions: i) a) NaOH, MeOH, MW, 120 
°C, 15 min. b) Re2CO10, DMF, MW, 220 °C, 15 min. ii) a) LuG, HOBt, EDC, DIPEA, DMF, 25 
°C, 24 h, 30 % (from 1a). b) NaOH, MeOH, MW, 120 °C, 15 min, 76 %. iii) a) Re2CO10, o-
Xylene, MW, 220 °C, 15 min, 76 %. b) NaOH, MeOH, MW, 120 °C, 15 min, 68 %. iv) a) LuG, 
HOBt, EDC, DIPEA, DMF, 25 °C, 24 h, 31 %. b) NaOH, MeOH, MW, 120 °C, 15 min, 56 %. 
 
To determine the PSMA-binding affinity of 30 and 32 LnCap (PSMA-positive) and PC3 
(PSMA-negative) cells were incubated for 1 h with different concentrations of the 
rhenium complexes. The cells were then washed, digested and the total amount of Re 
bound was determined by ICP-MS. Both compounds displayed binding affinities in the 
low nanomolar range (Table 1). With a KD of 1.6 nM, the binding affinity of the dimeric 
complex 32 is 8 times higher than for the monomeric 30, and comparable with PSMA-
binders currently in clinical trials.132 Interestingly, the amount of rhenium detected at 
the highest incubation concentrations for 30 is almost twice as high as for 32. Since 
roughly the same number of cells were used for both assays, this indicates that 32 
occupies two binding sites per metal atom.  
In order to confirm the results obtained with the rhenium complexes, the free ligands 
33 and 35 were prepared from 1a and LuG in two steps (Scheme 16). The pure ligands 
were then used directly and without deprotection for radiolabeling with 99mTc. Reacting 
33 and 35
 
with [99mTc(OH2)(CO)3]+ at 140 °C in a microwave reactor under basic 
condition led to formation of 34 and 36 as diastereoisomeric mixtures within 15 min, as 
evidenced by HPLC co-injection with the respective rhenium complex (Figure 14). The 
only detectable side-products were [99mTcO4]- and [99mTc(OH2)(CO)3]+. Of note, under 
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the employed reaction conditions, all the tert-butyl protecting groups are cleaved off 
and the fully deprotected compounds are obtained directly. 
 
 
 Kd [nM]  
30 1.6 ± 0.2a 
32 12.5 ± 5a 
34 TBDb 
36 TBDb 
 
Table 1. PSMA-binding affinity of complexes 30, 32, 34 and 36. aBinding affinities obtained by 
fitting rhenium content of cell-samples incubated with different concentrations of complex. 
Each data point is the average of three different samples. 
 
 
Figure 14. UV/vis- and y-traces of the co-injection of the rhenium compounds 30 and 32 with 
the 99mTc compounds 34 and 36 respectively. Time differences are due to detector separation. 
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Scheme 16. Synthetic route to 34 and 36. Reaction conditions: i) a) 0.93 eq. NaOH, MeOH, 
MW, 120 °C, 15 min. b) LuG, HOBt, EDC, DIPEA, DMF; 25 °C, 24 h, 17 % (from 1a). ii) a) 
NaOH, MeOH, MW, 120 °C, 15 min. b) LuG, HOBt, EDC, DIPEA, DMF; 25 °C, 24 h, 15 % 
(from 1a). iii) [99mTc(OH2)3(CO)3]+, NaOH, MW, 140 °C, 15 min. iv) [99mTc(OH2)3(CO)3]+, NaOH, 
MW, 140 °C, 10 min. 
 
3.2.3 Outlook 
This work demonstrates that the herein developed Cp-system lends itself to easy and 
straightforward functionalization with biomolecules. The coupling reactions proceed 
with good overall yields and the products are readily purified by preparative HPLC.  
Importantly, the synthesis of the respective 99mTc complexes is also possible from 
highly functionalized Cp-ligands. The successful conjugation of a targeting unit to our 
platform opens up the possibility to additionally attach a cytotoxic moiety to the 
complex. This would lead to a true theranostic system: The 99mTc complex is directed 
to prostate cancer cells but due to the low concentrations of the radionuclide it will not 
induce apoptosis in situ. On the other hand, the analogous rhenium complex would 
localize in the same way as its Tc-congener but in higher concentrations thereby 
inducing a therapeutic effect. In conclusion this proof-of-concept evidences the 
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potential of the multifunctional Cp-ligands and encourages its application with further 
targeting and bioactive modalities. 
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3.3 The Integrated Approach: Synthesis of Pemetrexed-Mimics 
3.3.1 Discussion of Preliminary Results 
We have shown that our ligand platform can be used to conjugated one or multiple 
targeting functions to rhenium and technetium. The ultimate goal, however, was always 
to use the versatility of the Cp-ligand synthesis to pursue an integrated approach as 
inspired by the antimalaria compound ferroquine.16 The first step was to find an organic 
molecule with known anticancer activity, containing a phenyl-ring system with a 
substitution pattern similar to our Cp-system. We turned our attention to the antifolate 
class of anticancer compounds, particularly the drug pemetrexed (Figure 15).133 The 
para-substituted central phenyl ring was an ideal candidate to be replaced by a Cp. 
Additionally, the two phenyl-pendent moieties could be obtained in a straightforward 
way. L-Glutamic acid (Figure 15, red) is commercially available and the synthesis of 
the 6,5-fused pyrrolo[2,3-d]pyrimidine nucleus (Figure 15, blue) including an additional 
amine group was already reported in the literature.134 
 
Figure 15. The integrated approach applied to pemetrexed. 
Pemetrexed was first reported in 1992 by Taylor et al. and subsequently developed for 
clinical evaluation in a cooperation with Eli Lilly.135 As an antifolate, pemetrexed inhibits 
several folate-dependent enzymes that are essential for DNA synthesis and cell 
proliferation.136 Today, pemetrexed is approved for use against malignant pleural 
mesothelioma and non-small cell lung cancer (NSCLC) in the U.S. and the E.U. Due 
to its proven clinical relevance as well as the afore-mentioned synthetic accessibility 
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we proposed complexes Re-trexed/43, 99mTc-trexed and ligand Cp-trexed 
(Figure 15) as metal-based pemetrexed mimics following an integrated approach. 
 
Scheme 17. Reaction conditions: i) Dess-Martin periodinane, DCM, RT, 16 h, 54%. ii) a) 
Me3SiBr, ACN/DMSO, RT, 4 h. b) 2,6-diamonopyrimidin-4-one, AcOH, H2O, RT, 16 h, 30%. 
iii) NH2NH2.H2O, EtOH, reflux/RT, 2 h/ 8 h. 
The building block 39 was prepared in three steps starting from commercially available 
2-(3-hydroxypropyl)isoindoline-1,3-dione according to a literature procedure 
(Scheme 17).134 In the reported synthesis, the deprotection of 38 was followed by an 
in situ boc-protection as the free amine could not be isolated in good yields. In our case 
we skipped the boc-protection and used the crude of the 38 phtalimide-deprotection 
directly for the amide coupling with a crude reaction mixture of 8b, yielding 40 after 
preparative HPLC purification (Scheme 18). Hydrolysis of the ethyl ester was followed 
by a second amide coupling with L-glutamic acid di-tert-butyl ester and 42 was 
obtained as a mixture of two diastereoisomers after purification by preparative HPLC. 
As before, the two diastereoisomers occur due to the combination of the planar chirality 
of the Cp-ligand with the chiral center on the glutamic acid. Deprotection with TFA and 
triethylsilane finally gave the target compound 43.  
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Scheme 18. Synthetic route towards 43. Reaction conditions: i) 39, HOBt, EDC, DIPEA, DMF, 
RT, 24 h, 20 % (from 38). ii) NaOH, MeOH, MW, 120 °C, 15 min. iii) H-Glu(OtBu)-OtBu.HCl, 
HOBt, EDC, DIPEA, DMF, RT, 24 h, 62 % (from 40). iv) TFA, triethylsilane, CH2Cl2, 25 °C, 
24 h, 38 %. 
Overall, the synthesis of 43 is analogous to the model synthesis of a heterodimeric 
tetrafunctional complex reported above (12c), highlighting once more the easy 
application of this concept to relatively complex target compounds. 
A similar route can be followed to obtain the respective free Cp-ligand that can then be 
labelled with 99mTc (Scheme 19). Due to a lack of time, this synthesis was not pursued 
before submission of this thesis. 
 
Scheme 19. Proposed synthetic route towards the free Cp-ligand (Cp-trexed) and 99mTc-
analogue of 43 (99mTc-trexed). 
In conclusion the newly developed Cp-platform allowed the straightforward synthesis 
of Re-trexed/43, an analogue of the clinically approved anticancer drug pemetrexed, 
with unprecedented structural similarity. While in vitro and in vivo evaluation of these 
compounds is still pending, it is clear that this approach can very easily be applied to 
a myriad of other compounds, opening up a new avenue in the research of Re/99mTc 
theranostic agents. 
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Part B: Multifunctional Cp-Complexes with Iron and 
Ruthenium 
3.4 Synthesis of Mixed-sandwich and Metallocene Complexes with 
Polysubstituted Cp-ligands 
The availability of the water-soluble Cp S1 prompted exploratory investigations into the 
aqueous synthesis of Cp-containing complexes with other metals. Although iron was 
the first candidate of choice, reactions of S1 with FeCl2 only lead to the detection of 
trace amounts of the corresponding ferrocene product by UPLC-MS under various 
attempted conditions. We therefore turned our attention to ruthenium. The dimers 44 
and 47 were prepared according to literature procedures (Scheme 20).137 Suspending 
these complexes in H2O and addition of silver nitrate, resulted in a color change and 
formation of a dark precipitate. Subsequent addition of S1 at room temperature and 
precipitation with NH4PF6 yielded complexes 45 and 48. Both compounds were 
characterized by NMR and single crystals suitable for X-ray analysis could be obtained 
by slow evaporation of a MeOH solution of 45 (Figure 15).  
  
Scheme 20. Reaction conditions: i) 1,3-cyclohexadiene, EtOH, reflux, 4 h, 93% ii) a) 4 eq. 
AgNO3, H2O, RT, 1 h; b) 1 eq. S1, H2O, RT, 1 h, 41%. iii), NaOH, MeOH, RT, 6 h. iv) 
α-terpinene, MeOH, MW, 140°C, 1 min, 59% v) a) 4 eq. AgNO3, H2O, RT, 1 h; b) 1 eq. S1, 
H2O, RT, 1 h, 73%. 
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By using the water-soluble Ru(II) synthon Ru(DMSO)4Cl2, and heating it with S1 in H2O 
by microwave at 120 °C for 10 min, the ruthenocene 49 could be obtained and purified 
by a simple extraction (Scheme 21). The complex was characterized by NMR and 
single crystals were obtained by vapor diffusion of hexane into a solution of 49 in DCM 
(Figure 16). 
 
Figure 16. ORTEP diagrams of 45, 49 and 51, with ellipsoids at 50% probability level. 
In both 45 and 49, the ester groups could easily be cleaved by stirring a solution of the 
complex in MeOH with KOH for several hours. The obtained compounds (46 and 50) 
display high water solubility and could potentially exhibit cytotoxic properties as has 
been shown for other ruthenium arene/Cp complexes.96 
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Scheme 21. Reaction conditions: i) H2O, MW, 120°C, 10 min, 67%. ii) KOH, MeOH, 
RT, 1 h, 54 % iii) KOH, diglyme, DMSO, RT, 2 h. iv) NaOH, MeOH, MW, 120 °C, 30 
min. 
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While reactions of FeCl2 with S1 were not very successful, it was possible to obtain 
multifunctional ferrocene derivatives from 1a by following a procedure analogous to an 
early ferrocene synthesis protocol.138 Due to the planar chirality of 51, two isomers 
were detected by UPLC but could not be separated. The compound was characterized 
by MS and NMR. Single crystals suitable for X-ray analysis could be obtained by the 
slow evaporation of a methanolic solution of 51 (Figure 15). In a trial reaction of the 
hydrolysis of the ester groups in 51, the formation of a couple peaks was observed at 
significantly lower retention time (i.e. more hydrophilic species), hinting at the formation 
of 52. Due to time constraints, this was not investigated further. 
These preliminary results clearly indicate that these multifunctional Cp-ligands offer 
the possibility to prepare interesting compounds with other metals as well.  
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Part C: Fundamental Investigations into the solution-
behavior of basic rhenium and technetium synthons 
3.5 13CO exchange in Re(CO)3 and 99Tc(CO)3-based complexes 
3.5.1 Preface 
Understanding the behavior of fundamental rhenium and technetium synthons is of 
high importance when designing complexes containing these metals. Since the 
carbonyl ligands in the fac-[M(CO)3]+-core are thought to be mostly inert, they 
represent an interesting potential probe into fundamental reaction mechanisms 
occurring at the metal center. In collaboration with the group of Prof. Andreas Roodt at 
the University of the Free State in South Africa, we embarked on a project to study 
these reactions.  Our initial strategy envisaged the enrichment of [NEt4]2[ReBr3(12CO)3] 
with 13CO in order to investigate the reaction of the metal core with Cp-ligands. 
Surprisingly, addition on 13CO gas to a solution of the rhenium tricarbonyl in DMF 
rapidly led to the formation of a new, at first unknown, species. Further studies showed 
that a rhenium tetracarbonyl species is formed in the process. The results obtained 
during the thorough examination of this process led to an in-depth understanding of 
the solution behavior of the tricarbonyl-core and to the publication of the following 
manuscript. 
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3.5.2 Manuscript 
Kinetics and Mechanism of CO Exchange in 
[MBr2(solvent)(CO)3]- (M=Re, 99Tc) 
Angelo Frei,[a] David Sidler,[a] Pennie Mokolokolo,[b] Henrik Braband,[a] Thomas Fox,[a] 
Bernhard Spingler,[a] Andreas Roodt*[b] and  Roger Alberto*[a] 
[a]
 Department of Chemistry, University of Zürich, Winterthurerstr. 190, CH-8057 
Zürich Switzerland 
[b]
 Department of Chemistry, University of the Free State, P.O. Box 339, Bloemfontein 
9300, South Africa 
Abstract 
The self-exchange kinetics of CO ligands in the solvated forms of the commonly used 
complex [MBr3(CO)3]2- (M=Re, 99Tc) were investigated in-depth by 13C NMR 
spectroscopy in organic solvents such as DMF and MeOH. The two homologues 
exhibit a surprisingly different chemical behaviour. In the case of rhenium, the stable 
intermediate [NEt4][ReBr2(CO)4] was isolated and characterized by 13C NMR and IR 
spectroscopy as well as by single crystal X-ray diffraction. For technetium, no such 
intermediate could be identified. The activation parameters (∆H≠ = 110 ± 7 kJ mol-1 
and ∆S≠ = 127 ± 22 J mol-1 K-1) and the observed influences of different ligands and 
solvents suggest a dissociative-interchange-type mechanism with a 2nd order rate 
constant for the formation of [NEt4][ReBr2(CO)4] k1 = 0.039 ± 0.001 M-1 s-1 at 274 K. 
Based on variable temperature NMR experiments, kinetic simulations and DFT 
calculations, a complete model for the CO self-exchange including all respective rate 
constants is reported. 
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Introduction 
Among the current imaging modalities in diagnostic medicine, single photon emission 
computed tomography (SPECT) is one of the most important methods. In SPECT, well 
over 80% of all diagnostic nuclear medicine studies are performed with 99mTc 
compounds.42, 99-101 In parallel, rhenium complexes are developed for chemo- and 
radioimmunotherapy applications.139-142 The labeling of targeting biomolecules with 
radionuclides such as 99mTc requires building blocks, ready to bind to chelators 
pendent to the targeting molecules. In recent years, fac-[99mTc(OH2)3(CO)3]+ and its 
rhenium homologue were extensively studied for this purpose since high kinetic 
stability of the CO ligands and the relative ease of water exchange are predominant 
and favorable characteristics.143 At least one compound finished Phase II clinical 
trials.38, 144-154,112, 155, 156 The precursor [99mTc(OH2)3(CO)3]+ is readily accessible from 
commercially available [99mTcO4]-.37 For rhenium, a common starting material for 
[Re(OH2)3(CO)3]+ and complexes thereof is [NEt4]2[ReBr3(CO)3]. The Br- ligands are 
readily exchanged by solvent molecules, either directly after dissolution in e.g. water 
or after precipitation with silver salts in less strongly coordinating solvents such as DMF 
(dimethyl-formamide).157 [Re(OH2)3(CO)3]+ is of highest importance due to its 
chemistry, paralleling the one of its prominent 99mTc counterpart.112, 155, 156 The 
structural and synthetic chemistry of low valent 4d and 5d elements is similar, 
wherefore rhenium complexes are often taken as models for technetium complexes. 
They differ, however, in their kinetic properties whereas thermodynamic properties 
such as redox potentials are very similar. A common feature among the group 7 triad 
complexes [M(OH2)3(CO)3]+ is the lability of the water ligands. This lability contrasts 
the high inertness of the CO ligands.18 Indeed, a literature survey reveals that the CO 
ligands rarely exchange by entering ligands in [Re(OH2)3(CO)3]+ or its 99mTc 
homologue. Only in organic solvents and under high temperature conditions, 
replacement of one CO by other ligands was reported.158-161 In contrast, the water 
exchange kinetics in [M(OH2)3(CO)3]+ for all group 7 elements has been studied 
extensively by Merbach et al., our own group and others.162-167 A detailed review of the 
respective literature was presented by Helm et al.143 The method of choice for these 
investigations was NMR spectroscopy, which allowed for a quantitative determination 
of exchange rate constants, spanning 15 orders of magnitude.168 Isotopically enriched 
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ligands, such as H217O, further enhance the sensitivity and applicability of this 
technique. While the water ligands found much attention, the exchange of CO ligands 
was only of scarce interest, if ever. In fac-[99Tc(CO)3(H2O)3]+, the three 12CO ligands 
could be exchanged for 13CO under 44 bar within 35 h, resulting in all complexes 
[99Tc(OH2)n(13CO)6-n]+ (n=3-6). CO exchange was shown to be up to three orders of 
magnitude slower than the substitution of H2O.169 In order to obtain best reaction 
conditions for radiopharmaceuticals, it is of fundamental interest to elucidate in detail 
similarities and/or differences in the chemical behaviour between the common rhenium 
and technetium starting materials.  
The behaviour of the CO ligands is of particular interest since the option of replacing 
them would lead to new classes of building blocks for molecular imaging agents. In 
that respect, rates and mechanisms of CO self-exchange rates are basic. Herein, we 
report an in depth investigation into self-exchange kinetics of the CO ligands in 
[ReBr3(CO)3]2- and its solvato complexes. Beside kinetic rates, we found [ReBr2(CO)4]- 
as a surprisingly stable intermediate, which could be isolated and fully characterized. 
High-level theoretical calculations and kinetic simulations support the proposed self-
exchange mechanism as deduced from the kinetic measurements.  
 
Results and Discussion 
Solution behaviour of [NEt4]2[ReBr3(CO)3]. Upon dissolution of [NEt4]2[ReBr3(CO)3] 
in coordinating solvents, up to four (Scheme 22, 1a-1d) species are potentially present, 
according to the binding strength of the solvent and the anion respectively. For “strong 
solvents” such as H2O or acetonitrile, one might expect the exchange of all halides, 
which is not the case as shown later (vide infra). Although 1a-1d could be detected 
and differentiated by 13C NMR, this has not been done before by this method to the 
best of our knowledge. Structures 1a and 1d for example exhibit equivalent carbonyl 
carbons, which results in a single peak in 13C NMR for each complex. For each 
complex 1b and 1c, a two-peak pattern with a relative integral intensity of 2:1 should 
be observed (Scheme 22). In case of one single signal in the 13C NMR spectrum, 
precipitation of Br- in 1a and eventual signal shift will then allow to discriminate between 
1a and 1d. The 13C NMR of a concentrated sample of [NEt4]2[ReBr3(CO)3] in weakly 
coordinating, deuterated DMF depicted two peaks at 200.4 and 195.0 ppm (red 
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spectrum in Figure 17), a pattern indicative for 1b or 1c. Refluxing [Re(CO)5Br] in DMF 
overnight must yield only compound 1c (blue spectrum in Figure 17) after cleavage of 
two CO ligands due to the cis-influence of the axial Br-.170 The 13C NMR spectrum 
shows two peaks at 198.0 and 193.1 ppm. By comparing the two spectra and taking 
the integral of the coordinated solvent peak into account, it is evident that dissolution 
of [NEt4]2[ReBr3(CO)3] in DMF leads to the exclusive formation of 1b. 
  
Scheme 22. Compounds in equilibria upon dissolution of [NEt4]2[ReBr3(CO)3] in DMF.  
 
 
Figure 17. 13C NMR spectrum of 1c (blue, 120 mM, 300 K) and 1b (red, 177 mM, 300 K) in d7-
DMF (163.15 ppm). 
In stronger coordinating solvents such as methanol (CH3OH), the equilibrium is shifted 
towards 1c upon dissolution of [NEt4]2[ReBr3(CO)3]. Dissolving [NEt4]2[ReBr3(CO)3] in 
CD3OD, the 13C NMR spectrum evidenced the di-solvated [ReBr(HOCH3)2(CO)3] and 
to a very minor extent the mono-solvated [ReBr2(HOCH3)(CO)3]- (Figure 107). In 
acetonitrile (d3-MeCN), we unambiguously identified only the mono-solvated complex 
[ReBr2(NCMe)(CO)3]- (Figure 108). This contrasts previous reports which described 
the formation of [Re(NCMe)3(CO)3]+ in this solvent without previous precipitation of the 
bromides.171  
 
Synthesis and Characterization of [NEt4][ReBr2(CO)4]. A solution of 
[NEt4]2[ReBr3(CO)3] in d7-DMF, containing [ReBr2(DMF)(CO)3]- (1b) as major 
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constituent, was bubbled with 13CO at room temperature. The 13C NMR spectrum 
showed the rapid formation of a single new peak at 187.9 ppm within minutes (solvated 
13CO in DMF: 185.4 ppm; Figure 110). The signals of 1b disappeared or were not 
detectable anymore due to low concentrations. When the solution was left standing for 
several days at r.t. or was heated to 310 K for 4 hours, three more peaks appeared at 
187.1, 195.0 and 200.4 ppm. The latter two peaks are identical to the ones of 
previously described 1b by comparison of chemical shifts and relative integrals. 
Clearly, a new compound formed under the presence of 13CO and at the same time 
12CO in the original 1b did exchange for 13CO in a statistical distribution, making 1b 
“visible” in the 13C NMR spectra. If the solution was left to equilibrate, the peak at 187.1 
ppm eventually reached the same integral as the one at 187.9 ppm.  
A concentrated solution of [NEt4]2[ReBr3(CO)3] in DMF was kept with stirring for a week 
in a sealed flask under 1 atm 13CO to determine whether the peaks at 187.9 and 187.1 
ppm belong to the same species. This yielded a mixture of compounds with high 13CO 
abundance (blue spectrum, Figure 18).  
 
Figure 18. 13C-NMR of 13CO enriched 1b and 2 before (red) and after (blue) addition of further 
13CO (DMF-d7, 100 mM, 300 K). Peaks at 163 ppm correspond to d7-DMF. 
 
After removal of 13CO/12CO from the head space, a second exposition of this solution 
to fresh 13CO resulted in a rapid and simultaneous decrease of the two peaks belonging 
to 1b by 50 % (200.4 and 195.0 ppm), while the other two peaks of the so far unknown 
compound at 187.1 and 187.9 ppm increased simultaneously (red spectrum, 
Figure 18). The equal rate of appearance of these two peaks strongly suggests that 
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they belong to the same species. The integral ratio of 1:1 points towards the formation 
of a complex comprising the [Re(CO)4]+ core with two pairs of equivalent CO’s. To 
corroborate this hypothesis, a solution of [NEt4]2[ReBr3(CO)3] in DMF was continuously 
bubbled with 12CO for 6 h. The infrared spectrum of the white solid obtained after 
removal of the solvent showed four strong vibration bands (2110, 1995, 1968 and 
1909 cm-1, Figure 109) in the CO region. The pattern and the relative intensities are in 
good agreement with those expected for an octahedral complex of C2v symmetry for 
which examples with rhenium have been reported in literature.172-175 As a confirmation, 
single crystals suitable for X-ray diffraction analysis could be obtained by slow 
evaporation of a DMF solution of [NEt4]2[ReBr3(CO)3] with a stream of CO gas. An 
ORTEP of [NEt4][ReBr2(CO)4] (2) is depicted in Figure 19 and affirms the conclusions 
from the NMR experiment (see also Table 11-12).  
Although one would expect one of the two trans-coordinating CO ligands to be easily 
released, complex 2 showed surprisingly high stability. Even after 4 weeks in DMF at 
room temperature, only trace amounts of 1b formed as evident from the 13C NMR 
spectrum (Figure 111). We note that the observation of a very slow CO release from 2 
to form 1b is of particular importance for the deduction of the mechanism and the 
interpretation of kinetic data (vide infra). The rapid coordination of CO to 1b to form 2 
does not follow a general pattern since the fully solvated complex 1d did not coordinate 
additional CO ligands in solution, both at 274 K and at r.t (Figure 112). This suggests 
a cooperative role of the equatorially bound bromide ligands, crucial for stabilization of 
2 as will be described later in the kinetic studies.  
99Tc behaves distinctly different from rhenium. We did not observe the formation of 
homologous complexes with 99Tc, e.g. the formation of [99TcCl2(CO)4]- when starting 
from [99TcCl3(CO)3]2- in DMF under else identical reaction conditions. For assessing if 
the cooperative behaviour of Br- would make the difference between 99Tc and Re, the 
three Cl- of [99TcCl3(CO)3]2- in DMF where precipitated with Ag[PF6] to form 
[Tc(CO)3(DMF)3]+ and 3 eq. of [NEt4]Br were then added to have the same conditions 
as with rhenium (Figures 113 - 115). While the rhenium complex 2 forms very rapidly 
(vide supra), no such reaction was observed for 99Tc, even under constant CO flow 
(~ 1 atm) for extensive time periods. 99Tc and Re therefore behave clearly different, 
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which is rather uncommon for such simple reactions of 4d and 5d complexes in low 
valencies.  
 
 
Figure 19. Crystal structure of [ReBr2(CO)4]- 2 ([NEt4]+ cation omitted for clarity). Ellipsoids are 
drawn on the 50 % probability level. Important bond lengths (Å) and angles (°) are: Re1-C1 
2.011(3), Re1-C2 1.983(3), Re1-C3 1.914(4), Re1-C4 1.900(3), Re1-Br1 2.6200(4), Re1-Br2 
2.6395(3), Br1-Re1-Br2 88.906(10), C1-Re1-C2 171.08(13). 
Formation kinetics of [NEt4][ReBr2(CO)4]. We chose DMF as solvent since the 
solubilities of [NEt4]2[ReBr3(CO)3] and 13CO are reasonably good in this solvent (for 
CO around mM levels). After dissolution, the starting material is exclusively present as 
1b (vide supra), facilitating the interpretation of the 13C NMR data. Complex 2 forms 
rapidly in DMF when exposed to 13CO. The new peak evolving at 187.9 ppm 
corresponds to the 13CO ligand coordinated trans to another CO ligand in 2. Since no 
other signals appeared on the same time scale, we conclude, that the entering 13CO 
replaces the originally coordinated DMF ligand in 1b and not a Br-. Simultaneously, the 
formation kinetics of 2 can be quantified by monitoring the disappearance of the signal 
of dissolved 13CO. An NMR spectrum of 13CO dissolved in DMF is shown in Figure 110. 
Since all subsequent “isomerization“ reactions are slow in comparison to this initial 
formation step of 2, its kinetics can be analyzed separately. We studied the rate of 
formation under pseudo first-order conditions with 2 in excess over 13CO. A precise 
concentration of 1b altered over a certain range (based on 1a) is obtained simply by 
weighing corresponding mass amounts into solution. The 13C NMR experiments were 
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performed at 274 K as the reaction was otherwise too fast for obtaining a satisfactory 
signal-to-noise ratio by 13C NMR. The integrals of the peaks at 185.4 ppm (13CO) and 
187.9 ppm (2) were plotted against time and fitted to a 1st order exponential. Figure 20 
illustrates a “waterfall” plot, showing the disappearance of free 13CO and the rise of the 
signal of the newly trans-coordinated 13CO. Linear correlation of kobs values vs. 
concentrations (Figures 116-117 and Table 7) gave a 2nd order rate constant at 274 K 
k1 of 0.039 ± 0.001 M-1 s-1.  
 
 
 
Figure 20. A plot of the time-dependent integrals of 2 (48 mM) and free 13CO (4 mM) and 
waterfall plot of the 13C NMR spectra, recorded during a typical measurement at 274 K.  
The question about the activation mechanism for this relatively rapid substitution of 
DMF by 13CO is evident. Therefore, an Eyring plot, i.e. the temperature dependence 
of k1, was recorded in a range between 274 K and 253 K (Figure 21). The range for 
these experiments was limited since the rate became too fast on the NMR time scale 
and solubility of 13CO too low above 274 K. Similarly, the rate became too slow below 
253 K. The activation parameters from the Eyring plot are ∆H≠ = 110 ± 7 kJ mol-1 and 
∆S≠ = 127 ± 22 J mol-1 K-1 (Table 8 and Figure 118). The estimated standard deviations 
(esd) for the activation parameters are probably underestimated given the fact that the 
individual kinetic runs show variation with respect to accurate integration. By subjecting 
this data in total to a global fit, this is indeed confirmed (global fit: ∆H≠ = 129 ± 23 kJ 
mol-1 and ∆S≠ = 198 ± 80 J mol-1 K-1).55, 176 The significantly positive ∆S≠ value is a clear 
indication for a strong, dissociative activation of the substitution reaction. The activation 
enthalpy is comparable with work by Bengali et al.55, where the substitution of THF by 
MeCN in a LRe(CO)2 system was shown to occur via a dissociative-type mechanism.  
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Figure 21. Eyring plot for the reaction of 1b with CO and Xyl-NC. 
The distinctly positive ∆S≠ value raised the question, if similar entering ligands would 
behave comparably. Therefore, the kinetics for the reaction of 1b with 2,6-
dimethylphenyl-isocyanide (Xyl-NC), a ligand with comparable electronic properties 
than CO reaction, was done and the activation parameters for the process were 
determined. Upon addition of Xyl-NC to a solution of 1b in DMF, both 13C NMR 
(Figure 119-120) and subsequent isolation and analysis of the product by single 
crystals X-ray diffraction evidenced formation of the complex [NEt4][ReBr2(CO)3(Xyl-
NC)] (4) (Figure 129, Table 13-14). In these experiments, the formation of 4 could be 
followed by UV/vis spectroscopy since the spectra of the starting materials 1b and Xyl-
NC differ significantly from the product at 326 nm (Figures 121-122). The same rate 
law was operative for this substitution process as for the CO exchange (Figure 123 
and Table 9). The combined Eyring plots of the two reactions (Figure 21) display a very 
similar reaction rate and activation parameters (∆H≠ = 99 ± 6 kJ mol-1 and ∆S≠ = 84 ± 
20 J mol-1 K-1 for the reaction of 1b with Xyl-NC, Table 10) within the experimental error 
margins. By subjecting this data for Xyl-NC as entering ligand to 1b to a global fit, a 
marginal variation in values and larger esd's, but still in very good agreement with those 
listed above, are obtained, (∆H≠ = 93 ± 8 kJ mol-1 and ∆S≠ = 64 ± 24 J mol-1 K-1). These 
findings imply that the nature of the entering ligand does not affect the rate significantly 
but that the dissociation of the solvent is most probably the rate determining elementary 
step.  
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A solvent dependence of the rate is expected since the formation of 2 and 4 are 
accompanied with the dissociation of a solvent ligand. Therefore, the reaction rates for 
the formation of 2 were also quantified in d3-MeCN under else identical conditions as 
in DMF. The 2nd order rate constant k1 for d3-MeCN is 0.0056 ± 0.0007 M-1 s-1 
(Figure 124). The reaction rate is slower in MeCN than in DMF. At the same time DMF 
is a more Lewis basic solvent as expressed, for example, by the donor strength scale 
(DS) by Persson et al. (MeCN: 12, DMF: 24).177 This corroborates the influence of the 
solvent-rhenium bond and supports the previous findings of a dissociatively activated 
substitution mechanism. However, the observation that the more Lewis basic solvent 
induces a faster reaction rate suggest an interchange-type of mechanism, where the 
solvent molecule is still present in the transition state.  In D2O, the solubility of 13CO is 
very low and a white precipitate formed during the reaction with CO. The IR spectrum 
of this precipitate was identical to the one of 2 which is essentially insoluble in D2O. 
Due to these constraints it was not possible to measure any exchange kinetics in D2O. 
Altogether, these experimental data, in particular the strongly positive S≠ value, are 
consistent with a dissociative-interchange mechanism.  
 
Mechanism of CO exchange. The observation of rapid 13CO coordination to 1b does 
not explain why the 13CO NMR shows, after some time, 13CO also coordinated to the 
equatorial plane and not only in the trans-[Re(13CO)(CO)]+ moiety. The detection of 
both, enriched 1b and 2, after incubation under a 13CO atmosphere at all sites implies 
that CO “self-exchange” is indeed operative to a significant extent. To elucidate this 
exchange and its related mechanism in more detail, a solution of 1b in DMF was 
bubbled with 13CO at room temperature. Under these conditions, 2 formed rapidly as 
described above. To account for isostructural complexes but with 13CO at different 
coordination sites, we will use henceforth numbers extended with characters according 
to Scheme 23, thus, complex cis,trans-[ReBr2(13CO)(CO)3]- 2 with a 13CO in the axis 
becomes 2a.  
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Scheme 23. Proposed model for the 13CO exchange and accumulation in 1b. Note that all 
complexes “2” and “3” are isostructural but the extensions “a” and “b” indicate 13CO in positions 
with distinguishable 13C NMR shifts. 
After formation of 2a, the solution was heated to 310 K and the changes monitored by 
13C NMR. Over time, the peak at 187.9 ppm (2a) decreased in intensity while three 
new peaks appeared at 200.4, 195.0 and 187.1 ppm (Figure 22).  
Due to the excess of 1b present at the time of the 13CO addition (pseudo first-order 
conditions in [Re]), only one molecule of 13CO is bound to the rhenium complexes at 
all time points for statistical reasons. Starting from 1b, 2a (187.9 ppm) forms in the first, 
rapid step, and three subsequent reactions can take place (Scheme 23). To prevent 
free CO diffusing out of the solution into the headspace, Shigemi stoppers were applied 
which reduce the surface area of the solvent significantly. 
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Figure 22. Time dependent change of the integrals of all species 1b in d7-DMF after 13CO 
addition and upon heating to 310 K over time. Superimposed is the KinTek178 simulation of the 
proposed model which corresponds to the elementary reactions depicted in Scheme 2.  
In a first possible subsequent reaction, one of the two axial CO ligands is re-substituted 
by a solvent molecule, i.e. back reaction to 1b or to the isostructural 3a, containing only 
one 13CO. Since these processes denote the same reactions, both occur with a rate 
constant of k-1 (not considering isotope effects, which are too small to be observed 
here). If the 13CO is released in this step, 1b is formed and the liberated 13CO will 
rapidly react with another 1b (in excess) to re-form 2a. If, on the other hand, the axial 
12CO is replaced by a DMF molecule in this step, species 3a forms, comprising of one 
13CO trans to the DMF. A signal at 200.4 ppm (Figure 17) appears, indicative for 1b 
but now detectable with much higher sensitivity due to enrichment in 13CO. If these 
reactions were the only ones to occur, we should observe a decrease of the signal at 
187.9 ppm and an increase of the signal at 200.4 ppm exclusively. We note at this 
point that an exchange of the equatorial CO or bromide ligands would break the 
symmetry of the molecule and affect the signal patterns in 13C NMR. Since we have 
found no evidence for this direct exchange of equatorial CO or bromide ligands under 
our conditions, we excluded this pathway from our interpretation. Starting from 2a, an 
equatorial 12CO and the axial 13CO could change their sites with k2 to form 2b. The 
peak at 187.1 ppm accounts for this complex. In complex 3a, the 13CO trans to the 
DMF could exchange its position for a 12CO trans to a bromido ligand with k3 as rate 
constant to form 3b, accounting for the peak at 195.0 ppm. The experimental data in 
Figure 22 show that the peaks of 3a and 3b appear first and maintain a 2:1 ratio 
throughout the reaction. This indicates that the replacement of the 13CO from trans-
DMF to trans-Br- and vice-versa is much faster than the reaction from 2a to 3a (i.e. 
k3 >> k-1). By recording 13C NMR spectra of a 13C enriched mixture of 1b and 2 at 
variable temperatures, the coalescence temperature for the exchange of 3a and 3b 
was found to be 350 ± 5 K (Figure 23). The rate constant k3 was determined to be 
approximately 75 s-1 at 310 K, corresponding to a Gibbs energy of activation ∆G≠ = 65 
± 1 kJ/mol.  
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Figure 23. 13C NMR spectra of 13CO enriched 1b and 2 at different temperatures (DMF-d7, 100 
mM). 
 
Figure 24. Optimized calculated structure of [ReBr2(DMF)(CO)3]- (top). Five (A-E) out of eight 
calculated intermediates from the NEB calculations performed to obtain the minimum energy 
path for the rotation in 3 (bottom).  
We propose a rotation around the C3 axis as a potential mechanism, formed by the 
rhenium center and the centroid of the plane formed by the three CO oxygen atoms as 
mechanism for 3a - 3b interconversion with a trigonal prismatic transition state 
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(Figure 24). In an attempt to support this mechanism by theory, we have performed 
DFT calculations (see experimental section). Eight intermediate structures (Figure 24) 
for a rotation in 3(a/b) as described before were optimized to obtain a minimum energy 
path to the transition state (Structure E, Figure 24). The resulting Gibbs free energy of 
activation was found as ∆G≠  = 56 ± 1 kJ/mol. Taking the restraints of these 
calculations, such as the molecule in vacuum and the limitations of DFT into account, 
the agreement with the experimental value ∆G≠ = 65 ± 1 kJ/mol is very good and 
supports the hypothesis of rotation as the fundamental mechanism. It is important to 
note that the calculations also showed that the Re-DMF bond length is significantly 
elongated in the transition state E compared to the ground state (Figure 130) providing 
further evidence for a dissociative-interchange type mechanism for the substitution of 
DMF via the same transition state. For comparison, the same calculations have been 
performed for a rotation between 2a and 2b which interconverts a 13CO trans to CO 
into the isostructure with 13CO trans to a Br- (Figure 125). The lack of a coalescence 
point in a 13C NMR experiment between 2a and 2b up to 383 K (Figure 126) shows 
that this rotation has a significantly higher activation barrier. Indeed, the calculated 
value for ∆G≠ = 117 ± 1 kJ/mol reveals that this rotation is a very slow, if active at all 
pathway at 310 K. Taken together, experimental values for both k1 (by extrapolation of 
k1 from 274 K to 310 K) and k3 (from the variable temperature NMR experiments) could 
be obtained separately. The absence of a coalescence point at 383 K and the very 
high calculated ∆G≠ indicate that k2 is very small at 310 K and does not compete with 
the k1 and k3 pathways. By restraining our proposed model (Scheme 23) with these 
experimental values, the data points were fitted in KinTekTM Explorer.178 The obtained 
simulated traces match the experimental data well (Figure 23) and gave a k-1 of 6.9 ± 
0.3 × 10-4 M-1s-1. In agreement with this, the plot of kobs vs [Re] obtained an intercept 
very close to zero (Figure 116 and 123). 13C enriched CO allowed an in-depth look at 
the mechanism of CO exchange in the [Re(CO)3]+ system. Under conditions in which 
13CO is present in excess over starting material 1b, the enrichment and rearrangement 
process would occur via continuous “cycling” between complexes 2a and 2b and 3a-
3b’ species and is hence rate limited by the reverse reaction rate k-1.  
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Conclusion 
Our studies on CO exchange mechanisms and kinetics in [ReBr3(CO)3]2- in DMF 
showed a surprisingly high affinity for CO with the concomitant formation of the stable 
tetra-carbonyl complex [NEt4][ReBr2(CO)4] at room temperature. [NEt4][ReBr2(CO)4] 
was characterized by 13C NMR, IR spectroscopy and X-ray crystallography. In 
experiments with [99TcCl3(CO)3]2- in DMF, the behaviour was different and no evidence 
for the formation of [99TcCl2(CO)4]- was obtained. Even when exchanging the chloride 
ligands for bromide, no tetra-carbonyl complexes formed. This distinct difference is 
unusual for ReI/TcI since the two centers are often described as a matched-pair. Co-
ligands influence substitution reactions as the two bromido ligands in 1b are essential 
as no reaction with CO is observed in 1d. Considering the experimentally determined 
activation parameters, the slower reaction rate in the less Lewis basic solvent MeCN 
and the invariance of kobs with regard to the entering ligand, a dissociative-interchange 
type mechanism is most likely. Isotopically enriched 13CO gas combined with DFT 
calculations enabled a comprehensive elucidation of the CO exchange mechanism in 
this system by 13C NMR spectroscopy. The slow release of the CO ligand from 2 
suggests it as a potential CO releasing molecule. Finally, the newly obtained 
[NEt4][ReBr2(CO)4] represents an interesting new symmetrical synthon for further 
coordination compounds.  
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3.5.3 Outlook 
The availability of 13CO enriched rhenium precursors opens up the possibility to study, 
in detail, very basic reaction mechanisms of these complexes with different ligands via 
13C-NMR. This technique is solvent-independent, possible on vast time and 
temperature scales and the reaction partners do not need to be labelled in any way. 
Investigations of this type are planned in collaboration with the group of Prof. Andreas 
Roodt at the University of the Free State in South Africa. 
The in-depth understanding into the CO exchange behavior of the rhenium tricarbonyl 
synthon gained in this work has led to a fruitful collaboration with the group of 
Prof. Peter Hamm at the University of Zurich. By using 13CO enriched 
[NEt4][ReBr2(13CO)4], it was possible to prepare a known CO2-reduction catalyst and 
adsorbed on a semiconductor surface. The ultrafast vibrational energy transfer 
between 13CO-enriched and natural 12CO containing complexes on the surface was 
then investigated by 2D-IR spectroscopy. The results of this study have resulted in a 
joint publication.179 Further experiments with 13C18O enriched complexes are currently 
underway. 
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Part D: Synthesis and Characterization of Multi-Nuclear, 
99mTc-containing Complexes 
3.6 Pre-assembly and Self-assembly of Multinuclear Re-99mTc 
Complexes 
3.6.1 Preface 
Metal complexes containing multiple, equal or different metal centers have been known 
for a long time. However, in the context of nuclear imaging they have only seldom been 
investigated. In our continued collaboration with the Roodt group in South Africa we 
have studied a series of dinuclear manganese and rhenium complexes with 
Schiff-base ligands.180 In a next step both 99Tc and 99mTc were incorporated into 
dinuclear complexes with rhenium. A similar approach with simple hydroxy-clusters led 
to two distinct strategies when preparing radioactively labelled multi-nuclear 
complexes. This work led to the submission of the following manuscript. 
  
  
 
96 
 
3.6.2 Manuscript 
Self-Assembled Multi-Nuclear Complexes Incorporating 99mTc 
 
Angelo Frei,a Pennie P. Mokolokolo,b Robin Bolliger,a Henrik Braband,a Mampotso S. 
Tsosane,b Alice Brink,b Andreas Roodt,* b and Roger Alberto*,a 
 
Abstract 
Multinuclear complexes or clusters are rarely investigated in medicinal inorganic 
chemistry although they represent structural intermediates between molecules and 
nanomaterials. We present in this report two strategies towards 99mTc containing 
clusters. In a pre-assembly approach, the preformed but incomplete cluster fragment 
[Re3(µ2-OH)3(µ3-OH)(CO)9]– reacts with a [99mTc(CO)3]+ to the highly stable 
[99mTcRe3(µ3-OH)4(CO)12] cube. The same structure self-assembles when reacting the 
mono-nuclear Re and 99mTc precursors in one pot. Integrating the coordinating OH 
groups from Schiff bases in this concept leads straight to dinuclear, mixed-metal 
complexes of the type [99mTcRe(µ2-O^N-R1)2(CO)6] in quantitative yield. Both 
strategies are unprecedented and open a future path towards clusters, incorporating a 
99mTc radiolabel while being decorated with targeting or cytotoxic moieties. 
Introduction 
Research in medicinal inorganic chemistry is focused on mononuclear organometallic 
complexes or coordination compounds.181-184 Their mode of action is often metal-
based as in the prototypical case of cisplatin, the inspiring lead compound for many 
current studies. Ligand-based reactivity or, more recently, recognition of the entire 
complex structure according to the 3D-space occupation are conceptual extensions in 
this field. For the latter modality of action, the complex is chemically innocent and 
designed as an inhibitor for specific receptors. The topology and the functional groups 
mimic pharmaceutical lead structures of known activity as in the case of e.g. ferrocifen, 
ferroquine or protein kinase inhibitors of the staurosporine type.185-192 Whereas most 
of these metal-containing drugs are based on group 8, 9 or 10 elements,193 complexes 
of group 7, the manganese triad, are rarely investigated. It has recently been pointed 
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out that the respective chemistry is not explored to a sufficient extent and the potential 
behind rhenium complexes might be much brighter than previously assumed.184, 194 
Since technetium is a group 7 element, the unique possibility of combining cytotoxic, 
rhenium-based complexes with 99mTc molecular imaging agents of identical structure 
emerges. This gave rise to a new concept of molecule-based theranostics, 
macroscopic amounts of rhenium complexes for therapy and microscopic amounts of 
99mTc homologues for diagnosis. This homology holds especially true for the low 
valences of the two elements in which highly robust complexes are formed. We 
showcased this principle recently with carbonic anhydrase inhibitors and mitochondria 
targeting agents.195, 196  
A class of compounds which is rarely considered in medicinal inorganic chemistry are 
clusters or multinuclear compounds. An exception to this observation are 
polyoxometalates (POMs), which are studied for nanomedicine purposes.197 In the 
context of this report, we understand clusters as polynuclear compounds in which two 
(or more) metal-cations are bridged by a single atom, e.g. an oxygen, which may 
belong to a larger ligand framework or not, and compounds with metal-metal bonds. 
The complexity of their syntheses might be one of the reasons for the little interest in 
multinuclear compounds but also the expected and even more diverse in vivo 
behaviour.  
Apart from the POMs, examples have been reported, mainly with Rh2 species 
exhibiting a RhII-RhII single bond,198-200 supramolecular Ru-arene complexes201-204 and 
mixed Pt-Re systems.205, 206 Multinuclear complexes have the advantage of delivering 
more than one metal or bioactive moiety at a time from the coordination periphery to 
the target, once bound to the corresponding receptor. The difficulty is to achieve a well-
defined composition and the integration of a targeting/bioactive entity. With respect to 
the aforementioned theranostic concept, non-invasively following the biological 
behaviour of such clusters or multinuclear compounds by integrating a radioelement, 
would be a decisive advantage. This radioelement can be an isotope of the cluster 
forming element or belong to the same triad as in case of 99mTc and Re. To 
prepare multinuclear complexes comprising a radionuclide of the same or homologous 
elements, two principal pathways are compatible with a potential application on a 
routine base: i) preparation of an incomplete fragment of the final, multinuclear complex 
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followed by introduction of the radiolabel in a second step (pre-assembly strategy, path 
A in scheme 24) or ii) combine all components and perform the synthesis in one step 
(self-assembly strategy, path B in scheme 24). 
 
Scheme 24. Strategies to multinuclear complexes comprising 99mTc: Pre-assembling of an 
incomplete cluster followed by incorporation of a 99mTc fragment (Pathway A) or self-
assembling of a multinuclear cluster starting from mononuclear components and ligands 
(Pathway B). The blue arrows indicate a bioactive moiety. 
We report here on model reactions for both concepts, showing the proof-of-concept of 
preparing multinuclear complexes labelled with 99mTc. In a targeting scenario, both 
approaches allow to combine multiple targeting and/or cytotoxic agents on one single 
multinuclear metal complex, thereby increasing their mode of action, target finding 
and/or drug delivery. 
Results and Discussion 
The introduction of a fragment into an incomplete multinuclear framework according to 
path A demands a sequential relationship between precursors and final products. Such 
a relationship is given by the build-up of the tetranuclear complex [Re4(µ3-OH)4(CO)12] 
with cubane-like structure. Under mildly basic conditions, this tetranuclear compound 
forms stepwise from the precursor fac-[Re(OH2)3(CO)3]+ (1) via [Re2(µ2-OH)3(CO)6]- 
(2) and [Re3(µ2-OH)3(µ3-OH)(CO)9]- (3) or from the 99Tc homologues (Scheme 25).166, 
207, 208
 Similar multinuclear complexes were also obtained with alcoholato or thiolato 
bridges.209-211 
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Scheme 25. Stepwise build-up of the trinuclear cluster [Re3(µ2-OH)3(µ3-OH)(CO)9]- (3). The 
pre-assembly leaves a vertex for coordination to 99mTc. "Re" denominates the fac-[Re(CO)3]+ 
fragment. 
As we understand multinuclear complexes in this report, the metals are bridged by 
single atoms, potentially bound to further organic functions, coordinating or just 
pendent. For the fac-[Re(CO)3]+ fragment, this might be an oxygen from an alcoholato 
group or a sulfur from a thiolate, from µ2- or µ3-O/SR motives. Since weakly 
coordinating as terminal donors, they exhibit a tendency to bridge to further metal-
centres, thereby forming multinuclear clusters with a single atom bridge. Incomplete 
clusters such as [Re3(µ2-OH)3(µ3-OH)(CO)9]- are therefore prone to coordinate to 
further metal centres or complex fragments and may be labelled with 99mTc.  
The reaction of the incomplete, separately prepared Re3 cluster 3 with the 99mTc 
precursor fac-[99mTc(OH2)3(CO)3]+ according to pathway A in Scheme 24 (pre-
assembly approach) should lead to a cubane cluster incorporating 99mTc. The missing 
vertex is filled with the fac-[99mTc(CO)3]+ fragment (or another metal) to complete the 
cube. It has been reported earlier that 3 can be considered as a tripod ligand with the 
bridging three µ2-hydroxides acting as coordinating groups. Indeed, the trinuclear 
cluster 3 coordinates to many 3d aqua-cations such as Co2+ Mg2+, Ca2+, Fe2+, Ni2+, 
and others.212 Two of the clusters provide an octahedral environment and coordinate 
securely to the corresponding M2+. Completing the cube with the [M(CO)3]+ moiety 
yields the extremely stable cubane complex [Re4(µ3-OH)4(CO)12] (5).   
We prepared [Re3(µ2-OH)3(µ3-OH)(CO)9]– and reacted it with fac-[99mTc(OH2)3(CO)3]+. 
In a very clean and fast reaction the mixed-metal tetranuclear cluster 
[99mTcRe3(µ3-OH)4(CO)12] (4) formed in quantitative yields. HPLC coinjection of the 
homologues 4 [99mTcRe3(µ3-OH)4(CO)12] and 5 [Re4(µ3-OH)4(CO)12] and comparing 
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the UV/vis and gamma-trace retention times confirmed the identity of the two 
compounds (Figure 25). The feasibility of the pre-assembly concept A is thus 
confirmed. Since the rhenium cluster 3 is present in large excess relative to the 99mTc 
complex (typically in the nanomolar range, 6h half-life time for 99mTc!), the majority of 
it is left unchanged after the labelling reaction. 
 
Figure 25. HPLC traces of 4 (γ-detection) and 5 (UV/vis detection) confirm the structural 
identity of the two homologues and feasibility of pre-assembly strategy A (top). In situ formation 
of the same cubane cluster 4 in one step from fac-[Re(OH2)3(CO)3]+ and fac-
[99mTc(OH2)3(CO)3]+ support self-assembly strategy B (bottom). 
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The tetra-nuclear rhenium cluster 5 and its 99Tc (the long-lived, macroscopic isotope 
of 99mTc) homologue form under mildly basic conditions by self-assembly of the mono-
nuclear compounds fac-[Re(OH2)3(CO)3]+ and fac-[99Tc(OH2)3(CO)3]+ respectively.208, 
213
 Analogous alkoxy clusters have been prepared along the same route.214 A self-
assembly strategy should thus allow for a one-step one-pot reaction of 4 from a slightly 
acidic mixture of 1 and fac-[99mTc(OH2)3(CO)3]+. This is indeed the case (Scheme 26 
and Figure 25B) and this reaction gave in one step and in quantitative yields 4 beside 
large amounts of 5 due to the very large excess of 1. An HPLC trace of the crude 
reaction mixture (no coinjection with 5!) is given in Figure 25B. It shows the UV-trace 
of 5 and the γ-trace of cluster 4. 
Extension of the self-assembly strategy as shown in scheme 26 will enable the 
introduction of targeting groups or bioactive moieties in such multinuclear clusters. 
Whereas alkoxides instead of hydroxides are principally possible, we were more 
interested in hydroxyl ligands with anchoring groups. In this context, Schiff base ligands 
comprise an aromatic hydroxyl-group which is prone to bridge two complex fragments. 
 
 
Scheme 26. Self-assembly reaction between the mono-nuclear precursors 1 and its 99mTc 
homologue under mildly acidic conditions yields the tetra-nuclear cubane type clusters 4 and 
5. "Re" denominates the fac-[Re(CO)3]+ fragment. 
In addition, the imine parts of the Schiff bases coordinate as well and are flexible with 
respect to the nature of the pendent group R1, i.e. they can represent a targeting moiety 
or another bioactive fragment. When the Schiff bases shown in Scheme 27 reacted 
with fac-[99TcCl3(CO)3]2- in acetonitrile at elevated temperature, we found rapid and 
essentially quantitative formation of the dinuclear complex [99Tc2(µ2-O^N-R1)2(CO)6] 
(R1=m-tol 6, =cpent 7, =EtPh 8; R2=H 6, or Me 7,8). Radio-HPLC showed one single 
peak after the syntheses (supporting information), and minute amounts of side 
products. The respective compounds could be isolated and complexes 6-8 were 
characterized by X-ray structure analysis. ORTEP diagrams are shown in Figure 26 
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and crystallographic details for all complexes are given in the supporting information. 
All three structures confirm the rigidity of the planar dinuclear frame structure and 
illustrates the stability induced therein. The agreement of the internal geometric 
parameters (such as the Tc-Tc’ and O1-O1’ bond distances, O1-Tc-O1’and O1-Tc-
O1’angles, and not the least the Tc-O1-Tc’-O1’-planar entity) is remarkable. This 
confirms that the only significant variable is the substituents on the peripheral outer-
sphere of the dinuclear compound, which is expected to influence the in vivo 
distribution significantly. Depending on the size of the Rn groups, molecular entities in 
the nanometer range may be easily obtained: for the examples described here, the 
dimensions of the dinuclear species when measured from the outer hydrogen atoms, 
already range from R1-R1’ and R2-R2’ 1.7 to 1.3 nm. 
 
Scheme 27. Three functionalized Schiff base chelators utilized in this self-assembly study 
(top). Reaction sequence for either of these Schiff bases Hsal-R (bottom). In a typical reaction, 
[NEt4]2[99TcCl3(CO)3], the Schiff base ligand and NEt3 were dissolved in acetonitrile and heated 
to 80 °C for 3 h. 
The course of the reaction is interesting; no mononuclear intermediate was detected 
during the procedure. Since a mononuclear complex must exist at some stage of the 
reaction path as an intermediate, we conclude that its dimerization is a very rapid 
process under our reaction conditions, much faster than the initial coordination of one 
Schiff base to one [99Tc(CO)3]+ moiety. 
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Figure 26. ORTEP diagrams (a)-(c) of 6-8, with ellipsoids at 50% probability level (for 7: only 
major component of disordered cpent shown). Important geometric parameters (in 6, 7 and 8, 
respectively) are: Bond distances (Å): Tc-C01: 1.899(4), 1.892(4), 1.904(4); Tc-C02 1.922(4), 
1.914(4), 1.919(4); Tc-C03 1.889(4), 1.899(4), 1.896(4); Tc-O1 2.157(2), 2.158(2), 2.150(2); 
Tc-N1 2.188(3), 2.172(3), 2.195(3); Tc-O1’ 2.189(2), 2.195(2), 2.192(2); Tc-Tc’ 2.4210(5), 
3.4335(3), 3.4235(5); O1-O1’ 2.6821(3), 2.677(3), 2.671(3).  Bond angles (°): OC-Tc-CO: 
85.7(1) to 88.1(2) for nine angles; C02-Tc-N1 179.31(13), 176.18(12), 176.13(13); O1-Tc-N1 
81.08(9), 82.01(9), 82.37(10); O1-Tc-O1 76.16(9), 75.87(8), 75.94(9); Tc-O1-Tc’103.81(9), 
104.12(8), 104.1(1).   
Aiming at the self-assembly strategy, the same reaction as described above with 99Tc 
was done but in the presence of fac-[99mTc(OH2)3(CO)3]+ in acetonitrile (Scheme 28b). 
As expected, we observed the formation of a 99mTc compound (γ-trace) with a retention 
time equal to the one from the reaction of pure 99Tc (β-trace). To unambiguously 
assess the identity of the 99Tc2 and the 99Tc99mTc compounds, they were co-injected 
into HPLC and the retention times compared (Figure 27). The equal retention times 
confirmed the formation of [99Tc99mTc (µ2-O^N-Hsal-m-tol)2(CO)6].  
Aiming at dinuclear compounds for application in life sciences, it is clear that a 
combination of 99Tc and 99mTc is a "no go". As in case of the pre-assembly strategy, 
only a combination between Re and 99mTc is an acceptable option. Thus, dinuclear 
complexes like 6-8 must comprise one 99mTc and one Re to be potentially applicable. 
However, the same reactions with fac-[ReBr3(CO)3]2- instead of fac-[99TcCl3(CO)3]2- 
with the Schiff bases as depicted in Scheme 27, in organic solvent or a water/MeOH 
mixture, yielded exclusively mononuclear complexes of the type fac-
[Re(O^N-R1)(CO)3] (Scheme 28a). No dimerization was observed under our 
conditions. Previously, we isolated and fully characterized these mononuclear rhenium 
complexes.215 This unequal behaviour between the two homologues Re and Tc is 
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rather based on a substantial different kinetics in low oxidations states than on 
thermodynamic features.216 
 
 
Figure 27. HPLC comparison of [99Tc2(µ2-O^N-m-tol)2(CO)6] 6 (β--trace) and [99Tc99mTc(µ2-
O^N-m-tol)2(CO)6] (γ-trace). 
The pivotal question is now how a mixture of fac-[ReBr3(CO)3]2- and fac-
[99m(OH2)3(CO)3]+ (prepared in water) would behave in acetonitrile in analogy to the 
99Tc reaction described above, and in the presence of the Schiff bases. 
This reaction c) in Scheme 28 under identical conditions as in reaction a) with Hsal-m-
tol gave the mononuclear rhenium complex 9 in quantitative yields as well as the 
mixed-metal dinuclear complex [99mTcRe(µ2-O^N-Hsal-m-tol)2(CO)6] (10). Due to the 
very low concentration of 99mTc (nanomolar) in this reaction, dimerization to yield the 
dinuclear 99mTc analogue of 6 is not expected for kinetic reasons. Figure 28 displays 
the HPLC traces of this reaction. The green and the dark red top-down traces represent 
the UV/vis and the β- trace of 6 as reference. The peaks have different retention times 
due to the separation of the respective detectors. The red trace (bottom-up) of the 
99mTcRe dinuclear complex 10 has exactly the same retention time as the green β- 
trace of the 99Tc99Tc complex 6. Complex 10 shows no UV/vis absorption peak (blue 
line) because its concentration is in the nanomolar range. It shows however a UV/Vis 
peak exactly at the position where the mononuclear rhenium complex 9 appears. 
These traces clearly demonstrate the formation of a mixed 99mTcRe complex and the 
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mononuclear complex 9. If this mononuclear complex 9 is the most stable form, 
dimerization with the 99mTc fragment and an additional ligand is not expected. It seems 
thus that dinuclear compound 10 is thermodynamically favoured over the monomer 9 
which allows the formation of the mixed-element dinuclear complex 10 (Figure 28).  
 
 
Scheme 28. Self-assembly of a dinuclear 99mTcRe complex. Path a) rhenium (blue) only yields 
only mononuclear complexes. Path b) 99Tc (green) only yields dinuclear complexes and path 
c) mixture of 99mTc (red) and Re gives mononuclear rhenium complexes and mixed 99mTcRe 
complexes. Reaction conditions for c): [NEt4]2[ReBr3(CO)3] and [99mTc(CO)3(H2O)3]+ where 
dissolved in acetonitrile. Hsal-m-tol and NEt3 were added and the mixture was heated to 80 °C 
for 3 h. 
This self-assembly reaction leads to the formation of a well-defined 99mTcRe complex. 
We emphasize that 10 is the first of its kind. The combination of the two elements in 
one and the same compound may open a new path in theranostics; particularly as the 
residual Rn functionality in the Schiff base framework can be selected according to the 
purposes of the complex, i.e. a targeting molecule or a bioactive agent. For application, 
these compounds incorporate traces of 99mTc which allows their in vivo pharmacology 
to be tracked.  
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Dinuclear complexes, labelled with 99mTc can thus be prepared in one single 
step. In contrast to the classic labelling procedure with bifunctional ligands and 
a single 99mTc atom, the metals self-assemble into a dinuclear cluster since their 
precursors themselves act as the ‘ligands’. 
 
 
Figure 28. HPLC traces of the crude reaction mixture for the preparation of 10 (containing 
mostly 9 due to the large excess of rhenium present) combined with the HPLC traces (UV and 
β-) of 6: UV/vis trace 9 and 10 (blue), γ-trace 9 and 10  (red), UV-trace 6 (dark green), β—trace 
6 (light green). For reaction conditions see Scheme 5  
The product may comprise two bioactive units (R1 and R2 in the Schiff base ligands) 
and, if desired, two metal-centres to exert their respective biological functions. These 
compounds integrate 99mTc atoms. We emphasize that the formation of the same 
compound is unlikely in the exclusive presence of 99mTc since its concentration is far 
too low and 2nd order kinetics therefore slow. The preparation of such a dinuclear 
complex is unprecedented in radiopharmaceutical chemistry and might open a new 
view towards potential building blocks or radiopharmaceuticals. Moreover, it yields a 
convenient pathway to obtain pre-designed nanomaterial molecular entities, which can 
be varied for functionality and size.  
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Conclusions 
Multinuclear complexes are rarely considered in medicinal inorganic chemistry. They 
would have the advantage of comprising more than one targeting unit or, optionally, 
delivering more than one bioactive moiety. As shown in this report, multinuclear 
complexes can be prepared along a very convenient self-assembly path form 
mononuclear precursors or by completing a pre-assembled cluster fragment, i.e. a 
fragment which serves as a ligand. If one metal in such an architecture is a -emitter, 
these assemblies are of theranostic potential. We have described in here the feasibility 
of both synthetic strategies; firstly an incomplete and separately prepared Re3 cluster 
that incorporates a [99mTc(CO)3]+ moiety to complete a cube. The bridging ligands, here 
hydroxide, can be replaced by functionalized alkoxides. A one pot reaction with the 
mononuclear precursors and, optionally a ligand, leads in one step to the identical 
product. The approach is not only synthetically facile, it is also highly flexible and will 
allow for a rapid screening of potentially useful architectures. Secondly with bridging 
ligands, here Schiff bases, dinuclear complexes were prepared in one step. 
Functionalization occurs at the ligand with a multitude of options. Both strategies 
exemplified in this study extend the theranostic modalities beyond mononuclear 
complexes and reveal the beauty of chemically combining 99mTc and Re in dinuclear 
complexes. 
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4. Conclusion & Outlook 
In our group we have previously investigated Cp-ligands as potential alternative to the 
otherwise large and bulky chelators used to coordinate the radiometal technetium. Cp’s 
form remarkably stable complexes with both 99mTc and Re and the possibility to 
functionalize the Cp’s enables both the attachment of targeting and bioactive 
modalities as well as the integration of the Cp-metal system into biomolecules with 
known pharmacology. However, the synthetic strategies towards such functionalization 
have been rather unexplored so far.  
In this work we have developed a unique Cp-ligand platform that allows for both tuning 
of the physico-chemical properties of the complex as well as both bis-homo and bis-
heterofunctionalization with biovectors. From these ligands, both “cold” rhenium and 
“hot” 99mTc complexes can readily be prepared. In a next step we applied this scaffold 
by preparing monomeric and dimeric probes for PSMA. These results showed that 
dimeric probes display significantly higher affinity for PSMA overexpressing cells than 
the monomeric complex. Additionally, this represented a proof-of-concept of the 
applicability of the multimodal ligand platform. In a third project, it was shown that these 
ligands can be used to prepare close structural mimics of the clinically approved cancer 
drug pemetrexed. The therein prepared complex is a potential theranostic agent, 
where the rhenium complex is the therapeutic and the 99mTc the diagnostic modality.  
Overall, the strength of this ligand-platform lies in its versatility, as it can be conjugated 
to essentially any biovector. Currently, the combination of a the PSMA-targeting unit 
with an additional cytotoxic payload is being explored in our group. Furthermore, the 
number of functionalities that can be incorporated in the Cp-ring is being expanded, 
which will enable more integrated approach type applications. 
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5. Experimental Procedures & Analytical Data 
5.0 General 
Materials.  All chemicals were of reagent-grade quality or higher and were obtained 
from commercial suppliers. Solvents were used as received or dried over molecular 
sieves. Sodium boranocarbonate was a gift from Mallinckrodt Medical B.V. (The 
Netherlands). Na[99mTcO4] in 0.9% saline was eluted from a 99Mo/99mTc UTK FM 
generator purchased from Mallinckrodt Medical B.V. (The Netherlands) 
Instrumentation and methods. 1H and 13C-NMR spectra were recorded in deuterated 
solvents on a Bruker DRX 400 (1H: 400 MHz, 13C: 100.6 MHz) or DRX 500 (1H: 500 
MHz 13C: 125.8 MHz) MHz spectrometer at 300 K. The chemical shifts, , are reported 
in ppm (parts per million) relative to residual solvent peaks. The abbreviations for the 
peak multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublets), t 
(triplet), q (quartet), m (multiplet), br (broad). IR spectra were obtained with a 
PerkinElmer Spectrum Two spectrometer. Microwave reactions were performed using 
a Biotage Initiator+ Robot Eight or Anton Paar (AP) Monowave 200 instrument. UPLC-
ESI-MS was performed on a Waters Acquity UPLC System coupled to a Bruker HCTTM, 
using an Acquity UPLC BEH C18 1.7µm (2.1 x 50 mm) column. UPLC solvents were 
formic acid (0.1% in millipore water) (solvent A) and acetonitrile UPLC grade (solvent 
B). The temperature was regulated with a Peltier thermostatic system to the specified 
temperatures. High-resolution mass spectrometry (HR-MS) was performed on a 
Thermo DFS double-focusing system (ThermoFisher Scientific, Germany). 
Preparative HPLC was performed on a Varian ProStar 320 system, using a Dr. Maisch 
Reprosil C18 100-7 (40 x 250 mm) column (flow rate: 40.0 ml/min) or a LiChroCART 
RP-18e (10 x 250 mm) column. HPLC solvents were 0.1% trifluoroacetic acid (solvent 
A) and acetonitrile (solvent B), HPLC grade. Analytical HPLC was performed on a 
Merck Hitachi L7000 system, equipped with a L-7400 UV-detector and an in-line radio-
detector Berthold FlowStar LB513, using an analytical Macherey-Nagel Nucleosil C18 
5 µm (4.6 × 250 mm) column. Analytical UPLC was performed on a VWR Hitachi 
Chrommaster Ultra, using an Acquity UPLC BEH C18 1.7µm (2.1 x 50 mm) column. 
UPLC solvents were trifluoroacetic acid (0.1% in millipore water) (solvent A) and 
acetonitrile UPLC grade (solvent B).  
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HPLC/UPLC Methods. 
UPLC-MS. The UPLC-MS runs (flow rate 0.6 mL/min) were performed with a linear 
gradient of A (acetonitrile (Sigma-Aldrich HPLC-grade)) and B (distilled water 
containing 0.1 % formic acid): t = 0–0.5 min, 5 % A; t = 4.0 min, 100 % A; t = 5.0 min, 
100% A. 
UPLC (U1). The UPLC runs (flow rate 0.5 mL/min) were performed with a linear 
gradient of A (acetonitrile (Sigma-Aldrich HPLC-grade)) and B (distilled water 
containing 0.1% TFA): t = 0–0.5 min, 5 % A; t = 4.0 min, 100 % A; t = 5.0 min, 100 % A. 
HPLC. The HPLC runs (flow rate 0.5 mL/min) were performed with a linear gradient of 
A (acetonitrile (Sigma-Aldrich HPLC-grade)) and B (distilled water containing 0.1 % 
TFA): t = 0–2.1 min, 10 % A; t = 25 min, 100 % A; t = 35 min, 100% A; t = 37 min, 10% 
A; t = 40 min, 10% A. 
radioHPLC. The radioHPLC runs (flow rate 0.5 mL/min) using a gradient of A (MeOH 
(Sigma-Aldrich HPLC-grade)) and B (distilled water containing 0.1 % TFA t = 0 – 3 min: 10% 
A; 3 – 3.1 min: 0 – 25% A; 3.1 – 9 min: 25% A; 9 – 9.1 min: 25 – 34% A; 9.1 – 18 min: 
34 - 100% A; 18 – 25 min: 100% A, 25 – 25.1 min: 100 - 10% A; 25.1 – 30 min: 10% 
MeOH. Comparison of the HPLC retention times for the 99mTc compounds with the 
corresponding 99Tc and Re compound confirms identity. 
Preparative HPLC (Method A). The preparative HPLC runs (flow rate 40 mL/min) 
were performed with a linear gradient of A (acetonitrile (Sigma-Aldrich HPLC-grade)) 
and B (distilled water containing 0.1 % TFA): t = 0–2.1 min, 10 % A; t = 25 min, 100 % 
A; t = 40 min, 100% A. 
99mTc experiments. Caution! 99mTc is a γ-emitter (E= 140 keV, t1/2= 6.02 h) which 
should only be handled in a licensed and appropriately shielded facility. Sodium 
boranocarbonate releases CO gas which is highly toxic, it is recommended to be 
handled only in ventilated hoods. 
Cell culture 
Cell lines were obtained from American Type Culture Collection (ATCC). LnCap cells 
were maintained in RPMI 1640 medium without phenol red (Gibco) at 37 °C, 5 % CO2. 
PC3 cells were maintained in DMEM/F12 medium (Gibco) at 37 °C, 5 % CO2. Cell 
culture media were supplemented with 10 % fetal bovine serum (Gibco) and penicillin-
streptomycin (Invitrogen).  
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Cell binding assay 
Cells were harvested at 70% confluence, washed once with PBS and resuspended in 
full medium. For cell binding assays, aliquots of 5 mio cells were incubated with the 
indicated concentrations of the complexes in 5 ml medium for 1 hour at 4 °C. 
Thereafter, cells were collected by centrifugation at 100 g and 4 °C for 10 min, and 
washed three times with ice-cold PBS.  
ICP-MS measurements 
Rhenium was measured against a Re single element standard (Merck 170344.100) 
and verified by a control (Agilent5188-6524 PA Tuning 2). The rhenium content of the 
samples was determined by means of a 6 calibration standards that were produced in 
the range between 0 and 100 ppb in Re (R>0.99) with a background equivalent 
concentration of BEC: 9.4 ppt and a detection limit of DL: 2.6 ppt. The isotope Re185 
(37.4 % abundance) Re187 (62.6 % abundance) was evaluated in “no-gas” mode and 
He-gas mode. Spiking the samples with untreated negative controls (to account for 
potential carbon content from the biological samples) resulted in equivalent values 
within error ranges. A solution containing indium (100 ppb) and was used as internal 
standard. The results are expressed as ppb Re as means ± standard deviations of 
three experiments. 
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5.1 Experimental Section Part A 
5.1.1 Synthetic Procedures and Analytical Data Part 3.1 
 
 
0.1. Ethyl levulinate (7.22 g, 50.0 mmol) was dissolved in MeOH (100 ml). The solution 
was cooled to 0 °C by means of a water-ice bath. Bromine (2.8 ml, 55 mmol) was 
added dropwise to the reaction mixture which turned red. Upon complete addition, the 
now orange solution was stirred for another 2 hours at room temperature. The solvent 
was removed in vacuo and the crude was dissolved in MTBE (50 ml) and washed with 
sat. NaHCO3 (2 x 50 ml). The combined aqueous phases were washed with further 
MTBE (50 ml). The combined organic phases were dried over MgSO4 and the solvent 
removed on a rotary evaporator. Column chromatography (silica gel, Hexane/EtOAc 
3:1) yielded pure 0.1 as a yellow oil (2.42 g, 11.6 mmol, 23 %). The analytical data 
matched that reported previously.217  
Rf = 0.38 (silica gel, Hexane/EtOAC 3:1). 1H NMR (400 MHz, CDCl3): δ (ppm) 2.64 (t, 
J3 = 6.5 Hz, 2H), 2.94 (t, J = 6.5 Hz, 2H), 3.66 (s, 3H), 3.94 (s, 2H). 
 
 
1.1. 3-methyl-2-butenoic acid (3.03 g, 30.2 mmol) was dissolved in ethanol (20 ml) and 
10 drops of conc. H2SO4 were added under stirring. The solution was heated to reflux 
overnight. The next day the solution was concentrated to about 5 ml and diluted in 
diethyl ether (50 ml). The organic phase was washed with sat. NaHCO3 (3 x 30 ml) and 
H2O (2 x 30 ml). The combined organic phases were dried over MgSO4 and the solvent 
removed on a rotary evaporator yielding 1.1 as a yellow oil (3.35 g, 26.2 mmol, 87%). 
The analytical data matched that reported previously.218  
1H NMR (400 MHz, CDCl3): δ (ppm): 1.23 (t, J = 7.1 Hz, 1H), 1.85 (d, J = 1.3 Hz, 1H), 
2.13 (d, J = 1.3 Hz, 1H), 4.10 (q, J = 7.1 Hz, 1H), 5.63 (m, J = 1.3 Hz, 1H). 
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1.2. 1.1 (0.884 g, 6.9 mmol) was dissolved in MeOAc (2 ml) in a Biotage microwave 
vial (2 – 5 ml). N-Bromosuccinimide (1.24 g, 7.0 mmol) and Azobisiobutyronitrile (25 
mg, 0.15 mmol) were added. The resulting suspension was heated by microwave to 
110 °C for 15 min (low absorbance settings). The reaction mixture was diluted with 
DCM (50 ml) and washed with sat. Na2SO3 (2 x 50 ml). The organic phase was dried 
over MgSO4 and the solvent removed on a rotary evaporator, yielding 1.2 as a 
yellowish oil (1.18 g, 5.7 mmol, 83 %). The product was determined to be a 1.4:1 
mixture of the cis- and -trans isomer by comparison of the 1H-NMR with the literature 
references.219 The crude product was used in the next step without further purification. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.24 – 1.30 (m, 2 x 3H), 2.02 (d, J = 1.4 Hz, 3H), 
2.25 (d, J = 1.3 Hz, 3H), 3.92 (d, J = 0.6 Hz, 2H) 4.12 – 4.22 (m, 2 x 2H), 4.53 (s, 2H), 
5.75 (d, J = 1.4 Hz, 1H), 5.93 (t, J = 0.6 Hz, 1H). 
 
 
1.3. 1.3 was synthesized according to a modified procedure published by Richmond et 
al.220 Triphenylphosphine (2.63 g, 10.0 mmol) was dissolved in dry toluene (80 ml). To 
this solution 1.2 (1.89 g, 9.13 mmol) in dry toluene (20 ml) was added. The mixture 
was stirred for 24 h at room temperature under nitrogen. The precipitate was collected 
by filtration (frit) and washed with cold toluene. The white solid was dried in vacuo 
yielding 1.3 as an off-whiteish powder (3.60 g, 7.70 mmol, 84 %). The crude product 
was used in the next step without further purification. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.03 (t, J = 7.1 Hz, 3H), 1.18 (t, J = 7.1 Hz, 3H), 
1.99 (m, 2H), 2.12 (m, 2H), 3.76 (m, 2H), 4.05 (q, J = 7.1 Hz, 3H), 4.49 (m, 2H), 5.07 
(m, 2H), 5.61 (m, 2H), 5.78 (m, 1H), 6.28 (m, 1H), 7.64 – 7.79 (m, 30H).  
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1a. A solution of 1.3 (0.815 g, 1.7 mmol) in DCM (25 ml) was layered with sat. NaHCO3 
(25 ml) and then stirred vigorously for 5 min under nitrogen atmosphere. The mixture 
turned bright orange. A solution of 0.1 (0.33 g, 1.6 mmol) in DCM (15 ml) was added 
dropwise to the biphasic mixture. The mixture was stirred vigorously for 48 h at room 
temperature under nitrogen atmosphere. The organic phase was then separated from 
the aqueous phase. The aqueous phase was further washed with DCM (2 x 30 ml). 
The combined organic phases were dried over MgSO4 and the solvent removed on a 
rotary evaporator. Column chromatography (silica gel, Hexane/Et2O 3:1) yielded pure 
1a as a colorless oil (0.248 g, 1.0 mmol, 66 %). 
Rf = 0.17 (silica gel, Hexane/Et2O 3:1). UPLC (gradient U1): RT = 2.89 min. 1H NMR 
(400 MHz, CDCl3): δ (ppm) 1.18 (t, J = 7.1 Hz, 3H), 2.18 (t, J = 2.5 Hz, 3H), 2.45 (m, 
2H), 2.62 (m, 2H), 3.12 (m, 2H), 3.56 (s, 3H), 4.08 (q, J = 7.1 Hz, 2H), 5.98 (s, 1H). 13C 
NMR (101 MHz, CDCl3): δ (ppm). 14.33, 15.26, 25.84, 33.15, 44.20, 51.49, 59.19, 
126.97, 132.39, 152.85, 155.38, 164.76, 172.97. HR-ESI mass spectrum (MeOH): 
found 261.10961 calcd. for [C13H18O4+Na+] 261.10973. 
. 
 
4.1. Ethyl trans-β-methylcinnamate (0.504 ml, 2.8 mmol) was dissolved in MeOAc (2 
ml) in a Biotage microwave vial (2 – 5 ml). N-Bromosuccinimide (500 mg, 2.8 mmol) 
and Azobisiobutyronitrile (25 mg, 0.15 mmol) were added. The resulting suspension 
was heated by microwave to 110 °C for 12 min (low absorbance settings). The reaction 
mixture was diluted with DCM (50 ml) and washed with sat. Na2SO3 (2 x 50 ml). The 
organic phase was dried over MgSO4 and the solvent removed on a rotary evaporator, 
yielding 4.1 as a yellowish oil (734 mg, 2.7 mmol, 97 %). The analytical data matched 
that reported previously.221 The product was used in the next step without further 
purification. 
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1H NMR (500 MHz, CDCl3): δ (ppm) 1.34 (t, 3J = 7.2 Hz, 3H), 4.27 (q, J3 = 7.1 Hz, 2H), 
4.98 (s, 3H), 6.21 (s, 1H), 7.41 – 7.42 (m, 3H), 7.54 – 7.56 (m, 2H). 
 
4.2. To a stirred solution of 4.1 (2.50 g, 9.29 mmol) in dry toluene (100 ml), 
triphenylphosphine (2.56 g, 9.75 mmol) was added. The mixture was stirred for 24 h at 
room temperature under nitrogen. The precipitate was collected by filtration (frit) and 
washed with cold toluene. The white solid was dried in vacuo yielding 4.2 as a white 
powder (3.21 g, 6.04 mmol, 65 %). The analytical data matched that reported 
previously.95 The product was used in the next step without further purification. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.11 (t, J3 = 7.1 Hz, 3H), 3.89 (q, J3 = 7.1 Hz, 2H), 
6.06 (d, J = 5.3 Hz, 1H), 6.13 (d, J = 17.5 Hz, 2H), 7.21 -7.26 (m, 3H), 7.52 – 7.57 (m, 
7H), 7.66 – 7.77 (m, 10H). 
 
 
4a. A solution of 4.2 (2.56 g, 4.8 mmol) in DCM (50 ml) was layered with sat. NaHCO3 
(50 ml) and then stirred vigorously for 5 min under nitrogen atmosphere. The mixture 
turned bright orange. A solution of 0.1 (0.958 g, 4.6 mmol) in DCM (10 ml) was added 
dropwise to the biphasic mixture. The mixture was stirred vigorously for 48 h at room 
temperature under nitrogen atmosphere. The organic phase was then separated from 
the aqueous phase. The aqueous phase was further washed with DCM (2 x 30 ml). 
The combined organic phases were dried over MgSO4 and the solvent removed on a 
rotary evaporator. Column chromatography (silica gel, Hexane/EtOAc 5:1) yielded 
pure 4a as a yellowish oil, that solidified upon cooling (0.379 g, 1.3 mmol, 27 %). 
Rf = 0.66 (silica gel, Hexane/EtOAc 3:1). UPLC (gradient U1): RT = 3.20 min. 1H NMR 
(400 MHz, CDCl3): δ (ppm) 1.18 (t, 3J = 7.1 Hz, 3H), 2.62 (m, J = 7.8 Hz, 2H), 2.81 (m, 
J = 3.9 Hz, 2H), 3.48 (s, 2H), 3.69 (s, 3H), 4.12 (q, 3J = 7.1 Hz, 2H), 6.33 (s, 1H), 7.33-
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7.39 (m, 3H), 7.47-7.49 (m, 2H). 13C NMR (125 MHz, CDCl3): δ (ppm): 14.29, 26.16, 
33.46, 445..83, 51.89, 59.833, 12.., 117.78, 128.33, 18.88, 132.01, 135.81, 153.11, 
155.76, 164.39, 173.26. HR-ESI mass spectrum (MeOH): found 301.14358; calcd. for 
[C18H21O4] 301.14344. 
 
6.1. 6.1 was synthesized following a previously published procedure.222 Methyl 
acetoacetonate (18.6 ml, 172 mmol), trimethylorthoformate (19.2 ml, 175 mmol) and 
concentrated H2SO4 (12 drops) were stirred at room temperature under a nitrogen 
atmosphere. After 24 h, isoquinoline (20 drops) was added. The reaction mixture was 
distilled (190 mBar, 140 °C) to give 6.1 (18.38 g, 141 mmol, 82%) as a colorless liquid. 
The analytical data matched that reported previously.222  
1H NMR (400 MHz, CDCl3): δ (ppm): 2.23 (s, 3H), 3.57 (s, 3H), 3.61 (s, 3H), 4.96 (s, 
1H). 
 
 
6.2. 6.1 (0.763 g, 5.9 mmol) was dissolved in MeOAc (3 ml) in an Anton Paar 
microwave vial (10 ml). N-Bromosuccinimide (1.1 g, 6.2 mmol) and 
Azobisiobutyronitrile (45 mg, 0.3 mmol) were added. The resulting suspension was 
heated by microwave to 85 °C for 30 s. The reaction mixture was diluted with DCM (75 
ml) and washed with sat. Na2SO3 (2 x 75 ml). The organic phase was dried over MgSO4 
and the solvent removed on a rotary evaporator, yielding 6.1 as a yellow oil (0.892 mg, 
4.3 mmol, 73 %). The analytical data matched that reported previously.223 The product 
was used in the next step without further purification. 
1H NMR (400 MHz, CDCl3): δ (ppm): 3.69 (s, 3H), 3.71 (s, 3H), 4.51 (s, 2H), 5.12 
(s, 1H). 
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6.3. To a stirred solution of 6.2 (2.68 g, 12.8 mmol) in dry toluene (100 ml), 
triphenylphosphine (3.70 g, 14.1 mmol) was added. The mixture was stirred for 24 h at 
room temperature under nitrogen. The precipitate was collected by filtration (frit) and 
washed with cold toluene. The white solid was dried in vacuo yielding 6.3 as a white 
powder (3.23 g, 6.9 mmol, 54 %). The product was used in the next step without further 
purification. 
1H NMR (400 MHz, CDCl3): δ (ppm) 3.48 (s, 3H), 3.53 (s, 3H), 5.06 (1H), 5.75 (d, J = 
15.5 Hz, 2H) 7.65 – 7.87 (m, 15H). 
 
 
 
 
6a. A solution of 6.3 (1.63 g, 3.5 mmol) in DCM (50 ml) was layered with sat. NaHCO3 
(50 ml) and then stirred vigorously for 5 min under nitrogen atmosphere. The mixture 
turned bright orange. A solution of 0.1 (0.655 g, 3.1 mmol) in DCM (10 ml) was added 
dropwise to the biphasic mixture. The mixture was stirred vigorously for 48 h at room 
temperature under nitrogen atmosphere. The organic phase was then separated from 
the aqueous phase. The aqueous phase was further washed with DCM (2 x 30 ml). 
The combined organic phases were dried over MgSO4 and the solvent removed on a 
rotary evaporator. Column chromatography (silica gel, Hexane/EtOAc 2:1) yielded 
pure 7a as a yellowish oil (0.170 g, 0.7 mmol, 23 %). 
Rf = 0.12 (silica gel, Hexane/EtOAc 3:1). UPLC (gradient U1): RT = 2.18 min. 1H NMR 
(500 MHz, CDCl3): δ (ppm): 2.52 (t, 3J = 7.46 Hz, 2H), 2.70 (t, 3J = 7.42 Hz, 2H), 3.15 
(s, 2H), 3.63 (s, 3H), 3.66 (s, 3H), 3.89 (s, 3H) 6.27 (s, 1H). 13C NMR (125 MHz, CDCl3): 
δ (ppm): 26.69, 32.99, 40.60, 50.67, 51.77, 58.62, 103.66, 120.55, 156.25, 164.21, 
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168.11, 172.84. HR-ESI mass spectrum (MeOH): found 241.10702; calcd. for 
[C12H16O5+H+] 241.10705. 
 
 
 
2a. 1a (31 mg, 0.13 mmol) was dissolved in MeOH (1 ml) in an Anton Paar microwave 
vial (10 ml) equipped with a stirring bar. 1 M NaOH was added (0.4 ml) and the solution 
was heated by microwave to 120 °C for 15 min. UPLC measurement showed complete 
consumption of the starting material. The reaction solution was diluted with H2O (5 ml) 
and neutralized to pH = 3 by dropwise addition of 1 M HCl. 2a was obtained by 
evaporating the solvent in vacuo and was used without further purification.  
UPLC (gradient U1): RT = 1.91 min. 
 
 
3a. 2a (48 mg, 0.21 mmol) was dissolved in DMF (2 ml). Benzylamine (0.53 ml, 0.49 
mmol) and HOBt (66 mg, 0.49 mmol) were added under stirring. After 5 min, EDC (93 
mg, 0.49 mmol) and DIPEA (0.170 ml, 0.98 mmol) were added and the solution was 
stirred at room temperature for 48 h. The solvent was removed in vacuo and the crude 
was purified by preparative HPLC (Method A) and 3a was obtained as a yellowish 
powder (30 mg, 0.08 mm, 38 %).  
UPLC (gradient U1): RT = 2.65 min. 1H NMR (400 MHz, CDCl3): δ (ppm) 2.25 (m, 3H), 
2.49 (m, 2H), 2.72 – 2.75 (m, 2H), 3.25 – 3.26 (m, 2H), 4.34 (s, 2H), 4.46 (s, 2H), 6.11 
(s, 1H), 7.19 – 7.30 (m, 10H). 13C NMR (125 MHz, CDCl3): δ (ppm) 15.39, 27.54, 36.51, 
43.78, 44.05, 44.69, 127.99, 128.18, 128.40, 128.48, 129.45, 129.52, 130.64, 133.87, 
139.95, 140.68, 152.27, 152.95, 168.03, 174.92. HR-ESI mass spectrum (MeOH): 
found 375.20669; calcd. for [C24H27O2N2] 375.20670. 
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1b. A solution of 1a (59 mg, 0.25 mmol) and Re2(CO)10 (82 mg, 0.13 mmol) in o-Xylene 
(2 ml) in a Anton Paar microwave vial (10 ml) equipped with a stirring bar was heated 
to 220 °C for 15 min (Careful, toxic CO gas is released during the reaction, take 
appropriate precautions). The solvent was evaporated in vacuo, yielding pure 1b (97 
mg, 0.19 mmol, 76 %) as a dark brown oil.  
UPLC (gradient U1): RT = 3.40 min. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.31 (t, J = 
7.1 Hz, 3H), 2.50 (s, 3H), 2.49 – 2.53 (m, 2H), 2.63 – 2.82 (m, 2H), 3.71 (s, 3H), 4.18 
– 4.34 (m, 2H), 5.22 (d, J = 2.0 Hz, 1H), 5.77 (d, J = 2.0 Hz, 1H). 13C NMR (126 MHz, 
CDCl3): δ (ppm) 13.89, 14.27, 23.31, 35.60, 52.11, 61.12, 84.65, 85.58, 86.02, 107.08, 
110.77, 164.92, 172.55, 193.40. IR bands (Golden Gate, cm-1): 2024, 1921. HR-ESI 
mass spectrum (MeOH): found 509.06060; calcd. for [C16H18O7Re+H+] 509.06046. 
 
 
2b. A solution of 1b (40 mg, 0.079 mmol) in MeOH (1 ml) and 1 M NaOH (0.5 ml) in a 
Anton Paar microwave vial (10 ml) was heated by microwave to 120 °C for 15 min. The 
crude was diluted with 1 M HCl (20 ml) and washed with DCM twice (2 x 20 ml). The 
combined organic phase was washed once with water (20 ml) dried over MgSO4 and 
the solvent removed in vacuo yielding 2b as a pale yellow solid (25 mg, 0.054 mmol, 
68 %). Single crystals were obtained by slow evaporation of a MeOH solution. The 
product was used in the next step without further purification.  
UPLC (gradient U1): RT = 2.51 min. 1H NMR (400 MHz, CD3OD): δ (ppm) 2.49 (s, 3H), 
2.50 – 2.80 (m, 4H), 5.53 (d, J3 = 2.0 Hz, 1H), 5.93 (d, J3 = 2.1 Hz, 1H). 13C NMR (126 
MHz, CD3CO): δ (ppm) 13.97, 24.29, 36.55, 85.94, 87.53, 88.00, 109.12, 112.11, 
167.99, 175.72, 194.97. IR bands (Golden Gate, cm-1): 2024, 1920. HR-ESI mass 
spectrum (MeOH): found 464.99870; calcd. for [C13H10O7Re-] 464.99895. 
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3b. 2b (47 mg, 0.1 mmol) was dissolved in DMF (5 ml). Benzylamine (0.023 ml, 0.21 
mmol) and HOBt (29 mg, 0.21 mmol) were added under stirring. After 5 min, EDC (41 
mg, 0.21 mmol) and DIPEA (0.073 ml, 0.42 mmol) were added and the solution was 
stirred for 24 h. The solvent was removed in vacuo and the crude was purified by 
preparative HPLC (Method A) and 3a was obtained as a pale yellow powder (10 mg, 
0.016 mmol, 16 %). Single crystals were obtained by slow evaporation of a MeOH 
solution.  
UPLC (gradient U1): RT = 3.20 min. 1H NMR (400 MHz, CDCl3): δ (ppm) 2.45 (t, 3J = 
7.2 Hz, 2H), 2.48 (s, 3H), 2.64 – 2.78 (m, 2H), 4.32 – 4.51 (m, 4H), 5.40 (d, J3 = 2.0 
Hz, 1H), 5.97 (d, J3 = 2.0 Hz, 1H) 7.21 – 7.30 (m, 10H) 8.40 – 8.44 (m, 2H). 13C NMR 
(125 MHz, CDCl3): δ (ppm) 14.17, 25.30, 38.73, 43.98, 44.12, 49.00, 84.82, 86.78, 
90.93, 108.57, 111.42, 128.14, 128.26, 128.38, 128.56, 129.50, 129.57, 139.85, 
139.99, 166.28, 173.85, 195.29. IR bands (Golden Gate, cm-1): 2017, 1906. HR-ESI 
mass spectrum (MeOH): found 645.13941; calcd. for [C27H26O5N2Re+H+] 645.13937. 
 
 
4b. 4a (96 mg,, 0.32 mmol) was dissolved in o-Xylene (2 ml) in a Anton Paar microwave 
vial (10 ml). Re2(CO)10 (104 mg, 0.16 mmol) was added and the mixture was heated 
by microwave to 220 °C for 15 min (Careful, toxic CO gas is released during the 
reaction, take appropriate precautions). The solvent was evaporated in vacuo and the 
crude was purified by column chromatography (silica gel, Hexane/EtOAc 5:1) yielding 
pure 4b as a yellowish oil (83%).  
Rf = 0.59 (silica gel, Hexane/EtOAc 3:1). UPLC (gradient U1): RT = 3.55 min. 1H NMR 
(500 MHz, CDCl3): δ (ppm) 1.20 (t, 3J = 7.1 Hz, 3H), 2.56 (t, 3J = 7.5 Hz, 2H), 2.74 – 
2.89 (m, 2H), 3.73 (s, 3H), 4.13 – 4.25 (m, 2H), 5.51 (d, 3J = 2.1 Hz, 1H), 5.91 (d, 3J = 
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2.1 Hz, 1H), 7.32-7.33 (m, 3H), 7.42-7.44 (m, 2H). 13C NMR (126 MHz, CDCl3): δ (ppm) 
14.05, 23.32, 35.70, 52.13, 61.35, 85.57, 87.00, 87.26, 106.95, 114.56, 127.94, 
129.10, 130.69, 131.02, 163.97, 172.44, 193.09. IR bands (Golden Gate, cm-1): 2023, 
1920. HR-ESI mass spectrum (MeOH): found 571.07646; calcd. for [C21H19O7Re+H+] 
571.07611. 
 
 
 
 
5b. A solution of 4b (82 mg, 0.144 mmol) in MeOH (2 ml) and 1 M NaOH (0.25 ml) in 
a Anton Paar microwave vial (10 ml) was heated by microwave to 120 °C for 15 min. 
The crude was diluted with 1 M HCl (20 ml) and washed with DCM twice (2 x 20 ml). 
The combined organic phase was washed once with water (20 ml) dried over MgSO4 
and the solvent removed in vacuo yielding 5b as a pale yellow oil (70 mg, 0.133 mmol, 
92 %). The product was used in the next step without further purification.  
UPLC (gradient U1): RT = 2.75 min. 1H NMR (400 MHz, CD3OD): δ (ppm) 2.59-2.63 
(m, 2H), 2.71 – 2.88 (m, 2H), 5.78 (d, J = 2.2 Hz, 1H), 6.07 (d, J = 2.2 Hz, 1H), 7.30-
7.32 (m, 3H), 7.47-7.49 (m, 2H). 13C NMR (125 MHz, CD3OD): δ (ppm): 24.27, 36.61, 
86.75, 89.06, 89.11, 109.13, 115.67, 128.73, 129.74, 131.96, 132.31, 167.00, 175.74, 
194.66. IR bands (Golden Gate, cm-1): 2024, 1918.  
 
 
6b. 6a (64 mg,, 0.27 mmol) was dissolved in o-Xylene (3 ml) in a Anton Paar microwave 
vial (10 ml). Re2(CO)10 (87 mg, 0.13 mmol) was added and the mixture was heated by 
microwave to 220 °C for 15 min (Careful, toxic CO gas is released during the reaction, 
take appropriate precautions). The solvent was evaporated in vacuo and the crude was 
purified by column chromatography (silica gel, Hexane/EtOAc 2:1) yielding pure 6b as 
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a yellow oil (64 mg, 0.12 mmol, 44 %). Rf = 0.14 (silica gel, Hexane/EtOAc 3:1). UPLC 
(gradient U1): RT = 2.97 min.  
 
1H NMR (500 MHz, CDCl3): δ (ppm): 2.47 – 2.51 (m, 2H), 2.59 – 2.85 (m, 2H), 3.71 
(s, 3H), 3.73 (s, 3H), 3.80 (s, 3H), 5.11 (d, J = 2.3 Hz, 1H), 5.58 (d, J = 2.2 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ (ppm): 23.85, 35.31, 52.07, 52.12, 59.00, 66.31, 72.52, 
80.02, 100.80, 145.14, 164.47, 172.39, 192.70. IR bands (Golden Gate, cm-1): 2024, 
1921. HR-ESI mass spectrum (MeOH): found 511.03967; calcd. for [C15H15O8Re+H+] 
511.03972. 
 
 
7b. A solution of 6b (51 mg, 0.101 mmol) in MeOH (3 ml) and 1 M NaOH (0.4 ml) in 
an Anton Paar microwave vial (10 ml) was heated by microwave to 120 °C for 15 min. 
The crude was diluted with 1 M HCl (10 ml) and washed with DCM twice (2 x 10 ml). 
The combined organic phase was washed once with water (10 ml) dried over MgSO4 
and the solvent removed in vacuo yielding 7b as a pale yellow solid (23 mg, 0.048 
mmol, 48 %). The product was used in the next step without further purification.  
UPLC (gradient U1): RT = 2.34 min. 1H NMR (500 MHz, CD3OD): δ (ppm): 2.46 – 2.83 
(m, 4H), 3.72 (s, 3H), 5.58 (s, 1H), 5.73 (s, 1H). 13C NMR (125 MHz, CD3OD): δ (ppm): 
24.95, 30.75, 36.35, 59.36, 68.49, 81.75, 103.04, 147.10, 167.45, 175.74, 194.49. IR 
bands (Golden Gate, cm-1): 2025, 1923. HR-ESI mass spectrum (MeOH+NaOH): 
found 504.99033; calcd. for [C13H11O8Re+Na+] 504.99037. 
 
 
8a. 1a (38 mg, 0.16 mmol) was dissolved in MeOH (1 ml) in an Anton Paar microwave 
vial (10 ml) equipped with a stirring bar. 1 M NaOH was added (0.150 ml, 0.150 mmol) 
and the solution was heated to 120 °C for 15 min. UPLC measurement showed 
complete consumption of the starting material. The reaction solution was diluted with 
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H2O (5 ml) and neutralized to pH = 3 by dropwise addition of 1 M HCl. 8a was obtained 
by evaporating the solvent in vacuo and was used without further purification.  
UPLC (gradient U1): RT = 2.49 min. 
 
 
9a. 8a (59 mg, 0.26 mmol) was dissolved in DMF (4 ml). Benzylamine (0.031 ml, 0.29 
mmol) and HOBt (39 mg, 0.29 mmol) were added under stirring. After 5 min, EDC (55 
mg, 0.29 mmol) and DIPEA (0.100 ml, 0.57 mmol) were added and the solution was 
stirred for 48 h. The solvent was removed in vacuo and the crude was purified by 
preparative HPLC (Method A) and 9a was obtained as a yellow oil (57 mg, 0.18 mmol, 
69 %).  
UPLC (gradient U1): RT = 2.76 min. 1H NMR (400 MHz, CDCl3): δ (ppm): 1.29 (t, J3 = 
7.1 Hz, 3H), 2.27 (t, J3 = 2.3 Hz, 3H), 2.48 (t, J3 = 7.5 Hz, 2H), 2.76 (t, J3 = 7.5 Hz, 2H), 
3.21 (m, 2H), 4.18 (q, J3 = 7.1 Hz, 2H), 4.42 (d, J = 5.7 Hz, 2H), 6.08 (s, 1H), 6.13 (t, J 
= 5.3 Hz, 1H), 7.20 – 7.33 (m, 5H). 13C NMR (126 MHz, CDCl3): δ (ppm): 14.57, 15.59, 
26.73, 35.89, 43.93, 44.42, 59.63, 127.20, 127.79, 127.89, 128.88, 133.07, 137.86, 
153.11, 155.85. 165.26, 172.61. HR-ESI mass spectrum (MeOH): found 314.17497; 
calcd. for [C19H23NO3+H+] 314.17507. 
 
 
10a. 9a (50 mg, 0.16 mmol) was dissolved in MeOH (2 ml) in an Anton Paar microwave 
vial (10 ml) equipped with a stirring bar. 1 M NaOH (1 ml) was added and the solution 
was heated to 120 °C for 5 min. UPLC measurement showed complete consumption 
of the starting material. The reaction solution was diluted with H2O (5 ml) and 
neutralized to pH = 3 by dropwise addition of 1 M HCl. 10a was obtained by 
evaporating the solvent in vacuo and was used without further purification.  
UPLC (gradient U1): RT = 2.33 min. 
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11a. The crude of 10a obtained from 9a (36 mg, 0.115 mmol) was dissolved in DMF 
(3 ml).  O-tertbutyl-L-Phenylalanine (33 mg, 0.13 mmol) and HOBt (17 mg, 0.13 mmol) 
were added under stirring. After 5 min, EDC (24 mg, 0.13 mmol) and DIPEA (0.044 ml, 
0.25 mmol) were added and the solution was stirred for 24 h. The solvent was removed 
in vacuo and the crude was purified by preparative HPLC (Method A) and 11a was 
obtained as a yellow oil (15 mg, 0.03 mmol, 26 % from 9a).  
UPLC (gradient U1): RT = 3.19 min. 1H NMR (500 MHz, CDCl3) δ (ppm) 1.41 (s, 9H), 
2.22 (t, J3 = 2.2 Hz, 3H), 2.43 (t, J3 = 7.6 Hz, 3H), 2.75 (t, J3 = 7.6 Hz, 2H), 3.12 – 3.16 
(m, 4H), 4.44 (d, J3 = 5.7 Hz, 2H), 4.86 (m, 1H), 5.80 (m, 1H), 5.98 (d, J3 = 7.5 Hz, 1H), 
6.04 (s, 1H), 7.15 – 7.33 (m, 10H). 13C NMR (126 MHz, CDCl3): δ (ppm): 15.37, 26.50, 
28.13, 35.98, 38.35, 43.83, 53.40, 76.90, 77.16, 77.41, 82.48, 127.05, 127.73, 127.94, 
128.46, 128.60, 128.89, 129.57, 129.74, 133.12, 136.54, 138.26, 150.68, 151.24, 
164.70, 171.23, 171.79. HR-ESI mass spectrum (MeOH): found 489.27518; calcd. for 
[C30H35N2O4+H+] 489.27478. 
 
 
8b. 8a (80 mg, 0.34 mmol) was dissolved in DMF (4 ml) in an Anton Paar microwave 
vial (10 ml). Re2(CO)10 (110 mg, 0.17 mmol) was added and the mixture was heated 
by microwave to 220 °C for 15 min (Careful, toxic CO gas is released during the 
reaction, take appropriate precautions). UPLC showed complete consumption of the 
starting material. The crude solution was dried in vacuo and used without further 
purification in the next step.   
UPLC (gradient UMS1): RT = 2.88 min. 
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9b. 8b (154 mg, 0.31 mmol) was dissolved in DMF (5 ml). Benzylamine (0.037 ml, 0.34 
mmol) and HOBt (46 mg, 0.34 mmol) were added under stirring. After 5 min, EDCI (66 
mg, 0.34 mmol) and DIPEA (0.120 ml, 0.69 mmol) were added and the solution was 
stirred for 24 h. The solvent was removed in vacuo and the crude was purified by 
preparative HPLC (Method A) and 9b was obtained as an orange oil (45 mg, 0.08 
mmol, 26%).  
UPLC (gradient U1): RT = 3.23 min. 1H NMR (400 MHz, CDCl3): δ (ppm): 1.31 (t, J3 = 
7.1 Hz, 3H), 2.40 (m, J = 3.3 Hz, 2H), 2.48 (s, 3H) 2.68 – 2.88 (m, 2H), 4.17 – 4.34 (m, 
2H), 4.45 (d, J = 5.7, 2 H), 5.20 (d, J = 2.1 Hz, 1H), 5.77 (d, J = 2.2 Hz, 1H), 5.85 (t, 1 
H), 7.25 – 7.36 (m, 5H). 13C NMR (125 MHz, CDCl3): δ (ppm): 13.87, 14.28, 23.75, 
38.07, 44.10, 61.13, 84.61, 85.73, 86.06, 107.58, 110.76, 127.95, 128.04, 128.99, 
137.78, 164.92, 171.19, 193.56. IR bands (Golden Gate, cm-1): 2021, 1918. HR-ESI 
mass spectrum (MeOH): found 584.10780; calcd. for [C22H23O6NRe+H+] 584.10774.  
 
 
10b. A solution of 9b (43 mg, 0.074 mmol) in MeOH (2 ml) and 1 M NaOH (0.15 ml) in 
an Anton Paar microwave vial (10 ml) was heated by microwave to 110 °C for 15 min. 
The crude was diluted with 1 M HCl (10 ml) and washed with DCM twice (2 x 10 ml). 
The combined organic phase was washed once with water (10 ml) dried over MgSO4 
and the solvent removed in vacuo yielding 10b as an orange solid (32 mg, 0.058 mmol, 
78 %). The product was used in the next step without further purification.  
UPLC (gradient U1): RT = 2.81 min. 1H NMR (400 MHz, CD3OD): δ (ppm): 2.45 (s, 
3H), 2.45 (m, 2H), 2.61 – 2.68 (m, 1H), 2.75 – 2.82 (m, 1H), 4.37 (m, 2H), 5.42 (d, J3 
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= 2.1 Hz, 1H), 5.89 (d, J3 = 2.2 Hz, 1H), 7.21 – 7.32 (m, 5H). 13C NMR (101 MHz, 
CD3OD): δ (ppm): 12.63, 23.71, 37.17, 42.77, 84.60, 86.65, 107.46, 110.82, 126.87, 
127.26, 128.18, 138.49, 166.58, 172.44, 193.60. IR bands (Golden Gate, cm-1): 2021, 
1917. HR-ESI mass spectrum (MeOH): found 554.06196; calcd. for [C20H18O6NRe-H+] 
554.06189.  
 
11b. 10b (181 mg, 0.326 mmol) was dissolved in DMF (2 ml). O-tertbutyl-L-
Phenylalanine (93 mg, 0.36 mmol) and HOBt (49 mg, 0.36 mmol) were added under 
stirring. After 5 min, EDCI (69 mg, 0.36 mmol) and DIPEA (0.125 ml, 0.72 mmol) were 
added and the solution was stirred for 24 h. The solvent was removed in vacuo and 
the crude was purified by preparative HPLC (Method A) and 11b was obtained as a 
pale red solid and directly used for the next step (112.8 mg, 0.149 mmol, 46%).  
UPLC (gradient U1): RT = 3.68 min. 
 
 
12b. 11b (15 mg, 0.02 mmol) was dissolved in DCM (2 ml) in an Anton Paar microwave 
vial (10 ml). TFA (0.5 ml) was added and the solution was heated to 80 °C by 
microwave for 15 min. The solvent was evaporated and the crude was purified by 
preparative HPLC (Method A) and 12b was obtained as an orange oil (15 mg, 0.16 
mmol, 80 %).  
UPLC (gradient U1): RT = 3.08 min, 3.13 min. 1H NMR (500 MHz, CD3OD): δ (ppm): 
2.31 (s, 3 H), 2.37 (s, 3H), 2.42 – 2.45 (m, 4H), 2.61 – 2.67 (m, 2H), 2.72 – 2.79 (m, 
2H), 3.04 – 3.09 (m, 2H), 3.25 – 3.29 (m, 2H), 4.34 – 4.35 (m, 4H), 4.71 – 4.75 (m, 
2H), 5.35 (d, J3 = 2.0 Hz, 1H), 5.38 (d, J3 = 2.0 Hz, 1H), 5.95 (d, J3 = 2.0 Hz, 1H ), 5.96 
(d, J3 = 2.0 Hz, 1H), 7.16 – 7.32 (m, 20H). 13C NMR (101 MHz, CD3OD): 13.98, 25.21, 
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25.25, 37.90, 38.07, 38.62, 38.78, 44.17, 44.19, 55.16, 55.23, 85.50, 85.65, 86.61, 
87.26, 90.94, 91.47, 107.56, 108.37, 110.41, 110.74, 127.81, 128.27, 128.36, 128.65, 
128.67, 129.53, 129.59, 130.15. 130.25, 138.46, 138.49, 139.84, 165.84, 166.12, 
173.85, 173.88, 174.37, 174.56, 195.12. IR bands (Golden Gate, cm-1): 2021, 1921. 
HR-ESI mass spectrum (MeOH): found 725.12675; calcd. for [C29H27N2O7Re+Na+] 
725.12680.  
 
 [99mTc(OH2)3(CO)3]+  
A Biotage microwave vial (2 – 5 ml) was charged with sodium boranocarbonate (4 mg, 
38.5 µmol), sodium tartrate dihydrate (7 mg, 30.4 µmol) and sodium tetraborate 
decahydrate (7 mg, 18.5 µmol). The vial was sealed and flushed with N2 for 5 min 
before adding [99mTcO4]- eluate (1-2 ml) from a commercial generator. The solution was 
heated by microwave to 110 °C for 7 min. In order to normalize the overpressure, 
evolving gases were released with a 1 ml disposable syringe. Excess sodium 
boranocarbonate was quenched via dropwise addition of 1 M HCl to pH = 2 and the 
solution was subsequently basified by addition of 1 M NaOH to pH = 8. 
 
General procedure for the labelling of Cp-Ligands 1a, 4a, 6a, 3a and 12a. 
Generally, 0.5 ml of a 5 mM stock solution of the respective ligand in MeOH was added 
to a Biotage microwave vial (2 – 5 ml). The vial was sealed, and the solvent was 
removed by passing a stream of N2 through the vial via two syringe needles for 30 min. 
Method A (1a, 4a, 6a). [99mTc(OH2)3(CO)3]+ (0.5 ml, pH = 8) was added to the dried 
ligand and the pH adjusted to 12 by addition of 1 M NaOH. The solution was heated 
by microwave to 120 °C for 30 min. In order to normalize the overpressure, evolving 
gases were released with a 1 ml disposable syringe-needle. 
Method B “one pot” (1a, 4a, 6a, 3a, 12a). The vial with the dried ligand was opened 
and sodium boranocarbonate (4 mg, 38.5 µmol), sodium tartrate dihydrate (7 mg, 30.4 
µmol) and sodium tetraborate decahydrate (7 mg, 18.5 µmol). The vial was sealed 
again and flushed with N2 for 5 min before adding [99mTcO4]- eluate (1-2 ml) from a 
commercial generator. The solution was heated by microwave to 120 °C for 30 min (1a, 
4a, 6a) or 140 °C for 30 min (3a) or 2 x 30 min (12a). Complexes 2c, 5c, 7c and 3c 
were obtained in radiochemical puritiy > 95%. For 12c, some [99mTcO4]- and 
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[99mTc(OH2)3(CO)3]+  was observed (< 20 %). 12c was purified by loading the reaction 
mixture onto a Chromafix C18 cartridge and washing it with H2O (2 ml). Pure 12c could 
be eluted by washing the cartridge with MeOH (2 ml). 
 
 
 
13. S2b (140 mg, 0.33 mmol), benzylamine (0.072 ml, 0.66 mmol), HBTU (251 mg, 
0.66 mmol) and DIPEA (0.115 ml, 0.66 was dissolved in DMF (6 ml) and stirred at room 
temperature for 2 h. H2O (4 ml) was added to the reaction solution and an off-white 
precipitate was observed. The precipitate was collected by centrifugation, washed with 
water (2 x 5 ml) and dried in vacuo yielding 13 (no yield was determined). 
1H NMR (400 MHz, CD3OD): δ (ppm) 4.47 (s, 4H), 6.21 (d, J3 = 1.8 Hz, 2H), 6.82 (t, J3 
= 1.8 Hz, 1H), 7.24 – 7.32 (m, 10H). 
 
 
15. 14 (1.34 g, 10.5 mmol) was dissolved in a DCM/DMF mixture (55 ml, 10:1 
DCM/DMF). HBTU (8 g, 21 mmol) and DIPEA (3.7 ml, 21 mmol) were added and the 
mixture was stirred for 24 h at room temperature. The solvent was evaporated in vacuo 
and the crude was purified by column chromatography on silica (3:2, Hexane/EtOAc) 
yielding pure 15 (0.62 g, 2.9 mmol, 28 %). 
Rf: 0.4 (silica gel, Hexane/EtOAc 3:2). 1H NMR (400 MHz, CD3OD): δ (ppm) 2.14 (d, 
J3 = 1.4 Hz, 3H), 2.39 (s, 3H), 4.48 (s, 2H), 6.87 (q, J3 = 1.4 Hz, 1H), 7.26 – 7.38 (m, 
5H). 
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16. 15 (0.295 g, 1.4 mmol) and benzylamine (0.164 ml, 1.5 mmol) were dissolved in 
toluene (10 ml). The solution was refluxed through a Dean-Stark apparatus overnight. 
The next day the solvent was evaporated in vacuo and the crude was purified by 
column chromatography on silica (3:2, Hexane/EtOAc) yielding pure 16 (0.171 g, 0.56 
mmol, 40 %). 
Rf: 0.34 (silica gel, Hexane/EtOAc 3:2). 1H NMR (400 MHz, CDCl3): δ (ppm) 1.25 (s, 
3H), 1.96 (d, J3 = 1.6 Hz, 3H), 3.06 (m, 2H), 4.43 – 4.61 (m, 2H), 5.98 (q, J3 = 1.6 Hz, 
1H), 7.04 – 7.28 (m, 10H). 
 
 
19. 18 (83 mg, 0.58 mmol) and aniline (0.06 ml, 0.64 mmol) were dissolved in toluene 
(15 ml). The solution was refluxed through a Dean-Stark apparatus overnight. The next 
day the solvent was evaporated in vacuo yielding 19. 
1H NMR (400 MHz, CDCl3): δ (ppm) 2.00 (s, 3H), 2.45 (s, 3H), 3.79 (s, 3H, 6.39 (s, 
1H), 6.69 (d, J3 = 7.4 Hz, 2H), 7.08 (t, J3 = 7.4 Hz, 1H), 7.33 (t, J3 = 7.4 Hz, 2H). 
 
 
20. 4-ocytne (0.1 ml, 0.7 mmol), α-trifluoromethylacrylic acid t-butyl ester (0.1 ml), 
Ni(cod)2 (186 mg, 0.7 mmol), and tricyclohexylphosphine (192 mg, 0.7 mmol) were 
dissolved in toluene (5 ml) in a glove-box. The solution was stirred at room temperature 
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for 48 h. The crude was filtered through a pad of silica with EtOAc (10 ml), concentrated 
in vacuo and purified by column chromatography on silica (20:1 Hexane/EtOAc) 
yielding pure 20. 
1H NMR (400 MHz, CDCl3): δ (ppm) 0.90 (m, 6H), 1.42 – 1.53 (m, 13H), 2.22 (t, J3 = 
7.5 Hz, 2H), 2.31 (t, J3 = 7.5 Hz, 2H), 3.07 (d, J3 = 7.5 Hz, 2H).  
 
 
 
 
Re
OC
CO
CO
Ph
O
N
H
O
N
H
Re
OC
CO
CO
Ph
O
OH
O
HO
benzylamine
HOBt, EDC
DIPEA
25 °C, 24 h
DMF
 
21. 5b (28 mg, 0.053 mmol) was dissolved in DMF (2 ml). Benzylamine (0.013 ml, 0.12 
mmol) and HOBt (16 mg, 0.12 mmol) were added under stirring. After 5 min, EDC (22 
mg, 0.12 mmol) and DIPEA (0.040 ml, 0.23 mmol) were added and the solution was 
stirred for 24 h. The solvent was removed in vacuo and the crude was purified by 
preparative HPLC (Method A) and 21 was obtained as a pale orange oil (18 mg, 0.026 
mmol, 49 %). 
UPLC (gradient U1): RT = 3.37 min. 1H NMR (400 MHz, CDCl3): δ (ppm) 2.44 (t, J3 = 
7.24 Hz, 2H), 2.26 – 2.93 (m, 2H), 4.36 (d, J3 = 5.7 Hz, 2H), 4.44 (d, J3 = 5.68 Hz, 2H), 
5.46 (d, J3 = 2.7 Hz, 2H) 5.66 (d, J3 = 5.5 Hz, 2H), 5.91 (m, 2H), 7.04 – 7.06 (m, 2H), 
7.24 - 7.29 (m, 13H). 13C NMR (125 MHz, CDCl3): δ (ppm): 23.64, 38.10, 44.05, 44.12, 
77.36, 86.00, 87.15, 107.04, 109.81, 127.74, 127.84, 128.02, 128.81, 128.94, 129.09, 
129.57, 130.31, 131.10, 137.20, 137.90, 162.81, 170.91, 193.55. IR bands (Golden 
Gate, cm-1): 2021, 1919. HR-ESI mass spectrum (MeOH): found 729.13591; calcd. for 
[C32H27N2O5Re+Na+] 729.13697. 
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22. 7b (23 mg, 0.048 mmol) was dissolved in DMF (2 ml). Benzylamine (0.011 ml, 0.11 
mmol) and HOBt (14 mg, 0.11 mmol) were added under stirring. After 5 min, EDC (20 
mg, 0.11 mmol) and DIPEA (0.037 ml, 0.21 mmol) were added and the solution was 
stirred for 24 h. The solvent was removed in vacuo and the crude was purified by 
preparative HPLC (Method A) and 22 was obtained as a pale orange solid (8 mg, 0.012 
mmol, 25 %). 
UPLC (gradient U1): RT = 3.13 min.  1H NMR (400 MHz, CDCl3): δ (ppm): 2.33 – 2.42 
(m, 2H) 2.62 – 2.69 (m, 1H), 2.85 – 2.97 (m, 1H), 3.68 (s, 3H), 4.44 – 4.46 (m, 2H), 
4.55 – 4.57 (m, 2H), 5.16 (d, J3 = 2.3 Hz, 1H), 5.77 (d, 2.2 Hz, 1H), 5.80 (m, 1H), 6.88 
(m, 1H), 7.26 – 7.34 (m, 10H). 13C NMR (126 MHz, CDCl3): δ (ppm): 24.18, 29.86, 
37.88, 43.28, 43.96, 59.34, 66.68, 80.47, 100.71, 127.42, 127.55, 127.97, 128.87, 
128.95, 138.05, 138.47, 141.29, 162.98, 170.73, 193.16. IR bands (Golden Gate, cm-
1): 2020, 1919. HR-ESI mass spectrum (MeOH): found 683.11702; calcd. for 
[C27H25N2O6Re+Na+] 683.11623. 
O
O
O
O
Br
O
O
O
O
PPh3
Br
PPh3
25 °C, 24 h
dry Toluene
 
26. 25 (800 mg, 3.0 mmol) was dissolved in dry toluene (60 ml) and kept under a 
nitrogen atmosphere. To this solution triphenylphosphine (870 mg, 3.3 mmol) was 
added. The solution was stirred at room temperature and under nitrogen for 24 h. The 
precipitate was collected by filtration (frit) and washed with cold toluene. The white 
solid was dried in vacuo yielding 26 as an off-whiteish powder (no yield was 
determined). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.04 (t, J3 = 7.16 Hz, 3H), 1.23 (t, J3 = 7.14 Hz, 
3H), 3.74 (q, J3 = 7.14 Hz, 2H), 4.12 (t, J3 = 7.14 Hz, 2H), 5.30 – 5.33 (m, 2H), 7.04 – 
7.05 (m, 1H), 7.63 – 7.93 (m, 15H). 
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28. 27 (482 mg, 1.85 mmol) was dissolved in dry toluene (50 ml) and kept under a 
nitrogen atmosphere. To this solution triphenylphosphine (0.5 mg, 1.9 mmol) was 
added. The solution was stirred at room temperature and under nitrogen for 24 h. The 
precipitate was collected by filtration (frit) and washed with cold toluene. The white 
solid was dried in vacuo yielding 28 as a white powder (no yield was determined). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.05 (t, J3 = 8 Hz, 3H), 3.87 (q, J3 = 8 Hz, 2H), 
5.55 - 5.60 (m, 2H), 6.37 – 6.38 (m, 1H), 7.63 – 7.73 (m, 15H). 
 
 
 
 
 
Figure 29.1H NMR of 0.1 in CDCl3. 
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Figure 30. 1H NMR of 1.1 in CDCl3. 
 
Figure 31. 1H NMR of 1.2 in CDCl3. 
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Figure 32. 1H NMR of 1.3 in CDCl3. 
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Figure 33. 1H NMR of 1a in CDCl3. 
 
Figure 34.13C NMR of 1a in CDCl3. 
 
Figure 35. 1H NMR of 1b in CDCl3. 
  
 
138 
 
 
 
Figure 36.13C NMR of 1b in CDCl3. 
 
Figure 37. 1H NMR of 2b in CD3OD. 
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Figure 38.13C NMR of 2b in CD3OD. 
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Figure 39.1H NMR of 3b in CDCl3. 
 
 
Figure 40. 13C NMR of 3b in CDCl3. 
 
 
Figure 41. 1H NMR of 3a in CD3OD. 
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Figure 42. 13C NMR of 3a in CD3OD. 
 
 
Figure 43.1H NMR of 4.1 in CDCl3. 
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Figure 44. 1H NMR of 4.2 in CDCl3. 
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Figure 45. 1H NMR of 4a in CDCl3. 
 
Figure 46. 13C NMR of 4a in CDCl3. 
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Figure 47. 1H NMR of 4b in CDCl3. 
 
 
Figure 48. 13C NMR of 4a in CDCl3. 
 
Figure 49. 1H NMR of 5b in CD3OD. 
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Figure 50. 13C NMR of 5b in CD3OD. 
 
 
Figure 51. 1H NMR of 6.1 in CDCl3. 
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Figure 52.1H NMR of 6.2 in CDCl3. 
 
 
Figure 53.1H NMR of 6.3 in CDCl3. 
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Figure 54. 1H NMR of 6a in CDCl3. 
 
 
Figure 55. 13C NMR of 6a in CDCl3. 
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Figure 56. 1H NMR of 6b in CDCl3. 
 
 
Figure 57. 13C NMR of 6b in CDCl3. 
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Figure 58. 1H NMR of 7b in CD3OD. 
 
 
Figure 59. 13C NMR of 7b in CD3OD. 
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Figure 60. 1H NMR of 9a in CDCl3. 
 
 
Figure 61. 13C NMR of 9a in CDCl3. 
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Figure 62. 1H NMR of 11a in CDCl3. 
 
 
Figure 63. 13C NMR of 11a in CDCl3. 
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Figure 64. 1H NMR of 9b in CDCl3. 
 
Figure 65. 13C NMR of 9b in CDCl3. 
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Figure 66. 1H NMR of 10b in CD3OD. 
 
 
Figure 67. 1H NMR of 10b in CD3OD. 
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Figure 68. 1H NMR-shift assignments for 12b in CD3OD (Amide and Carboxylic protons are 
not visible due to deuterium exchange).  
 
Figure 69.13C NMR of 12b in CD3OD. 
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Figure 70. The two possible diastereoisomers of 11b formed due to the planar chirality of the 
Cp-ligand combined with the chiral center at the attached aminoacid. 
 
Figure 71. 1H NMR of 13 in MeOD. 
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Figure 72. 1H NMR of 15 in CDCl3. 
 
Figure 73. 1H NMR of 16 in CDCl3. 
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Figure 74. 1H NMR of 19 in CDCl3. 
 
 
Figure 75. 1H NMR of 20 in CDCl3. 
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Figure 76. 1H NMR of 21 in CDCl3. 
 
Figure 77. 13C NMR of 21 in CDCl3.  
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Figure 78. 1H NMR of 22 in CDCl3. 
 
Figure 79. 13C NMR of 22 in CDCl3. 
 
 
  
 
160 
 
 
 
 Figure 80. 1H NMR of 26 in CDCl3. 
 
Figure 81. 1H NMR of 28 in CDCl3. 
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Table 2.  Crystal data and structure refinement for 2b. 
Empirical formula  C13H11O7Re 
Diffractometer  Xcalibur Ruby 
Wavelength [Å]  0.71073 
Formula weight  465.42 
Crystal system  Triclinic 
Space group  P-1 
a [Å]  7.9181(4)  
b [Å]  8.2128(4)  
c [Å]  12.5431(6)  
a [°]  92.787(4) 
b [°]  103.453(5) 
g [°]  117.593(5) 
Volume [Å3]  691.40(7)  
Z 2 
Density (calculated) [Mg/m3]  2.236  
Absorption coefficient [mm-1]  8.818 
F(000) 440 
Crystal size [mm3]  0.270 x 0.110 x 0.090  
Crystal description colourless prism 
Theta range for data collection [°]  2.846 to 32.886 
Index ranges -11<=h<=11, -12<=k<=12, -18<=l<=18 
Reflections collected 13095 
Independent reflections 4680 [R(int) = 0.0416] 
Reflections observed 4283 
Criterion for observation I > 2(I) 
Completeness to theta  100.0 % to 25.242°  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.37184 
Data / restraints / parameters 4680 / 0 / 195 
Goodness-of-fit on F2 1.023 
Final R indices [I>2sigma(I)] R1 = 0.0256, wR2 = 0.0482 
R indices (all data) R1 = 0.0300, wR2 = 0.0499 
Extinction coefficient n/a 
Largest diff. peak and hole [e.Å-3]  1.312 and -1.135 
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Table 3.  Crystal data and structure refinement for 3b. 
Empirical formula  C27H25N2O5Re 
Diffractometer  Xcalibur Ruby 
Wavelength [Å]  0.71073 
Formula weight  643.69 
Crystal system  Orthorhombic 
Space group  Fdd2 
a [Å]  36.3108(13)  
b [Å]  23.5876(8)  
c [Å]  11.6762(4)  
a [°]  90 
b [°]  90 
g [°]  90 
Volume [Å3]  10000.5(6)  
Z 16 
Density (calculated) [Mg/m3]  1.710  
Absorption coefficient [mm-1]  4.900 
F(000) 5056 
Crystal size [mm3]  0.280 x 0.200 x 0.100  
Crystal description colourless prism 
Theta range for data collection [°]  2.244 to 32.788 
Index ranges -29<=h<=54, -14<=k<=34, -17<=l<=11 
Reflections collected 13972 
Independent reflections 6394 [R(int) = 0.0283] 
Reflections observed 5853 
Criterion for observation I > 2(I) 
Completeness to theta  99.9 % to 25.242°  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.52864 
Data / restraints / parameters 6394 / 1 / 317 
Goodness-of-fit on F2 1.043 
Final R indices [I>2sigma(I)] R1 = 0.0318, wR2 = 0.0846 
R indices (all data) R1 = 0.0359, wR2 = 0.0878 
Absolute structure parameter -0.009(12) 
Extinction coefficient n/a 
Largest diff. peak and hole [e.Å-3]  1.333 and -1.093 
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5.1.2 Synthetic Procedures and Analytical Data Part 3.2 
 
29. 8b (136 mg, 0.275 mmol) was dissolved in DMF (5 ml). LuG (148 mg, 0.3 mmol) 
and HOBt (41 mg, 0.3 mmol) were added under stirring. After 5 min, EDC (58 mg, 0.3 
mmol) and DIPEA (0.105 ml, 0.61 mmol) were added and the solution was stirred for 
24 h at 25 °C. The solvent was removed in vacuo and the crude was purified by 
preparative HPLC (Method A) and 29 was obtained as a pale-yellow oil (79 mg, 0.082 
mmol, 30 % overall yield from 1a).  
UPLC (gradient U1): RT = 3.81 min. 1H NMR (500 MHz, CDCl3): δ (ppm) 1.28 – 1.34 
(m, 5H), 1.42 – 1.43 (m, 9H), 1.43 – 1.44 (m, 9H), 1.46 (m, 9H), 1.46 – 1.59 (m, 3H), 
1.72 – 1.80 (m, 1H), 1.81 – 1.88 (m, 1H), 2.03 – 2.11 (m, 1H). 2.29 – 2.35 (m, 2H), 
2.36 - 2.41 (m, 2H), 2.47 – 2.48 (m, 3H), 2.63 – 2.70 (m, 1H), 2.78 – 2.89 (m, 1H), 3.07 
– 3.39 (m, 2H), 4.17 – 4.34 (m, 4H), 5.26 (d, J3 = 2.1 Hz, 1H), 5.38 (t, J3 = 7.9 Hz, 1H), 
5.53 (t, J3 = 7.4 Hz, 1H), 5.78 (d, J3 = 2.1 Hz, 0.5H), 5.84 (d, J3 = 2.1 Hz, 0.5H), 6.53 – 
6.58 (m, 1H). 13C NMR (125 MHz, CDCl3): δ (ppm) 13.91. 13.96, 14.24, 14.28, 22.61, 
22.82, 22.87, 23.79, 23.87, 27.98, 28.11, 28.14, 28.15, 28.18, 28.68, 28.82, 29.84, 
31.74, 31.82, 32.48, 32.59, 37.31, 37.67, 39.10, 39.22, 53.31, 53.34, 53.39, 53.54, 
61.03, 61.23, 80.81, 80.83, 81.82, 81.87, 82.50, 82.58, 84.39, 84.46, 85.81, 85.97, 
86.04, 86.09, 108.19, 108.26, 110.46, 110.64, 157.37, 157.42, 165.06, 165.40, 171.41, 
171.43, 172.41, 172.43, 172.47, 173.27, 173.39, 193.69. HR-ESI mass spectrum 
(MeOH): found 964.36010; calcd. for [C39H58N3O13Re+H+] 946.35999. 
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30. 3 (16 mg, 0.017 mmol) was dissolved in MeOH (2 ml) in an Anton Paar microwave 
vial (10 ml) and 1 M NaOH was added. The solution was heated by microwave to 
120 °C for 15 min. The crude was diluted with H2O (5 ml) and neutralized to pH = 3 by 
dropwise addition of 1 M HCl. The solvent was evaporated in vacuo and the crude was 
purified by preparative HPLC, yielding 30 as a yellowish oil (10 mg, 0.013 mmol, 76 %). 
UPLC (gradient U1): RT = 2.35 min. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.38 – 1.57 
(m, 4H), 1.62 – 1.74 (m, 1H), 1.78 – 1.98 (m, 2H), 2.10 – 2.20 (m, 1H), 2.36 – 2.46 (m, 
4H), 2.49 (s, 3H), 2.59 – 2.81 (m, 2H), 3.16 – 3.21 (m, 2H), 4.23 – 4.34 (m, 2H), 5.49 
(d, J3 = 1.96 Hz, 1H), 5.90 (d, J3 = 1.96 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ (ppm) 
14.02, 23.95, 25.10, 28.85, 28.95, 29.89, 29.95, 31.09, 31.11, 33.05, 33.18, 38.57, 
40.15, 40.19, 53.56, 53.58, 54.04, 86.11, 87.44, 87.94, 108.95, 112.15, 159.98, 
160.12, 168.14, 174.04, 175.90, 176.02, 176.48, 176.56, 176.59, 195.02. HR-ESI 
mass spectrum (MeOH): found 766.12671; calcd. for [C25H29N3O13Re+H+] 766.12634. 
 
 
 
31. 2b (78 mg, 0.168 mmol) was dissolved in DMF (5 ml). LuG (164 mg, 0.34 mmol) 
and HOBt (50 mg, 0.37 mmol) were added under stirring. After 5 min, EDC (71 mg, 
0.37 mmol) and DIPEA (0.129 ml, 0.74 mmol) were added and the solution was stirred 
for 24 h at 25 °C. The solvent was removed in vacuo and the crude was purified by 
preparative HPLC (Method A) and the two diastereoisomers of 31 (31a and 31b) were 
obtained as a pale-yellow oil (31a, 38.3 mg, 0.027 mmol; 31b, 35.9 mg, 0.026 mmol; 
yield: 31 %). 
31a. UPLC (gradient U1): RT = 4.11 min. 1H NMR (500 MHz, CDCl3): δ (ppm) 1.35 – 
1.50 (m, 58H), 1.50 – 1.64 (m, 5H), 1.72 – 1.96 (m, 5H), 2.01 – 2.14 (m, 2H), 2.25 – 
2.43 (m, 6H), 2.49 (s, 3H), 2.57 – 2.68 (m, 1H), 2.83 – 2.93 (m, 1H), 3.09 – 3.20 (m, 
1H),  3.27 – 3.38 (m, 3H), 4.23 – 4.38 (m, 4H), 5.19 (s, 1H), 5.33 – 5.39 (m, 1H), 5.45 
– 5.51 (m, 1H), 5.54 – 5.60 (m, 1H), 5.66 – 5.71 (m, 1H), 5.89 (s, 1H), 6.59 – 6.63 (m, 
1H), 6.68 – 6.74 (m, 1H). 13C NMR (126 MHz, CDCl3): δ (ppm) 13.93, 22.16, 22.58, 
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23.92, 28.16, 28.18, 28.22, 28.45, 28.80, 31.69, 31.82, 32.66, 32.78, 37.50, 38.98, 
39.42, 53.20, 53.25,53.35, 53.48, 77.16, 80.84, 80.88, 81.89, 82.01, 82.42, 82.45, 
82.95, 85.19, 90.93, 107.85, 109.04, 157.45, 157.71, 164.47, 171.62, 172.53, 172.59, 
172.63, 172.65, 172.87, 173.21, 194.31, 194.39. HR-ESI mass   spectrum (MeOH): 
found 1405.64555; calcd. for [C61H97N6O19Re+H+] 1405.64388. 
31b. UPLC (gradient U1): RT = 4.13 min. 1H NMR (500 MHz, CDCl3): δ (ppm) 1.35 – 
1.50 (m, 58H), 1.50 – 1.64 (m, 5H), 1.72 – 1.96 (m, 5H), 2.01 – 2.14 (m, 2H), 2.25 – 
2.43 (m, 6H), 2.49 (s, 3H), 2.64 – 2.76 (m, 2H), 3.09 – 3.20 (m, 1H),  3.27 – 3.38 (m, 
3H), 4.23 – 4.38 (m, 4H), 5.16 (m, 1H), 5.58 – 5.62 (m, 2H), 5.73 (m, 1H), 5.89 – 5.91 (m, 
2H), 6.77 – 6.82 (m, 2H). 13C NMR (126 MHz, CDCl3): δ (ppm) 13.41, 13.73, 18.03, 22.13, 
22.30, 22.90, 23.55, 27.41, 27.61, 27.63, 27.65, 27.70, 28.11, 28.97, 29.04, 29.24, 29.27, 
29.32, 29.35, 31.19, 31.26, 31.54, 32.19, 32.51, 33.06, 37.19, 38.73, 38.82, 52.60, 52.73, 
52.94, 80.24, 80.34, 81.30, 81.64, 81.87, 81.98, 82.97, 84.32, 90.32, 106.62, 108.70, 157.18, 
163.90, 171.14, 171.87, 171.97, 172.21, 172.33, 172.37, 172.88, 193.77. HR-ESI mass   
spectrum (MeOH): found 1405.64572; calcd. for [C61H97N6O19Re+H+] 1405.64388. 
 
 
 
32. A 1:1 mixture of 31 (60 mg, 0.043 mmol) was dissolved in MeOH (2 ml) and 1 M 
NaOH (1 ml) in an Anton Paar microwave vial (10 ml) and was heated by microwave 
to 120 °C for 15 min. The solution was adjusted to pH = 3 by addition of 1 M HCl. The 
solvent was evaporated in vacuo and the crude was purified by preparative HPLC 
(Method A), yielding 32 as a yellowish oil (25.7 mg, 0.024 mmol, 56 %). 
UPLC (gradient U1): RT = 2.24 min. 1H NMR (500 MHz, CD3OD): δ (ppm) 1.39 – 1.74 
(m, 10H), 1.79 – 1.96 (m, 4H), 2.10 - 2.19 (m, 2H), 2.36 – 2.46 (m, 6H), 2.50 (s, 3H), 
2.62 – 2.74 (m, 2H), 3.15 – 3.27 (m, 4H), 4.23 – 4.28 (m, 2H), 4.30 – 4.35 (m, 2H), 
5.43 (m, 1H), 5.99 (m, 1H). HR-ESI mass spectrum (MeOH): found 1067.25684; calcd. 
for [C37H48N6O19Re-H+] 1067.25372. 
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33. 2a(41 mg, 0.210 mmol) was dissolved in DMF (5 ml). LuG (225 mg, 0.462 mmol) 
and HOBt (62 mg, 0.462 mmol) were added under stirring. After 5 min, EDC (89 mg, 
0.462 mmol) and DIPEA (0.161 ml, 0.924 mmol) were added and the solution was 
stirred for 24 h at 25 °C. The solvent was removed in vacuo and the crude was purified 
by preparative HPLC (Method A) and 33 was obtained as a pale-yellow oil (36 mg, 
0.032 mmol, 15 % overall yield from 1a).  
UPLC (gradient U1): RT = 3.78 min. 1H NMR (400 MHz, CDCl3): δ (ppm) 1.18 – 1.29 
(m, 4H), 1.31 – 1.38 (m, 54H), 1.38 - 1.57 (m, 6H), 1.60 – 1.80 (m, 4H), 1.92 – 2.03 
(m, 2H), 2.12 (s, 3H), 2.17 – 2.28 (m, 4H), 2.28 – 2.40 (m, 2H), 2.51 – 2.60 (m, 1H), 
2.67 – 2.75 (m, 1H), 2.83 – 2.96 (m, 2H), 3.03 – 3.11 (m, 1H), 3.19 – 3.32 (m, 3H), 
4.14 – 4.27 (m, 4H), 5.30 – 5.36 (m, 1H), 5.36 - 5.40 (m, 1H), 5.49 – 5.56 (m, 1H), 5.86 
– 5.93 (m, 1H), 5.95 (s, 1H), 5.97 – 6.00 (m, 1H), 6.50 – 6.57 (m, 1H). 13C NMR (125 
MHz, CDCl3): δ (ppm) 15.73, 22.41, 23.21, 27.50, 28.38, 28.60, 28.62, 28.67, 28.68, 
29.01, 29.80, 30.29, 32.21, 32.37, 32.89, 33.11, 36.57, 39.17, 39.60, 44.15, 53.55, 
53.62, 53.81, 54.02, 81.14, 81.16, 82.05, 82.20, 82.53, 82.63, 131.41, 133.78, 149.43, 
151.01, 157.76, 158.13, 166.96, 172.89, 172.92, 173.01, 173.04, 173.12, 173.15, 
173.96 HR-ESI mass spectrum (MeOH): found 1135.71147; calcd. for 
[C58H99N6O16Re+H+] 1135.71121. 
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35. 8a (57 mg, 0.253 mmol) was dissolved in DMF (5 ml). LuG (136 mg, 0.278 mmol) 
and HOBt (38 mg, 0.278 mmol) were added under stirring. After 5 min, EDC (53 mg, 
0.278 mmol) and DIPEA (0.097 ml, 0.557 mmol) were added and the solution was 
stirred for 24 h at 23 °C. The solvent was removed in vacuo and the crude was purified 
by preparative HPLC (Method A) and 35 was obtained as a pale-yellow oil (30 mg, 
0.043 mmol, 17 % overall yield from 1a).  
UPLC (gradient U1): RT = 3.48 min. 1H NMR (500 MHz, CDCl3): δ (ppm) 1.27 – 1.40 
(m, 3H), 1.38 – 1.53 (m, 31H), 1.74 – 1.92 (m, 3 H), 2.03 – 2.11 (m, 1H), 2.27 (s, 3H), 
2.32 – 2.38 (m, 2H), 2.40 – 2.53 (m, 2H), 2.65 - 2.72 (m, 1H), 2.81 – 2.88 (m, 1H), 2.97 
– 3.05 (m, 1H), 3.16 – 3.25 (m, 1H), 3.36 – 3.45 (m, 2H), 4.19 – 4.36 (m, 4H), 5.30 – 
5.36 (m, 1H), 5.58 – 5.64 (m, 1H), 6.12 (s, 1H), 6.39 – 6.44 (m, 1H). 13C NMR (125 
MHz, CDCl3): δ (ppm) 14.53, 15.70, 22.28, 27.02, 27.92, 28.08, 28.11, 28.16, 28.66, 
31.82, 32.45, 35.63, 38.88, 44.17, 53.21, 53.36, 59.83, 80.78, 81.72, 82.29, 127.05, 
133.14, 154.08, 155.91, 157.52, 165.84, 172.40, 172.52, 172.56, 173.35. HR-ESI 
mass spectrum (MeOH): found 694.42714; calcd. for [C36H59N3O10+H+] 694.42732. 
 
General procedure for the labelling of Cp-Ligands 33 and 35. 
Generally, 0.5 ml of a 5 mM stock solution of the respective ligand in MeOH was added 
to a Biotage microwave vial (2 – 5 ml). The vial was sealed, and the solvent was 
removed by passing a stream of N2 through the vial via two syringe needles for 30 min. 
 [99mTc(OH2)3(CO)3]+ (0.5 ml, pH = 13) was added to the dried ligand and the solution 
was heated by microwave to 140 °C for 10 (35) or 15 (33) min. In order to normalize 
the overpressure, evolving gases were released with a 1 ml disposable syringe-needle. 
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Figure 82. 1H NMR of 29 in CDCl3 with assigned proton signals.  
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Figure 83. 13C NMR of 29 in CDCl3. 
 
 
 
Figure 84. 1H NMR of 31 in CDCl3 with assigned proton signals.  
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Figure 85. 13C NMR of 31 in CDCl3. 
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Figure 86.  1H NMR of 33 in CDCl3 with assigned proton signals. 
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Figure 87.  1H NMR of 35 in CDCl3 with assigned proton signals. 
 
Figure 88. 13C NMR of 35 in CDCl3. 
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Figure 89. 1H NMR of 32 in D2O. 
 
Figure 90. 1H NMR of 30 in MeOD with assigned proton signals. 
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Figure 91. 13C NMR of 30 in MeOD. 
 
Figure 92. 1H NMR of 32 in MeOD with assigned proton signals. 
 
 
  
 
175 
 
5.1.3 Synthetic Procedures and Analytical Data Part 3.3 
 
37 was prepared according to a previously described procedure.134, 224 
 
39. 38 (75 mg, 0.242 mmol) was dissolved in EtOH (10 ml) and hydrazine hydrate (0.13 
ml (50 wt%), 2.09 mmol) was added. The mixture was heated to reflux for 2 h and then 
stirred at room temperature overnight. The solvent was evaporated in vacuo and the 
obtained crude 39 was used in the next step without furher purification.  
 
 
40. Crude 39 (ca. 0.242 mmol) and crude 8b (ca. 0.285 mmol)  were dissolved in DMF 
(3 ml) and HOBt (42 mg, 0.31 mmol) was added. After 5 min, EDC (60 mg, 0.31 mmol) 
and DIPEA (0.109 ml, 0.63 mmol) were added and the solution was stirred at room 
temperature for 16 h. The solvent was removed in vacuo and the crude was purified 
by preparative HPLC (Method A) and 40 was obtained as a yellow oil (32.3 mg, 0.049 
mmol, 20 % overall yield from 38).  
UPLC (gradient U1): RT = 2.59 min. 1H NMR (400 MHz, CD3CN): δ (ppm) 1.22 (t, 3J = 
7.2 Hz, 3H), 2.35 – 2.41 (m, 5H), 2.55 – 2.76 (m, 2H), 3.29 (s, 4H), 4.09 – 4.25 (m, 
2H), 4.39 – 4.40 (m, 2H), 5.36 (d, 3J = 2 Hz, 2H), 5.76 (d, 3J = 2 Hz, 2H), 6.65 (s, 1H), 
7.45 (s, 1H), 7.60 – 7.88 (m, 2H), 10.50 (1H). 13C NMR (126 MHz, CD3CN): δ (ppm)  
13.90, 14.40, 24.56, 35.80, 38.25, 49.90, 61.78, 85.46, 87.27, 87.43, 99.96, 109.23, 
111.79, 117.28, 117.87, 152.40, 158.97, 165.59, 172.74, 195.13. HR-ESI mass 
spectrum (MeOH): found 656.11514; calcd. for [C22H22N5O7Re+H+] 656.11495. 
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41. 40 (32.3 mg, 0.049 mmol) was dissolved in MeOH (2 ml) in an Anton Paar 
microwave vial (10 ml) and 1 M NaOH (1 ml) was added. The solution was heated by 
microwave to 120 °C for 15 min. The crude was diluted with H2O (5 ml) and neutralized 
to pH = 3 by dropwise addition of 1 M HCl. The solvent was evaporated in vacuo and 
the crude was used in the next step without further purification. 
UPLC (gradient U1): RT = 2.25 min. 
 
 
42. 41 (Assume 0.049 mmol), H-Glu(OtBu)-OtBu.HCl (16 mg, 0.054 mmol)  and HOBt 
(8 mg, 0.06 mmol) were dissolved in DMF (3 ml). After 5 min, EDC (11 mg, 0.06 mmol) 
and DIPEA (0.020 ml, 0.11 mmol) were added and the solution was stirred at room 
temperature for 16 h. The solvent was removed in vacuo and the crude was purified 
by preparative HPLC (Method A) and 42 was obtained as a mixture of two 
diastereoisomers as a clear oil (26.5 mg, 0.031 mmol, 62 % overall yield from 40). 
UPLC (gradient U1): RT = 2.59 min. 1H NMR (400 MHz, CD3OD): δ (ppm) 1.44 – 1.45 
(m, 9H), 1.47 – 1.49 (m, 9H), 1.87 – 2.22 (m, 2H), 2.33 – 2.45 (m, 7H), 2.59 – 2.82 (m, 
2H), 4.43 – 4.49 (m, 3H), 5.34 – 5.36 (m, 1H), 6.05 – 6.07 (m, 1H), 6.66 (s, 1H). 
13C NMR (126 MHz, CD3OD): δ (ppm) 13.99, 14.05, 25.22, 25.36, 27.44, 27.60, 32.65, 
36.52, 36.55, 28.86, 53.80, 54.16, 81.92, 81.97, 83.17, 83.19, 84.82, 85.28, 86.66, 
86.90, 90.14, 90.59, 100.08, 100.10, 108.29, 108.83, 111.09, 111.68, 116.45, 116.50, 
116.62, 116.68, 117.04, 150.82, 150.87, 153.75, 161.51, 161.53, 166.45, 166.44, 
172.52, 172.76, 173.47, 173.98, 195.24, 195.34. HR-ESI mass spectrum (MeOH): 
found 869.25262; calcd. for [C33H41N6O10Re+H+] 869.25144. 
 
 
43. 42 (10 mg, 0.010 mmol) was dissolved in CH2Cl2 (3 ml). TFA (0.1 ml) and 
triethylsilane (0.05 ml) were added and the solution was stirred at 25 °C for 24 h. The 
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solvent was evaporated in vacuo and the crude was purified by preparative HPLC 
(method A) and 43 was obtained as a mixture of two diastereoisomers as a reddish 
solid (3 mg, 0.004 mmol, 38 %). 
UPLC (gradient U1): RT = 2.21 min. 1H NMR (400 MHz, CD3OD): δ (ppm) 1.99 – 2.10 
(m, 1H), 2.18 – 2.31 (m, 1H), 2.35 (s, 1.5 H), 2.40 (s, 1.5H), 2.39 – 2.50 (m, 4H), 2.56 
– 2.85 (m, 2H), 4.34 – 4.54 (m, 3H), 5.29 – 5.32 (m, 1H), 6.05 – 6.08 (m, 1H), 6.64 (s, 
1H). 13C NMR (126 MHz, CD3OD): δ (ppm) 13.83, 14.02, 25.13, 25.49, 26.50, 27.41, 
27.46, 31.32, 31.41, 36.46, 36.53, 38.80, 39.09, 49.85, 53.28, 53.32, 68.87, 84.66, 
85.10, 86.67, 86.77, 90.21, 90.32, 100.08, 100.12, 108.62, 108.73, 111.35, 111.70, 
116.72, 116.81, 117.05, 117.17, 150.20, 153.66, 161.33, 161.35, 166.42, 166.56, 
173.47, 175.25, 175.44, 176.71, 176.73, 195.13, 195.32. HR-ESI mass spectrum 
(MeOH): found 757.12671; calcd. for [C25H26N6O10Re+H+] 757.12624. 
 
 
 
 
 
Figure 93. 1H NMR of 40 in CD3CN. 
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Figure 94. 13C NMR of 40 in CD3CN. 
 
Figure 95. 1H NMR of 42 in CD3OD with assigned proton signals. 
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Figure 96. 13C NMR of 42 in CD3OD. 
 
Figure 97. 1H NMR of 43 in CD3OD. 
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Figure 98. 13C NMR of 43 in CD3OD. 
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5.2 Experimental Section Part B 
 
49. Ru(DMSO)2Cl2 (73 mg, 0.15 mmol) and S1 (62 mg, 0.3 mmol) were dissolved in 
H2O (2 ml) in a Biotage microwave vial and the mixture was heated by microwave to 
120 °C for 10 min. The crude was diluted with H2O (10 ml) and extracted with DCM (2 
x 10 ml). The combined organic phases were dried over anhydrous MgSO4, filtered and 
the solvents evaporated in vacuo yielding 49 as a light brown solid (35 mg, 0.1 mmol, 
67%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 3.77 (s, 6H), 4.85 (t, J3 = 2.6 Hz, 1H), 5.22 (d, J3 
= 2.6 Hz, 2H). 13C NMR (101 MHz, CDCl3): δ (ppm) 52.35, 75.92, 78.28, 80.86, 167.25. 
 
 
50. 49 (48 mg, 0.104 mmol) was suspended in MeOH (10 ml) and 1 M NaOH (1.04 ml) 
was added. The mixture was stirred at room temperature for 1 h. The precipitate was 
collected by filtration and dried in vacuo yielding 5 (23 mg, 0.056 mml, 54%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.16 (s, 1H), 7.50 (s, 2H). 
 
 
45. 44 (61 mg, 0.12 mmol) was suspended in H2O (2 ml) and AgNO3 (83 mg, 0.49 
mmol) was added and the mixture was stirred at room temperature for 1 h. The dark 
precipitate was removed by filtration and S1 (52 mg, 0.26 mmol) was added to the 
filtrate and the solution was stirred for another hour at room temperature. The solvent 
was evaporated in vacuo and the crude was re-dissolved in the minimal amount of H2O 
required. NH4PF6 was added until no more precipitate formed. The mixture was cooled 
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overnight and the next day the precipitate was collected by centrifugation and dried in 
vacuo yielding 2 as a brown precipitate (36 mg, 0.1 mmol, 41%).  
1H NMR (400 MHz, CD3CN): δ (ppm) 3.84 (s, 6H), 5.49 (t, J3 = 2.6 Hz), 5.78 (d, J3 = 
2.6 Hz, 2H), 6.24 (s, 6H). 13C NMR (126 MHz, CD3CN): δ (ppm) 54.21, 82.38, 83.26, 
90.07, 96.07, 164.90. 
 
 
46. 45 (25 mg, 0.06 mmol) was dissolved in MeOH (3 ml) and 1 M NaOH (0.2 ml) was 
added. The mixture was stirred at room temperature for 6 h. The solution was diluted 
with H2O (5 ml) was neutralized to pH = 7 by addition of 1 M HCl and the crude was 
purified by filtration through a short 18C (2 x 10 ml H2O, 2 x 10 ml MeOH). The solvent 
was evaporated, yielding 46 (3.6 mg, 0.011 mmol, 18 %). 
1H NMR (400 MHz, D2O): 5.80 (s, 1H), 6.11 (s, 2H), 6.40 (s, 6H). 
 
 
 
48. 47 (66 mg, 0.11 mmol) was suspended in H2O (2 ml) and AgNO3 (73 mg, 0.43 
mmol) was added and the mixture was stirred at room temperature for 1 h. The dark 
brown precipitate was removed by filtration and S1 (46 mg, 0.23 mmol) was added to 
the filtrate and the solution was stirred for another hour at room temperature. The 
solvent was evaporated in vacuo and the crude was re-dissolved in the minimal 
amount of H2O required. NH4PF6 was added until no more precipitate formed. The 
mixture was cooled overnight and the next day the precipitate was collected by 
centrifugation, washed with H2O (3 x 5 ml dried in vacuo yielding 2 as a brown 
precipitate (67 mg, 0.16 mmol, 73%).  
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1H NMR (400 MHz, CD3CN): δ (ppm) 1.22 (s, 3H), 1.23 (s, 3H), 2.22 (s, 3H), 2.71 (m, 
1H), 3.83 (s, 6H), 5.44 (t, J3 = 2.62 Hz, 1H), 5.70 (d, J3 = 2.64 Hz, 2H), 6.11 – 6.18 (m, 
4H). 
 
51. 1a (28 mg, 0.12 mmol) was dissolved in diglyme (4 ml) and bubbled with N2 for 15 
min. Finely grounded KOH (42 mg) was added to this solution and kept under nitrogen 
atmosphere and the solution turned yellow immediately. In a separate beaker, FeCl2 
(8 mg, 0.06 mmol) was dissolved in previously degassed DMSO (4 ml). The 1a 
containing solution was slowly added to the FeCl2 solution and stirred at room 
temperature for 4 h. The reaction mixture was neutralized by adding 1 M HCl until a 
yellow precipitate could be observed. The precipitate was collected by filtration and 
washed with H2O (2 x 10 ml) and dried in vacuo (no yield was determined). 
1H NMR (400 MHz, CD3Cl): 1.36 – 1.41 (m, 3H), 2.15 – 2.16 (m, 3H), 2.50 – 2.64 (m, 
4H), 3.70 (m, 3H), 4.00 (m, 1H), 5.25 – 4.32 (m, 2H), 4.42 (m, 0.5H), 4.49 (m, 0.5H). 
 
 
 
 
 
 
  
 
184 
 
 
Figure 99. 1H NMR of 49 in CDCl3. 
 
Figure 100. 13C NMR of 49 in CDCl3. 
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Figure 101. 1H NMR of 50 in CDCl3. 
Figure 102. 1H NMR of 45 in CD3CN. 
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Figure 103. 13C NMR of 45 in CD3CN. 
 
 
Figure 104. 1H NMR of 46 in D2O. 
  
 
187 
 
 
Figure 105. 1H NMR of 48 in CD3CN. 
 
Figure 106.1H NMR of 51 in CDCl3 assigned proton signals. 
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Table 4.  Crystal data and structure refinement for 45. 
Empirical formula  C15 H15 F6 O4 P Ru 
Diffractometer  Xcalibur, Ruby 
Wavelength [Å]  0.71073 
Formula weight  505.31 
Crystal system  Monoclinic 
Space group  P 1 21/n 1 
a [Å]  11.5596(5)  
b [Å]  12.6616(5)  
c [Å]  12.4950(6)  
α [°]  90 
β [°]  109.789(5) 
γ [°]  90 
Volume [Å3]  1720.81(14)  
Z 4 
Density (calculated) [Mg/m3]  1.950  
Absorption coefficient [mm-1]  1.086 
F(000) 1000 
Crystal size [mm3]  0.23 x 0.14 x 0.06  
Crystal description colourless plate 
Theta range for data collection [°]  2.469 to 32.907 
Index ranges -17<=h<=17, -19<=k<=17, -19<=l<=18 
Reflections collected 17987 
Independent reflections 5881 [R(int) = 0.0455] 
Reflections observed 4653 
Criterion for observation I > 2(I) 
Completeness to theta  99.9 % to 25.242°  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.75543 
Data / restraints / parameters 5881 / 0 / 246 
Goodness-of-fit on F2 1.048 
Final R indices [I>2sigma(I)] R1 = 0.0375, wR2 = 0.0802 
R indices (all data) R1 = 0.0546, wR2 = 0.0904 
Extinction coefficient n/a 
Largest diff. peak and hole [e.Å-3]  1.433 and -0.526 
 
 
  
 
189 
 
Table 5.  Crystal data and structure refinement for 49. 
Empirical formula  C18 H18 O8 Ru 
Diffractometer  Xcalibur, Ruby 
Wavelength [Å]  0.71073 
Formula weight  463.39 
Crystal system  Monoclinic 
Space group  P 1 21/c 1 
a [Å]  8.1481(5)  
b [Å]  14.3423(6)  
c [Å]  14.8462(9)  
α [°]  90 
β [°]  92.831(6) 
γ [°]  90 
Volume [Å3]  1732.85(16)  
Z 4 
Density (calculated) [Mg/m3]  1.776  
Absorption coefficient [mm-1]  0.951 
F(000) 936 
Crystal size [mm3]  0.15 x 0.12 x 0.04  
Crystal description colourless plate 
Theta range for data collection [°]  2.747 to 30.508 
Index ranges -10<=h<=11, -20<=k<=18, -21<=l<=20 
Reflections collected 12171 
Independent reflections 5291 [R(int) = 0.0536] 
Reflections observed 3739 
Criterion for observation I > 2(I) 
Completeness to theta  99.9 % to 25.242°  
Absorption correction Analytical 
Max. and min. transmission 0.968 and 0.904 
Data / restraints / parameters 5291 / 0 / 257 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0507, wR2 = 0.0995 
R indices (all data) R1 = 0.0808, wR2 = 0.1164 
Extinction coefficient n/a 
Largest diff. peak and hole [e.Å-3]  1.958 and -1.224 
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Table 6.  Crystal data and structure refinement for 51. 
Empirical formula  C26 H34 Fe O8 
Diffractometer  XtaLAB Synergy, Dualflex, Pilatus 200K 
Wavelength [Å]  0.71073 
Formula weight  530.38 
Crystal system  Monoclinic 
Space group  P 1 2/c 1 
a [Å]  13.4268(3)  
b [Å]  7.67030(10)  
c [Å]  13.2464(3)  
α [°]  90 
β [°]  115.275(3) 
γ [°]  90 
Volume [Å3]  1233.62(5)  
Z 2 
Density (calculated) [Mg/m3]  1.428  
Absorption coefficient [mm-1]  0.660 
F(000) 560 
Crystal size [mm3]  0.11 x 0.08 x 0.06  
Crystal description clear red cube 
Theta range for data collection [°]  2.655 to 32.974 
Index ranges -19<=h<=20, -11<=k<=11, -19<=l<=19 
Reflections collected 38307 
Independent reflections 4274 [R(int) = 0.0287] 
Reflections observed 3854 
Criterion for observation I > 2(I) 
Completeness to theta  100.0 % to 25.242°  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.94524 
Data / restraints / parameters 4274 / 0 / 162 
Goodness-of-fit on F2 1.061 
Final R indices [I>2sigma(I)] R1 = 0.0260, wR2 = 0.0704 
R indices (all data) R1 = 0.0299, wR2 = 0.0720 
Extinction coefficient n/a 
Largest diff. peak and hole [e.Å-3]  0.477 and -0.231 
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5.3 Experimental Section Part C 
 
Materials.  All chemicals were of reagent-grade quality or higher. Solvents were used 
as received or dried over molecular sieves. Deuterated NMR solvents were obtained 
from ARMAR chemicals. Carbon-13C monoxide (<5 atom % 18O, 99 atom % 13C) was 
obtained from Sigma Aldrich. 2,6-dimethylphenyl isocyanide (>98%) was obtained 
from Fluka.  
 
Instrumentation and methods. 13C-NMR spectra were recorded in deuterated 
solvents on a Bruker AV2 and DRX 500 (13C: 125.8 MHz) MHz spectrometer at the 
specified temperatures and concentrations. The chemical shifts, , are reported in ppm 
(parts per million) relative to residual solvent peaks. IR spectra were obtained with a 
PerkinElmer Spectrum Two spectrometer. UV/Vis spectra were measured on a Varian 
Cary 50 Scan UV/Vis spectrophotometer. The temperature was regulated with a Peltier 
thermostatic system to the specified temperatures. 
 
Synthesis of [NEt4][ReBr2(CO)4] (2). [NEt4]2[ReBr3(CO)3] (100 mg g, 0.13 mmol) was 
dissolved in DMF (5 ml). The clear solution was bubbled with ~1 atm of CO gas through 
a canula for 6 h, resulting in a pale yellow crystals suitable for X-ray diffraction analysis. 
Dissolution of the crystals in d8-THF and subsequent filtration yielded a solution of pure 
2. 13C NMR (125.8 MHz, d8-THF) δ 188.5, 187.1. IR bands (neat cm-1): νCO = 2110, 
1995, 1968, 1909.  
 
Synthesis of [NEt4][ReBr(CO)3(Xyl-NC)] (4). [NEt4]2[ReBr3(CO)3] (65.0 mg, 0.084 
mmol) was dissolved in d7-DMF (0.250 ml) and added to a solution of 2,6-
dimethylphenyl isocyanide (10.8 mg, 0.082 mmol) in d7-DMF (0.450 ml) in an NMR 
tube. After one hour at room temperature, complete consumption of the free isocyanide 
was observed. Slow evaporation of the solution yielded single crystals of 4 suitable for 
X-ray diffraction analysis (13C NMR and IR spectra of free 2,6-dimethylphenyl 
isocyanide and 4 are reported in the SI (Figure 119-120 and 127)). 13C NMR (125.8 
MHz, d7-DMF) δ 191.1, 136.6, 130.5, 129.2,19.0. IR bands (neat cm-1): νCO = 2008, 
1925, 1882, νCN = 2171. 
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Synthesis of [ReBr(DMF)2(CO)3] (1c). ReBr(CO)5 (30 mg, 0.074 mmol) was dissolved 
in d7-DMF (1 ml) and heated to 130 °C for one day. 13C NMR showed complete 
consumption of ReBr(CO)5 and quantitative formation of 1c (13C NMR spectra of 1c 
and ReBr(CO)5 are reported above (Figure 17) and in the SI (Figure 128) respectively). 
13C NMR (125.8 MHz, d7-DMF) δ 198.0, 193.1, 169.6 (t). 
 
99Tc experiments. Caution: 99Tc is a weak β- emitter (Emax = 0.292 MeV, half-life time 
= 2.12 × 105 y. It should be handled only in appropriately equipped laboratories. 
[99TcCl3(CO)3]2-. [NEt4]2[99TcCl3(CO)3] (4.5 mg, 8.2 µmol) was dissolved in DMF (1 
ml) and a 99Tc NMR spectrum was recorded (Figure 113). Bubbling of this solution with 
~1 atm of CO gas through a canula for 6 h resulted in no significant changes in the 
99Tc NMR. 
[Tc(CO)3(DMF)3]+. [NEt4]2[99TcCl3(CO)3] (4.4 mg, 8.0 µmol) was dissolved in DMF (1 
ml) and AgPF6 (6.07 mg, 24.0 µmol) were added. Formation of a precipitate was 
observed immediately. The suspension was left standing for 24 h, filtered and a 99Tc 
NMR spectrum was recorded (Figure 114). Bubbling of this solution with ~1 atm of CO 
gas through a canula for multiple hours resulted in no significant changes in the 99Tc 
NMR. 
[TcBrn(CO)3(DMF)3-n]+. [NEt4]2[99TcCl3(CO)3] (5.3 mg, 9.6 µmol) was dissolved in 
DMF (1 ml) and AgPF6 (6.07 mg, 24.0 µmol) were added. To this solution, three 
equivalents of NaBr (3.0 mg, 29.2 µmol) were added and a 99Tc NMR spectrum was 
recorded (Figure 115). Bubbling of this solution with ~1 atm of CO gas through a canula 
for multiple hours resulted in no significant changes in the 99Tc NMR. 
 
Kinetic Studies. 
Formation kinetics of [NEt4][ReBr2(CO)4].  All the kinetic runs were performed under 
pseudo first-order conditions with the metal complex in excess. Depending on the 
concentration of 1b required for the measurement, one of two experimental procedures 
was followed. For concentrations smaller than 75 mM, the respective quantity of 1a 
was dissolved in a small volume of the respective deuterated solvent. An NMR tube 
containing (typically 0.5 ml) of deuterated solvent and 20 l of p-Xylene was bubbled 
  
 
193 
 
steadily with 13CO via a 20 ml syringe equipped with a needle long enough to reach 
the bottom of the NMR tube. Measurement of the 13C-NMR spectrum of this solution 
allowed the determination of the 13CO concentration in solution by comparison of the 
integral (and taking into account the relative abundance of 13C) with both the solvent 
peak as well as the quaternary carbon peak of p-Xylene, which was used as a second 
internal standard. The NMR sample was then cooled down to the required temperature 
and the experiment started upon addition of 1b. The number of scans per experiment 
was adjusted depending on the starting concentration and temperature to maintain a 
reasonable balance between time resolution and signal to noise ratio. NMR spectra 
were measured until the signal of free 13CO disappeared. For the measurements at 
concentrations higher than 75 mM it was not possible to dissolve 1a in a small enough 
volume so a different procedure was followed. Starting compound 1a was dissolved in 
(typically 0.5 ml) the respective solvent together with 20 l p-Xylene. The sample was 
locked and shimmed in the NMR spectrometer at the respective measuring 
temperature. The 13CO was then added to the sample, which was cooled to 5-10 °C 
below the measurement temperature. After the addition was complete the sample was 
placed in the NMR machine and the measurement was started upon stabilization of 
the shim. The first experiment was used to estimate the initial 13CO concentration 
analogously to the first method. 
Treatment of NMR data. From the NMR measurements, two curves were obtained 
from each run by integrating the peaks of the free and coordinated 13CO respectively. 
The data points were computer fitted via least square to a single exponential in Origin 
to obtain the respective observed pseudo first-order rate constant (kobs). Both the plot 
for the determination of k1 as well as the Eyring plots were linearly fitted in Origin.52 
Global fits of the kinetic data to evaluate the activation parameters using the 
exponential form of the Eyring equation were done as previously described.55, 176 
13CO exchange experiments. In a typical experiment, the appropriate amount of 1a 
was weighed in and dissolved in (typically 0.5 ml) d7-DMF together with 20 l p-Xylene 
in a 5 mm diameter NMR tube. The solution was bubbled with 13CO as described above 
and sealed with a Shigemi glass stopper to ensure minimal “out-diffusion” of CO. The 
sample was placed into the NMR at 300 K. The temperature was then raised to 310 K 
and the measurement started. 
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UV/vis Kinetics. All the kinetic runs were performed in DMF and under pseudo first-
order conditions with the metal complex in excess. In a typical experiment an aliquot 
of a 100 mM stock solution of 1b in DMF was added to 2.5 ml of DMF in a quartz 
cuvette ([1b] = 0.2 – 1.6 mM) at room temperature (25 ± 1 °C). A constant aliquot of 
an 8 mM stock solution of Xyl-NC was then added to this solution and spectra were 
recorded every 15 seconds until no more significant changes were observed in the 
UV/vis spectrum ([Xyl-NC] = 0.04 mM). 
 
Kinetic Simulations. The experimental NMR data displayed in Figure 22 were fit by 
simulation to a single kinetic model (Scheme 2) using the computer program KinTek 
Explorer (KinTek Corp, Austin, Texas, USA).178 This program simulates experimental 
results by using direct numerical integration of the rate equations for the full model. 
 
X-ray Crystallography. Crystallographic data were collected at 183(2) K with Mo Kα 
radiation (λ = 0.71073 Å) that was graphite-monochromated on an Oxford Diffraction 
CCD Xcalibur system with a Ruby detector. Suitable crystals were covered with oil 
(Infineum V8512, formerly known as Paratone N), placed on a nylon loop that is 
mounted in a CrystalCap Magnetic™ (Hampton Research) and immediately 
transferred to the diffractometer. The program suite CrysAlisPro was used for data 
collection, multi-scan absorption correction and data reduction.62 The structures were 
solved with direct methods using SIR97225 and were refined by full-matrix least-
squares methods on F2 with SHELXL-97.226 All four ethyl groups of the disordered 
tetraethylammonium cation in compound 4 were located on two positions each (ratio 
85:15). Due to the disorder, all carbon atoms of the minor component were refined 
isotropically. (CCDC numbers 1484435 and 1484436) 
 
DFT Calculations. DFT calculations on the level of generalized gradient 
approximation are carried out with Perdew-Burke-Ernzerhof exchange and correlation 
functional.227 All calculations are performed using the mixed Gaussian- and Plane 
Wave algorithm implemented in the CP2K software.176 The core electrons are 
approximated on the basis of GTH pseudopotentials.228-230 For elements C, O, H, and 
N only the valence electrons are treated explicitly. For Re the outermost 15 electrons 
are treated explicitly. The electron density is expanded in a double zeta basis set.231 
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Plane waves are cut off at 350 Ry. All calculations are done in singlet state and in 
vacuum.  
First, the structures are optimized. From the optimized structure, the minimum energy 
path for the rotation of the (CO)3 unit is found using the climbing image nudged elastic 
band method (CI-NEB).232 The path is represented by 8 structures for 
[Re(CO)3Br2(DMF)]- and by 5 structures for [Re(CO)4Br2]-, respectively. 
 
 
Figure 107. 13C NMR of [NEt4]2[ReBr3(CO)3] in MeOD (300 K). 
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Figure 108. 13C NMR of [NEt4]2[ReBr3(CO)3] in CD3CN (300 K). 
 
 
Figure 109. IR spectrum of 2 (neat). 
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Figure 110. 13C NMR of 13CO in d7-DMF (300 K). 
 
Figure 111. 13C NMR of [NEt4][ReBr2(CO)4] (2) in d7-DMF (70 mM, 300 K). 
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Figure 112. A: 13C NMR of 1b (22.19 mg, 0.029 mmol) and silver trifluoromethane-sulfonate 
(22.17 mg, 0.086 mmol) in d7-DMF (0.6 ml, 300 K). B: 13C NMR of A bubbled with 13CO (2x 
~20 ml) at 274 K. C: 13C NMR of B after >2d (and heating to 300 K after 6 h). 
 
Figure 113.99Tc NMR of [99TcCl3(CO)3]2- in DMF (8.2 mM, 300 K). 
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Figure 114. 99Tc NMR of [99Tc(CO)3(DMF)3]+ in DMF (8.0 mM, 300 K). 
 
Figure 115. 99Tc NMR of [99TcBrn(CO)3(DMF)3-n] in DMF (9.6 mM, 300 K). 
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Figure 116. The observed rate constants (kobs) for the formation of 2 as a function of the 
concentration of 1b in d7-DMF at 274 K. 
 
Table 7. Observed rate constants (kobs) for the formation of 2 at different concentrations of 1b 
in d7-DMF at 274 K ([13CO] = 5 ± 1 mM). 
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Figure 117. Example of a typical kinetic trace for 1a (85.3 mM, 187.9 ppm) + 13CO (5 mM, 
185.4 ppm) in d7-DMF at 274 K.  
 
 
 
Table 8. Observed rate constants (kobs) for the formation of 2 at different temperatures ([1b] 
= 48 mM, [13CO] = 5 ± 1 mM). 
 
 
 
 
  
 
202 
 
 
Figure 118. Example of a typical kinetic trace for 1a (48.0 mM) + 13CO (6 mM) in DMF-d7 
at 263 K. 
 
Figure 119. 13C NMR of 2,6-dimethylphenyl isocyanide in d7-DMF (300 K). 
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Figure 120.13C NMR of 4 in d7-DMF (300 K). 
 
 
Figure 121. Selected UV/vis spectra recorded during a typical measurement of the reaction 
of 1b (0.4 mM) with 2,6-dimethylphenyl isocyanide (0.04 mM) at 304 K. 
  
 
204 
 
 
Table 9. Observed rate constants (kobs) for the formation of 4 at different concentrations of 1b 
in d7-DMF at 298 K ([Xyl-NC] = 0.04 mM). 
 
 
 
 
Figure 122. Example for the change in UV/Vis absorption at 326 nm for 1a (0.4 mM) + 2,6-
dimethylphenyl isocyanide (Xyl-NC, 0.04 mM) in 2.5 ml DMF at 300 K.  
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Figure 123.The observed rate constants (kobs) for the formation of 4 as a function of the 
concentration of 1b in d7-DMF at 298 K. 
Table 10. Observed rate constants (kobs) for the formation of 4 at different temperatures ([1b] 
= 0.4 mM, [Xyl-NC] = 0.04 mM). 
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Figure 124. Kinetic trace for 1a (48.0 mM, 187.6 ppm) + 13CO (4 mM, 185.1 ppm) in d3-
ACCN at 274 K.  
 
 
 
Figure 125. The first four out of eight optimized structures from the NEB calculations 
performed to obtain the minimum energy path for the rotation in 2. 
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Figure 126. 13C NMR spectrum of 13CO enriched 1b and 2 at 383 K (DMF-d7, 100 mM). 
 
Figure 127.  IR spectrum of 4 (neat). 
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Figure 128. 13C NMR of ReBr(CO)5 in d7-DMF (75 mM, 300 K). 
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Table 11. Crystal data and structure refinement for 2. 
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Table 12. Selected bond lenths (Å) and bond angles (°) for 2.
 
 
Figure 129. Crystal structure of [NEt4][ReBr2(CO)3(Xyl-NC)] 4 ([NEt4]+ cation omitted for 
clarity). Ellipsoides are drawn on the 50 % probability level.  
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Table 13.  Crystal data and structure refinement for 4. 
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Table 14. Selected bond lenths (Å) and bond angles (°) for 4. 
 
DFT Calculations 
Calculation of ‡from Normal modes.  
The energy correction 	 and the entropy correction 
	 to the DFT energy are 
arising from the normal modes. They are calculated by  
	 =  12ℎ +	
ℎ

1 −	

 !
 

	 =	−  " ln %1 − 
 & +	ℎ'

1 − 

 !
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where N is the number of atoms in the molecule, R is the gas constant, is 
Avogadros number, h is plancks constant, k is Boltzmann constant, T is temperature, 
and 	is the frequency of the i’th normal mode.61 Gibbs free energy for one state is 
then obtained by 
( = )*+ + 	 − '	
	. 
 
[ReBr2(DMF)(CO)3]- 
In the ground state structure, the ligands adopt an octahedral geometry to Re(I). The 
calculated binding distance from Re to DMF is 2.22 Å, which is in good agreement with 
the experimental binding distance found for [Re(DMF)3(CO)3]- (2.2 Å).233  
   
 
 
 
 
 
Figure 130. Left: Optimized structure of the octahedral complex 1b. The Re-O binding 
distance is 2.22 Å. Right: Transition state structure of complex 1b. The DMF is formally 
dissociated from the complex and the remaining ,"-./0-12034 unit is between a 
trigonal bipyramidal and square pyramidal configuration, leaving space for another 
DMF (or CO) molecule to coordinate from below. 
 
The energy of the transition state converges only very slowly, which is due to the 
concurrent dissociation of DMF during the rotation of the (CO)3 unit. Vibrational 
analysis of the transition state (TS) structures gives only one negative frequency, which 
confirms that it is indeed a TS of this rotation. However, vibrational analysis needs the 
structures to be tightly converged. Otherwise, low frequency modes are not calculated 
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correctly. Therefore, Δ‡ and Δ
‡ calculated from these frequencies are limited in their 
accuracy.  
 
[ReBr2(CO)4]- 
The calculated Re-Ligand binding distances match well with the X-ray crystal structure 
(Table 12, vide supra) 
 Crystal structure PBE 
C1 1.98 1.98 
C2 2.01 1.98 
C3 1.90 1.90 
C4 1.91 1.90 
Br1 2.64 2.67 
Br2 2.62 2.67 
Table 15. Binding distances of the ligands to the Re atom in [ReBr2(CO)4]-, obtained 
from the DFT calculations, and X-ray crystal structure. 
In this case, the transition state converges more easily and the values for Δ‡ and Δ
‡ 
are of higher accuracy. 
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5.4 Experimental Section Part D 
Instrumentation information and crystallographic details are given in the ESI. The Schiff 
bases216, 234, 235 as well as the precursor complexes [NEt4]2[ReBr3(CO)3], 
[NEt4]2[99TcCl3(CO)3], [99mTc(OH2)3(CO)3]+ and the trinuclear cluster 3 were prepared 
as described elsewhere.166 Caution! 99Tc is a weak β- emitter with a half-life of 200 ky 
and should be handled in specially equipped laboratories only. 
 
Preparation of tetranuclear 99mTcRe3 cluster 4 from 3 (path A): The pH of an 
aqueous [99mTc(CO)3(H2O)3]+-solution (0.9 ml) was adjusted to 5 with HCl and an 
acetate buffer (0.2M, 0.2ml). This-solution (0.5ml) was transferred to a N2-purged 
microwave vial containing 3 (3.0 mg, 2.97 mol) and heated in a microwave for 10 min 
at 100°C. HPLC analysis evidences 94% yield of 4. HPLC: Rt=21.2 min.  
 
Preparation of tetranuclear 99mTcRe3 cluster 4 from 1 (path B): The pH of an 
aqueous solution of [99mTc(CO)3(H2O)3]+-solution (0.5ml) was adjusted to 5 as 
described before and transferred to a N2-purged microwave vial containing 
[NEt4]2[ReBr3(CO)3] (3.1mg, 4.02 mol). Stirring at 20°C for 10 min and subsequent 
heating at 100°C in a microwave oven for 10 min afforded 4 in 90 % yield according to 
HPLC analysis. 
 
Syntheses of 6-8 (indicated for Hsal-m-tol): [NEt4]2[99TcCl3(CO)3] (25mg, 0.05mmol) 
was dissolved in acetonitrile (3ml). Hsal-m-tol (16mg, 0.07mmol) in acetonitrile (2 ml) 
was added to the solution. An excess of NEt3 (0.1 ml) was added. After stirring at 80 
°C for 3 h, HPLC analysis (UV/vis and radiodetector) evidenced the quantitative 
formation of 6. The solution was filtered and the solvent removed under vacuum. The 
[Et4N]Cl was removed by extraction of the product with THF. The yellow product 6 was 
crystallised from a CH2Cl2 solution. The product was further purified by preparative 
column chromatography on C18 (final yield after all purification steps: 4 %).1H NMR 
(500 MHz, CDCl3): δ (ppm) 2.54 (s, 3H), 6.79 (m, 1H), 6.94 (m, 1H),7.25 – 7.27 (m, 
2H) 7.35 – 7.38 (m, 2H), 7.44 (m, 1H), 7.50 (t, 1H), 8.48 (s, 1H). 13C NMR (126 MHz, 
CDCl3): δ (ppm) 21.60, 119.34, 120.54, 121.16, 122.51, 123.84, 128.03, 129.25, 
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134.94, 135.42, 139.52. 154.96, 167.96, 169.23. 99Tc NMR (90 MHz, CDCl3): δ (ppm) 
-691.5 (s, ∆ν1/2 = 1763 Hz). 
 
Preparation of dinuclear 99mTc99Tc complex 6*: A solution of [99mTc(OH2)3(CO)3]+ 
(0.5ml) was dried under nitrogen flow, taken up in acetonitrile (1 ml) and added to a 
solution of [NEt4]2[99TcCl3(CO)3] (40.1mg, 0.073mmol) in acetonitrile (3ml). Hsal-m-tol 
(17mg, 0.080mmol) in acetonitrile (2ml) and an excess of NEt3 (0.1ml) were added and 
the solution was stirred at 80°C for 3 h. HPLC analysis (UV/vis) evidenced the 
quantitative formation of 6 together with the 99mTc99Tc homologue 6* (-trace) as 
shown in Figure 4. 
 
Preparation of dinuclear 99mTcRe complex 10: A solution of [99mTc(OH2)3(CO)3]+ 
(0.5ml) was dried under nitrogen flow, taken up in acetonitrile (1ml) and added to a 
solution of [NEt4]2[ReBr3(CO)3] (20mg, 0.026mmol)  in acetonitrile (1ml). Hsal-m-tol 
(6mg, 0.028mmol) in acetonitrile (1ml) and an excess of NEt3 (8 drops) were added 
and the solution was stirred at 80 °C for 3 h. HPLC analysis (UV/vis) showed the 
formation of the mononuclear rhenium complex 9 together with the mixed-element 
complex 10 (-trace) as shown in Figure 4. 
 
Characterization  
1H, 13C, and 99Tc NMR spectra were recorded on a BrukerDRX 400 MHz or BrukerDRX 
500 MHz spectrometer. 1H and 13C chemical shifts were referenced with the residual 
solvent resonances relative to TMS, while 99Tc was referenced relative to the signal of 
[99TcO4]- (δ = 0).  
HPLC analyses of the 99mTc and 99Tc complex was performed on a Merck Hitachi 
LaChrom L 7100 pump coupled to a Merck Hitachi LaChrom L7200 tunable UV 
detector and a radiodetector. UV/Vis detection was performed at 250 nm. The 
detection of radioactive 99mTc/99Tc complexes was performed with a Berthold LB508 
radiodetector equipped with BGO/YG cell. Separations were achieved on a Macherey-
Nagel C18 reversed-phase column (Nucleosil 10 lm, 250 4 mm) using a gradient of 
MeOH/ 0.1% CF3COOH as eluent, and a flow rate of 0.5 mL/min. Gradient: t = 0 – 3 
min: 0% MeOH; 3 – 3.1 min: 0 – 25% MeOH; 3.1 – 9 min: 25% MeOH; 9 – 9.1 min: 25 
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– 34% MeOH; 9.1 – 18 min: 34 - 100% MeOH; 18 – 25 min: 100% MeOH, 25 – 25.1 
min: 100 - 0% MeOH; 25.1 – 30 min: 0% MeOH. Comparison of the HPLC retention 
times for the 99mTc compounds with the corresponding 99Tc and Re compound confirms 
identity. 
 
 
Figure 131. HPLC chromatogram obtained for [99Tc(Sal-CyHex)(CO)3]2 (β-trace). 
 
Figure 132. HPLC chromatogram obtained for [99Tc(Sal-Cyp)(CO)3]2 (β-trace). 
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Crystal Data  
X-ray Crystallographic data were collected at 183(2) K with Mo Kα radiation (λ = 0.7107 
Å). Compound 6, 7 and 8 were measured on an Oxford Diffraction CCD Xcalibur 
system with a Ruby detector. Suitable crystals were covered with oil (Infineum V8512, 
formerly known as Paratone N), placed on a nylon loop that is mounted in a CrystalCap 
Magnetic™ (Hampton Research) and immediately transferred to the diffractometer. 
Data were corrected for Lorentz and polarisation effects as well as for absorption 
(numerical). The program suite CrysAlisPro was used for data collection, multi-scan 
absorption correction and data reduction.62 Structures were solved with direct methods 
using SIR97236 and were refined by full-matrix least-squares methods on F2 with 
SHELXL-2014.237 The structures were checked for higher symmetry with help of the 
program Platon.238238 Supplementary crystallographic data can be obtained free of 
charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/structures. 
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Table 16: X-Ray crystallographic data and refinement parameters for fac-[99Tc2(µ2-O^N-m-
tol)2(CO)6] (6), fac-[99Tc2(µ2-O^N- cpent)2(CO)6] (7) and fac-[99Tc2(µ2-O^N- EtPh)2(CO)6]  (8) 
 fac-[99Tc2(µ2-O^N-m-
tol)2(CO)6] (6) 
fac-[99Tc2(µ2-O^N- 
cpent)2(CO)6] (7) 
fac-[99Tc2(µ2-O^N- 
EtPh)2(CO)6] (8) 
Empirical formula C34 H24 N2 O8 Tc2 C32 H30 N2 O8 Tc2 C38 H32 N2 O8 Tc2 
Formula weight 784.55 766.58 840.65 
Temperature/(K) 183(2) 183(2) 183(2) K 
Wavelength Å 0.71073 0.71073 0.71073 
Crystal system Triclinic Triclinic Monoclinic 
Space group P Ī P Ī P 21/n 
a/Å 7.7230(3) 8.5234(6) 7.5595(5) 
b/Å 9.6213(5) 9.4839(4) 19.5030(9) 
c/Å 11.4744(6) 10.3293(7) 12.0691(8) 
α/° 103.910(4) 96.671(5) 90 
β/° 102.384(4) 113.343(7) 97.395(7) 
γ/° 99.338(4) 95.370(5) 90 
Volume/Å3 787.52(7) 752.46(9) 1764.58(19) 
Z 1 1 2 
Density (g.cm-3) 1.654 1.692 1.582 
µ(mm-1) 0.933 0.974 0.838 
F(000) 392 386 848 
Crystal Colour Yellow Yellow Yellow 
Crystal Morphology Plate Plate Plate 
Theta range (°) 2.772 to 26.370 2.634 to 26.371 2.694 to 27.997 
Completeness (%) 99.9 99.9 99.9 
Index ranges h = -8 to 9 
k = -10 to 12 
l= -13 to 14 
h = -10 to 10 
k = -11 to 7 
l = -12 to 12 
h = -9 to 9 
k = -25 to 25 
l = -15 to 15 
Reflections collected 6179 6758 20701 
Independent 
reflections 
3217 3074 4245 
RInt 0.0451 0.0391 0.0638 
Data/restraints/ 
parameters 
3217 / 0 / 209 3074 / 18 / 231 4245 / 0 / 226 
Goodness-of-fit on F2 1.042 0.935 1.064 
 
Final R indexes 
[I>=2σ (I)] 
R1 = 0.0401 
wR2 = 0.0727 
R1 = 0.0342 
wR2 = 0.0827 
R1 = 0.0421 
wR2 = 0.0712 
Final R indexes [all 
data] 
R1 = 0.0508 
wR2 = 0.0779 
R1 = 0.0392 
wR2 = 0.0856 
R1 = 0.0713 
wR2 = 0.0833 
ρ max, ρ min (e.Å-3) 0.777,  -0.853 0.942, -0.714 0.720, -0.528 
CCDC number 1581119 1581120 1581121 
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7. Appendix 
7.1 Index of Compounds 
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7.1.2. Compounds Synthesized in Part B 
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7.1.4. Compounds Synthesized in Part D 
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7.2 Abbreviations 
ACN 
 
acetonitrile 
AcOH 
 
acetic acid 
AIBN 
 
azobisisobutyronitrile 
BBB 
 
blood brain barrier 
CA 
 
carbonic anhydrase 
CO 
 
carbon monoxide 
Cp 
 
cyclopentadiene 
DFT 
 
density functional theory 
DG 
 
deoxyglucose 
DIPEA 
 
N,N-diisopropylethylamine 
DLT 
 
double ligand transfer 
DMF 
 
N,N-dimethylformamide 
E.U. 
 
European Union 
EC 
 
ethylenedicysteine 
EDC 
 
1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide 
EDDA 
 
ethylenediaminediacetic acid 
EtOAc 
 
ethyl acetate 
EtOH 
 
ethanol 
Fc 
 
ferrocene 
FDA 
 
food and drug administration 
FGD 
 
fluorodeoxyglucose 
FR 
 
folate receptor 
HOBt 
 
hydroxybenzotriazole 
HPLC 
 
high pressure liquid chromatography 
HR 
 
high resolution 
HYNIC 
 
hydrazinonicotinyl 
ICP-MS 
 
inductively coupled plasma mass spectrometry 
IR 
 
infrared 
mAChR 
 
muscarinic acetylcholine receptor 
MeCN 
 
acetonitrile 
MeOH 
 
methanol 
MS 
 
mass spectrometry 
MW 
 
microwave 
NBS 
 
N-bromosuccinimide 
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NEt3 
 
triethylamine 
NMR 
 
nuclear magnetic resonance 
NOE 
 
Nuclear Overhauser Effect 
NSCLC 
 
non-small cell lung cancer 
ORTEP 
 
Oak Ridge Thermal Ellipsoid Plot 
POM 
 
polyoxometalate 
PSMA 
 
prostate specific membrane antigen 
Rf 
 
retention factor 
RGD 
 
arginine-glycine-aspartic acid 
ROS 
 
reactive oxygen species 
Rt 
 
retention time 
SPECT 
 
single photon emission computed tomography 
TFA 
 
trifluoroacetic acid 
TLC 
 
thin layer chromatography 
U.S. 
 
United States 
UPLC 
 
ultra high pressure liquid chromatography 
UV 
 
ultraviolett 
VIS 
 
visible 
Xyl-NC 
 
2,6-dimethylphenyl-isocyanide 
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